var title_f38_7_39024="Intraarticular fracture of the little toe";
var content_f38_7_39024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Intraarticular fracture of the little toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 306px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEyAhUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDhLz/XtVTa7EAHnPGKt3v+ub61ADg5HBHegBkY+Y579qePqaKSgAIGDjvTXQqp55PUU49OKRlBxmgCPBzjjNGCD83XFPxtIIzSlec8UrCGKCRzx6UqpjIPQ1JjPBoxngmmMj2e/PoKUffO4DpTuhOKKAFPQCkyfwopQMmgAxnmnKvenAACpEjJwT0oAjwKjb71WxGAOOarlRz60CEi++KvjqKooBvAq9Fyy0hloAk4Hepo4R/F1psAG6tO2hDEZ796YFeK3U8kcehqK5tSDlB1Ga00QbuQcUSIoHJOBQBzTpt5HSmHnirkq5Zj2JNQ7Pl98daQFKWPI96rHqa0XU96qzJzmmBXopT1pKACt/45/wDH34L/AOxYsv5yVgVv/HP/AI+/Bf8A2LFl/OSmho8yzngUyQfKRjk4704Lhy2Tk0yVsNtJwpB7UwEiHyn5fmzjjvRIfnRlPIOPpUSlRGVyR3FOWQbVZcKvoT1qRCSTZ4XAHfHSomJNKxUkEY3HsBxQ5BVSOvepYhtKTkCkooAKKKKACiiigAooooAKKKKACiilAJIx64oAQAnoKlWEk/NgfSp4o9g9WqZI6drDsluRpGqjgZPqafs9KnWIsDt7dqGjZRkimBn3YIZfpipLZcIMdTzS3UZYZXOe1PgXao9QKALVtHlix6CrseADkVBBgx8DFTwH96BjPIoDoXraJiAW6Ctazg5GMc1HapuIIIwO1bllEpQMV9zQBWEBCk5GR2xVLULRXU/Jh8/nXUpaNJGWUKePu+lZuqwPFbvI3VeaAOGuYfLfB/Cs2ePB3evWtyf96efvE5rOlGQRjK0AYNzHsfcOhqGtO8i3Bh26is0jHHekxCUUUUgPRr7/AFp+tVqs33+tP1qtVDCiiigAooooAWkoooAPrRRRQAUUtOC8UAMqROv40mMClTpQBKUzIwXlc1MBj6U1BtUVKnakIcy7QO9VnTOcDnNXZQcDAzz0qCQYagZTxhxVuM4IPpUEo5zU69KYGjbHLYrYgIVBkEVz8THaGHVa1oZ/MVDzmgC8W6EdAKceM55FQq4JYtxn0qTzAFI7DpQBkXkWyTIHymqpFbVzGrL6g8/SsuWFk7ZHrQBUlUnkdqrSDK4q6ynGCCKrSJigCg64JplWLhear0AFb/xz/wCPvwX/ANixZfzkrArf+Of/AB9+C/8AsWLL+clNDR5k2ccDJqGRwytn1xzUkj7R2zVU4YZA4zxz0NJsTYZ+YEADB6DvTW55PrTgpBPGQOetNzwaliA5pKDRQAUUUUAFFFFABRRRQAUUUUAFHfFAqxFDkZccdqErgVzxVi1Xgt+FP8pAR8tOhXamPeqSsNIlRcDNWLZRvye1RDjAq1AoWMN1JpbiJVXtjg08xjGTTgRjpTwR3Hai4XMuWPa2M5zyKTy2Q9MVdYc89ulOMYKg8kmnYdhi/cGeuKliBGD0OeDUeMVMvCCmxs6WxjHlxlRknr9a2IJPLB+Xiuc0a5dk2OeO2K2reX5sNyM8ZpCNi3l3AjkfSm3hWa1khbHmEGoYAoGGf72ehqK5ZUwwBBzzjmgDkZECOR3U4qhdrgnjrzWzqiBLkkdGGR71m3KjbuPTpxT6DMm4UCME+tY9yu2U8da3ZhkOPyrJu1+UHHSkJlOiiipEejX3+tNVqs33+tP1qtVDCiiigAooooAKKKWgBKKKcozQAqipFQt0pFGSAKsqvA9KQFd0xj070wAgn0q0wyCKhddpzjjNFgJU5xVy3QMM5A9zVMe1W7U4GTz9aYFoCIKNxBqCVVwG5K1OZVxwgqGR8q26gCg65Yc8ZzT1pr8H2zTloAmh71fs2wGyenNZ8P3+atRsV6d6ALqOc5z3qwDnOTVND+dW0J9BigB2SSQMYp6Rll9KckR5I4H86dkq3C8elAFWe3Vsise6haM4bqP1rp5LdzGHIwvqKxtWdXKImCQOSKAMOdeKqEYNXpQcEVSYYNADa3/jn/x9+C/+xYsv5yVgVv8Axz/4+/Bf/YsWX85KaGjyy4HQjmoQpZgBmppZQvy9yc8HpTIyNrM2cnjp1pWEMYbT94Ee1IVPQDnrTiVDDaowB3700/JnaeTUkjaKPpxRQMKKKKACiiigAooooAKKD0qe3QcsRn0oSuA+GIKAXHzfyqyg7kUipxzzViGLeuSSBntVeQ/QhIphUg96veUgX7vXvUEqhWwOnqaNg2GL2zVyEfIoPNU/5Vch/wBWtJAjSghRgpUE/U1cW0jXKtIik8kZqpZTZILAFh0HatMy25UGSJd/tTAoXFnEHwh3e4NVJE8skdV7Gtu3nUykBFUY61Uu4lWQkYINAGQ/3vapE6AUlym1sds0sY3Mo96GwZr6cAJ0wMYrUjI3DccYrKs8K7O2cCtBSCQc5HrQM1YJQWxknHOCvrUk6K8GQx35zVS3ADbhyMY5q7GCynaOlAjCvYfMhLDkryDWPNGXGOmDXcNbsqK5U4xn8aw7y2VpchQCemO5oA5SZVDfKeO1Zd6nDD05rbv4/KmZWXGOlZl2oIB9cg0AYlFKRgkelFSSei3v+tP1qtVi9/1zVX/nVFCgZpKQEE01nHTqBQA/3oByMjpTd/JUjg9KR25H932ouA+lxTUJIzUqgdaAGkcdKVBTvYipIfvGgQQjqc/hVhelNRMgAVMkR6HikBGajqy8RHOeKgYAGmMah9e1TQsQp4zUAPzNT4GO045z2oAnEnz/AOzSSMDnFHlnd0wKesYA5GTQBTl+6fSkjck+mKluIzzjoeaqBiH5oAug9CKvwYIJrNjOQKv2hLDjvx1oBF63jLsMCtm1sJnHyoAPestLgoFjgXEhPWtu2iuGiVpZsYHrQBN/Zso5bgdaqyqsGWddx7L61cAlJw8vFDCFY92Nxx1NAGMwurrKhti9vSse6geKRlkHPY10sUo5BG0Z4zWZqy/uNx55x9KAOenHP1rOlGGxWtMuRn0rMuRhqAIa3/jn/wAffgv/ALFiy/nJWBW98dRm78FjOP8AimLL+clNDR5a0eWcgDsckUjlyflIycjGM4olJIC8g45+lMZguQhOM8GkIjznmkp7DGOCAf501sfw5qRCUUUUAFFFFABRRRQAVJFEZAecUJGzEccepq3HEAOOh/WnYCk8ZQkN09auRL8q46YpLiLcgHp0p8GcDIwQKY1oSqCxAHerkabExVe3GZFJ+tXYwcEn6UkCFdflwKjmQEY9qtiFyucfhUMqYzkcigCkqZDxsQGHINSW7ZTb3Wo7pNpBpkL7H9jxT2BGrbSBEbI5qXz2JAAqpGflxT84pXE2TRykTkk8dMVcY44rOOSSR1qZ33eXk4BAyR2oGmRXQwxOG/GkgJBUjrmnXBJJyeo4+lLZLmRfWmBfjGVwfXpWpboQqdyBVBFYksozjrWrpkTyyKM9D1xQBYgjcckfJ3GK1bWJ0w0vAPQVZsraMRYku0Qj+EnFWI7e3Zx+8DA993egBr4lXy0UH1x0rLuLCWOXa0eMDIYdK3YJrGwnczyh/wDdNZXiPXpJ7by7SJmH3QQvQf1oA4rxKqLdoo/1gXk+tc7eYK5C7RmtO+DFsyZ35wc1mXSnYfagDDlAErAdKKddAiWigVj0C8/1zVSds+uat32fNfGPxqlnNJjDtS57EZpO1AOOlIQA+hpyqSD9abT4QSc/hQgJ0Xj0qaOMY5701Bu/CrUSbiRkcVQyIxjHQU1Uw+R0q00eB161C42k0APU4IIq2Qvl8kg1TWrDHcnFACqykYX9aqyctmnhCenWnNCcA/pSuK5RJO446nirVkM4BBx9KNmO2Ku2i7WT3pgWUtlYDIPrmni2j5C5J9+1WyuF4PFMIYkYFAzIvYiuen5VlTLtfPrXTXaAxE96yLqEOhI6jpQBThbjHcVbifafaqkK5bryKvxxevJoAvac4W4BY9q6YO+xTGcDFc1CoUDpkV0Fm+6BOaAGM8hJySDQGYjg8VaMQdyVHbIz3oEG1hxzmgCq6kEknvVPUtptSvfNa0kO2NgRkmsW/UhT6cUAYzj9RWdcLlcgVqSLg4qhMvysKAKJ61vfHP8A4+/Bf/YsWX85KwSOTW98c/8Aj78F/wDYsWX85KaGjzHjJxgnGKhcA7lIKqBninS4CjeQv061DIrLgHO3sc9aTEx0hXylwpwOPoaiABBJNKWJAB7U2pYgP5UUUUAFFFFABU1vFuO4jjt70yJdzhe3etBFAAPUU0AgTgVMkbMfQVNbxA4Y8+1Wo4yTjqaYyi0BxwQcVCqkMc1qyxFVzgiqssW9d2cMKEFiO3XDHI59607HBfnr9aoMS0auOo61ZtJFV9wPGO1AGupZV4VCDxyahkiVmJds46AVXNwcE7cjNNac7DgEMfT0oAp3IwGB5xVAHv6VenJZCAOelR/Zz5Q7NmgC1ApZRgEnHaraWrBQzkD1Heq1mHEoAOBjk1rRxxjHnRv67hQA1bZsACM5qjLCYpCrngeh6GtcSxiJ1SUg44yP0rMuwNgI5x1oAr8sOnTrS27+WwJ5qPOelInDnPrSEdNYkCJWbG0ckkcVsaQrXxxAAi5/AD61ySMdoAJwR0rr/B0621u4dSVY55pjN9NGhTi4lk5HVakbQoDgxSzEnpyOaJLwzyKYlAx05qCfUpjjeVIHHAoAqTaXBa3JWdy5xnnnFF15SIGgVeBgmmSuWl3ykkkdT7VVaRsYdR6/WgDB8TRrKPOUYkXhuOPrXK3IJU8dq7LXBus2JxtIHsQa46bp6jBoAw7wfOv0op1yPmFFAHc3n+tYGqVXr3/XNVGkwCiigDPSkIMEjocVNBUYRh0p8WQSDTsBbgBz9avRBV7gt3qjC2DirCkjkHFAFxsMOSv4CqUhy3TGKkEmMY//AF1E3cgUxiKeKsQr5u1QwHtVZVO3JrV0qJQGJ+91oAkS07ZzjvTpYgE4FSFmDc/hTjyMP17UAZTLnIIqWM4I4okHzH1zRGeg7UAbFt+8GMDpT5ItrDGTmodLYCXB6VozFWcgDvjIoAyrtSowazZFwCK2NTG1lx0rKl6k546UAZ0a4kwPWr6D5hVZR++q3FwQPWgC1EOuME+9amkMW3RkjjpWTGdrZrS0ph9qXHQk0AdGkX7osRyDxTmiQKcHBHXPrUzgeWVUg8ZxUOHYYPA96AESEyAg4PpWFq8e1mAHAHWt6AeUCdp5PWqevwiS3WVBgcgj0oA42Uc9OtUp171qTKOQM1nzLlTQBkycMRW58c/+PvwX/wBixZfzkrFuBh81s/HUkXXgzAyf+EYsv5yUIaPK3fLMMglT6VET8oFTN80RLKEOfzqHIwcjntSZLG0UUUgCiiigAooHPSigCe16savL0APSqdpyGFX4BmYDGRTA0baNSygg47Yq/FDs5KYaqtgfLlLuoKj19a2ZbmORQGjFMZRki4IwcGs2VNjYIxW60sWwYiU+5NYt6xa4bPHsKAKh+WN/zqWyjZwuBnNQyozsqrnaTzW7pUKxsEbOeCKAI47RhkHJz2xVyLTlK5cY9q3I4QzAMgAAxlT1qwiRqmFHX1Oc0Acjd2YSQnop6VUlhKr2Irp9Xt18rfnAHPFYkkZYHPTFAFS1/wBbW6ql4snLKRx7VkQoEIIBLd66fS4RNBu25yMAUAYksTs20qMjnIqpc5jjPrnFdc9miy8LyRj6VR1TTI1ibMYDn370AcbFICzKeoNSLkux9amlsljuAcEjoexFMYfvGC9KQFuBsxg9619MmZccjIrKt4yECntzVq2LRyAA9TzTBs7O1kyilTznFWDEcsrjJ7YqjpIzEq9z/Otq0jY7WOST0xQBnTQDY2c78d6qXKSAFmA7DAroLi33xEuuJO5HpVSeDc0S9yPzoA4nW5Wx5eTjJNcxLnb09a6nxFj7YVB+UVzMwxkCgDEuB8woqS4Vd/zZH0ooA7S9/wBc2KpN1xnirt9/rX9ao9aTAVVLfSrCoFXHamwj5easImRySKBEeBSFRVjyxjFROu2gAT74ycVowIWUYU4+lZ7DAUjpir1mSUz1H1oQEv2cbznK/wCzSXEYVcAe9SZI7mh8kcnJxTGVEGWArSs2Cv8AUVmkbW46g1bQ4waANQxjBIHBprp8uV61PAwktsjqBSOB5TcfhQBkycu31pg4FTSAbsnpUY6gUAaFi2J0OcVqSk+Yx71kQHEsZ9DW1doY5Rk8lQaAKeooTGr9jzWPKD6cetbkq+ZZEAAsnPPesiZcrxQBTI5qWPk89BSFCGHrUqqBzjmgCWM/OK0dO/4/I/Tdis5RWrpEbPfwKPWgDolOAWyM0MuGTdkjGankTZwBxnFRHO8cnI6mgBUyUIIJ9CaguEL2ksZPIGRmtCygLK2T05qK4gwd3XnFAHCSqd596pzrg/Wta/h8qeRD/C3FZs4yOnSgDFu1xWn8dXC3ngsZGf8AhGLI8/WSqd6mQTVj4+qGu/BOSAf+EZsv5yUAeXSSBkwOB6VEetPIAYqc5FNOM1LEJ39qKKKAHHG1eD0596bRk4+lWbaH+JuT6UIBsUBYZbI+lOa244zn3q7EBuAP6VLNCETIJx70xmVHmKXB71pwEYO7v0xVWeIOMjhuoNTWp3FQ3rzTA0YmP3cnr61obipAJ7ckdBVC1Qs4wGbvitm2sJZ3yyleOnrQMqFv3m0cnrUE8DlyxH5V0lrp0W7c+eODjr+VVdRgKf6tcKvoc0CMLyirxlhjJyK1LXPnr65qrOBtDd1OatWrBZQT0yKAOmYYA5/gH51HGiqTgdMVLEDIobOQVGKFUbzk/lQNEV0gktZARkDmuelULkc/jWzfOyE5+70wKyZNjqzYIcnoehoEV4wCa7DwyoMCsRwprkox84HPJ612OjAQ6axAGW5X/CgC9CFmmJIGN3FZeuZSUIRg46VpWSMmwA/MG7Vl69/yEWz24P1oAwb6HKbsc9zWXGgEjkj6VuyjO5exFY5HzEd80IES2+zB3jP41ZtE3Nkjp0NVVHFX7UERqG+opAdb4WjEsZ38EnjPauiih2s7ojBl+6KxPD+IbcBcbz3PatvzvmByvPGfTFMCjNNILpxNwOpz3qwsDSQyHZhlG5DUGGkuMK2VB5JHatKCQhJGDZEny5IxQB5d4jXbfFSOa5q4H7xuMV1vi2PZqMm48+1cvdAGQ+uKAMa4AMp4oqS64cEcZFFAHVXv+tcVRAy2Kv33EzfWqkIDPnmkwLEajgdqtIox7VFbpnJ7mraJj73X+VMCN0waglwV5zntV2UDac9aqsODQBXJG3FaFjjyfeqKxk9eBVy3JU9KQi6kfzfN0HpRIhUZzkVZUAxhsdRTbgDyCMcg0xmdKvBI61LGSQM0nanJ6CgDU05v3ez9KsLyxDcVS0kZvY1J4JFX7hdkzFQMA0AZki4ZgexqMIM5PJq7cxhsug69RVXG3jGKALWnxeZMufugjNbl4BLI7jPFZlggWIH1PNbAUtGMKSegoAylZgz46VXubcbztzjrWvPC6n7g6VRlUkbRng0AZDL83Y470dTUjjaxHvQBk4AoAdEPmz6V0vh2AJm4blsYUenvWBbp8wHrXW2IRURG4HqKALkitIhzwR+VQlCR+VaMcayp8rdu/FXV0xGw2/B4oAo2CckdSRTJwUz+fT9K2UtUiLHLdOTWdfhVAKnjoTigDktes9+ZYxyBz7j1rmZlO0g8Gu8lKAMpHynpntXJazGEumCAYPNAHP3K/JUnx8QG98F7iQB4Ysv5yUtwvUUfH5tl94N4Y/8AFM2f06yUAeVFD5YYHKk4NNOGwFAGKeMKCW9cbTTGb5doPFJiYhOcewpKKKQEkKh3AI471fiXjoeewqvaJhc+vNaFuCTu9OPxpoCeFPlHyjNSlAVORU8cRJUnoe9SSW/dD09aYzLuIxs+UYI/lVaH5Zh2FaEvoOvc1EINsfqeuTQBoWHyTgkcdz6V1KMqwqyoCT/Ee9ctZ/ON2fSujLEpHj0AAPagCSGVw5A4qO8RDbPt3GTHPHWp44yGJJHK5AqB5CisSMCgRizIDG30ot2DKp9qmkBxk96jt0Jk2rgCgZ1nh1g9qWY5CcEGpCBvLYIzyKreHwPscgY4yefer0yBTkckk8elDAxdRHmSgHovPFZ1wN0gVF4ArTuublx2FVenIHWjcCpED5qjvmuqBMUccY7LzisfTLVZLhAFGByx61tXD/MQuCBRYC9p+XcbTgn5se9YOpyF7yVmJPPetzTiykEDGcgGsHUQBdSqfWgRTY5PFZ0i4lJFaGMVVmUvNtwAQMk0PYpjLYZlFaEC75VHqcVXt4thJPJrb8P2huboHjy0GWoQkbtmvkui5xkenWtGTKcMvvmmwx/vECpuAXg+lS3CFpiAQewANAEDEhTgY75FPjkdYE2tkHOKnEflQgY3HOT/AIVSuv3URC8dwPTmgDi/GPOot6kZNctdffHuK6jxYM6iccjbjNczdjAUAZ5oAyLrll+lFFz95fpRSe4M6u9wZj6VXhHBI71NfcSv+NR2wyFpgXIweB7VZ2nn5jS2qAgnKknj6VNJHt7jGcUAQspMZFVimDWgAcYRfqTVKThzmgCJuOBViA8YqB+tSwnHU8fzoA1rJg8RB7VKYgUcc8iqunsBKwPQirbFhzx1oAymBVsHqKkiI3DcOO9T3MW474+h7VBg9CCKANDT1C3G9DwOR9a0NvJLZPt61n6cccMQO/NaPnHH7pcnoSRmgCCVApIAI4qvNGMbu4q25kx8y9fQVWkwwwKAJbG4RBtkB4ORWk13JNkR8IPSseJPmx6mta2wMLjjFACt52OWBP1qrPMwOH+9Wg68ehIqlcRg7lHJHegDPIyc9+9PjGTjtQVoQEtgd6AHBNrD1rfsXLKoB5FYojAYE81r2F9HbrnZlsd+RQB0umwERl5SAOtakeoWiYXcSB6CuTWe5ujwSEbpzgVo2mmbiC7npyKAOkN3aTRlTLjPIqneWcUigRyq+ecA1nvpyKQInkAFVZ7W8iG5AWX260AU762lV2DggCuY1oD7VIB2reuNXu1DJIAe3zCueufmYsxyTQBjTjv60vx641Dwd/2LVn/OSpLlcA8dKi+PhxqXg/jg+GrPn8ZKBo8scIwBKkcnHFVxjBzgn6U4keYdpJxxk0w9aTJYlKo3OBSVLbDMvsKQF6MYTFaVlEhCjPB5rPT7yitG3RnYAfTNUM0xwMDtRx3Bx6Uxg2wBWwRUlvbsRnDHnOTTuMovH5kmEGPYnpUjwYjJzz6VdMRBO4c1EwIBBpAVLI5J+ldLo6rNHtOTt61zduv7wAdMHNdF4eOJSOeeBQI10iAlf8hWZq2dyoo6mtZN2c459azdQx56gthiOKBGZcAoUUj7o6+tQAYYtViaKQ4LHdx1pLa3eeRVUHDHGRSA3tCjYabK7D5S2M+9XIvmVgAMhc59qawFvZLbITtHJ9zSaeN0mGJwRimMyLg5u3+tLBCZpgqg/WiaMi5k4IKnvWtoUAkLsSF7AmgCxaWohi8uLl26nFN8vDlnztBxjHeta1gwwZeR0HFTG1Kfehzk0AZ9tFthUuSqnvWTqUGJ33DnqD611M+1YMNHt4wDjpWBqEZ2BjyQcZoAwmBI96hEYdsleBxVuRCHYD/9VNRS3C4z60thXsEUJkkVIlJYnAxXYWtkum6cowDM/LeopPDmlGK0F04yT0OK1PLEo/egl24ApjKVrvkB74yBgc1qadGssn7zd8g5J7VDZ2kiBSynOcgAVt2tofJ5ABJJIP8AjQBHPbru2xpuQjjHasXUoWMjJg/Jg9K6h7d/nXJVQucjvWPqMDPGcHG4YPrQB5n4pXddl1Hy7RXK3gwB7Gu68S2x8vdggJxmuKvQNpA7UAYlypLCipJ9u75jj8KKAOlvv9a1R2nanXx/eP8AjTbXpn2oA0rTHJIz7VabYB8qgNVO2baW9xVsjcoIHOaAELHOSajlUbs9wKlVMmo3+8R2oAqEc0q/eFNkdEnERdRIwJVCeSB3AqFLky3Qit1DKjfvJD0X2Hqf5UhGzYjM6k9B1rTjUM2McHtWfZcqQvDd8VpK8cWNxyaYyCSIR5Kk8Go2TejNgZFWnlDj7hHvmoHYFDz1oAhiGXAzitSHcFAyQp5xWZFwy960ISw/CgCaSQ8dwKpzj5jtNaMsYMecDOB0qgw6igBicMMVpqGEig9x2qhbLvlGenetaQD5XAOelAE+3coyOg4xVK5Rkkbgj3rViA8sgnnAGapzR53BsAH0oAxmXDEU4J7/AIipHj/enPHampw+3HFAE0UbSEKvJ6VsadpayzIkhIwefSk0qELb+Z3c4xiujsLfY6HuME0AC2yw/uynC8cVdtYsAJzg8cVZvU3KrgAH6U6wAWZCc8UAaNlZxqpYrux3pk8ashwowO1X0c+WcAAY5z61Vn2gAKMMw6E0AcXrFnG8zfKCh5rktUtPs8hxzH/Ca7fXdqS4BIb1FYGobmsJHkXgUAcVdDhqqftBf8hHwf8ANj/im7PjPX5pKvXIz9Ko/tApu1HwhyP+Ras+G6fekoA8mk27ztPFNpWGKSpJCrdqvAI6nrVTrxWjCvQAU0NFy0QMT05OK37GwkYAIoz6msiGMKoHYdK6HSYiFDeaQx9DTGOWwwwBDM544HeryRxQ/ugDJLjAQevvU8j+UgQyuQT602K4EbFY12g9cdaAMm83C4O9Nh/ug5xVWX7ta+pKGLlMHcM596y5AGQjoelIChb/AOt47g10Xhtd1wfYVgwIUDZ65xXReH1aGOWbHA4FMDbjXBXeBgnODWTrcQN2pB6A9KvM4bnkn09Kr6sm3yGCkAr196AKAULCC7bt2RgdhWhp0PkxBhwTyKzQMD261v2bo8OeAmPyoAdsEqFc7mFPih8sbwcMKljuYVQYiO7PXpU32m2k2ptaP3PNAGPqKiV2lHXual0lxGuJCFQnrmnXqgMSDuQ8VTjQqmG69aAsdXDrdtax+XBGHbP3m7VKPEt1s/5Z+3yCs3SbWERhnXc/UEjpW/HEjRklAM8cUARRa7aXKGO9iVWJ4cf4Vg6xtVSoZWQtlSO9al1p8Tq5kxuA59cVz11F5UpUndgcc8YoAqBAzluSTTfLCyZHbtUq/Kc9qTlmJ70Adn4d1QDTY45grKhxjvitO3W2ubhXiJxn7pJrltGtnliCI4XJyfWut0r7Jp+17m4jXHHX5qAOu0yACRP9GWRegzXSx29o1qqy2cS5PPFeeyeMkgkK2iwgDoTyatQeL7udBtaQrjpt4oA6nUbWHDtFbrhR0HQiuTvBHyjRrkngelW4vF+HUzom5RyuMZqGbVLHUWKlRHLJzyetAHFeJLWEwXJK/JsJBB6NXlF9H+8OccjtXsviTTpILSVht8ojgbs8eteQaig3lhwM9hQBzso+c8UVJMP3hoppXA3bzmZh71XmjRrZzK5iWMb/ADAcbMc5qxef65vrSQqCDnkYwRSA42y8ZyTa5axOYxZN+7Y7cEk8Bjnpzjj0Nen2v7yLodwFcRq3g7TtQJaBfsk5/ijHyn6r/hiu08MwXEFlGt66STIgVnUnDY6Hnvjk0AW/KY44+aqVwuyQg9q2JMg5H4Vm6nbJco+4HypAUcAkHB46igDxnWry917xRJNpccsvknZD5eflA/iz2ycn8a9P0aOeLS7ZbuKOO4VAHSPkA+386tW1jBZQLFaQxxRDosa4FSYwcGgCSF3jbMZwa0YFP3mOT15rNiA3DNaluMYJHFAExLFO5A/Wq0sY6gYNXlHAAwKrMpHuKAI7VN0g9q0I+rAd6pRfIx/uk1bgK73DscgZH1oAuxEEA45IwTiqc0YMmQu0VoQDeoAGBVa8DAkr0FAFSD5ZCPetSybeGVuT1rGU7Wz6Vs2pGFcj7w4NAGjEhxwBg981VvF2qWI59auKPlUZqtqylYd2OTwKAMUnLZp0g+deg4oQfMDjpUk/LjjoKAOi05NsC98AYroLBN75PpniuW0W5DYifGO1dZpkLPnHBzwBQBcmH7tuR0zUETtGyMDx3zUl2QgYHAbjj0qosirnO7HODQBthywXrg8kVWvWy+OckcGqVvqRQFXwRnjFNvL7eHVE5BxmgDK1gl7jZwCB9c1la6jR6SqHHzPnjpVy5dmuc55FZ3iG43xiIZIXkn3oA5G5HGaoftAsBqfhDOMHw3Z5/wC+pKv3Rz/Osv8AaF51TweP+pasz/49JQB5QfvHHSkp7Hjbgcd6ZUkjohmUdxWvarubPpWdarli2Pata1GEb61SKRaTlRXRabnyckDtzmufiXBHPetrT8vKY89RkUgNBh0waa3WrKWzBGyOcZ5p3lF4h8oVhTApynEeBjPvWcWP3fftVzcJJ2jIyAOc1UZcOQvOD2pMTEtbdrmcIvGTyfSuptoVESwQjhefqe9ZuixqI5Gx+875res4cnczbB78A0xlQW8gA3jHvTpf3kJhlGV7c9KvboC5HmKCf9qormExQs0eGBPJBzQBzs6eXJt7fzqaziMj43MB6A8U+9UFxkc4p9hy7AdcdaANi3QIMKPzOafNGsjYbgjoR2osZcxscAuT+lSyJwCTxuxj1oAx51Ik2sSccj3pvA+lWL9cXT8YHaoUGWxjjvT6DOj04D7JGRwSMEntWtAQIRjAIOCKjjtRFpsA2EkjP4GrEMREXHUjmkIrTAyMA6kMTwR0NYGsxpHOUTGQe1dY2F2MAMgZrntdgH2oy7SFk+bPvQDMFlz34pQgx1qZYCw4I+lWINMuJVLBcAetIWpUDMvKswPcg1raRpc1+TLI7CPvk8mq8VjLHMUdST0wOldpo8JMI4Kr0AX0poaH6PoUMKb1UBsdW5zXQQRCCNTEoJx020tlZyXE8SR5yOD9K6h9IQWv7xSB9aAONu7eKWNzLGuMZ4HWuZvrAqXa3Jjf+HPIrrr9TGjbm3KuenauduCXk3ZGxuhoA4XWb/VYWaC4mbymGCSMg1yV8vynHUcV6xdW8NwpinjDAjHNeceI9PawnkjPMfVT7UAchOP3h6UVLOAZTRQBr3v+uaiHoaL7/XGiHofpQHUtwLukUH1ragyCAvIPGBWJExV1IGSK2LS7Ea5K/MOR7GgRqi3PlhpGCe1UbpVST9225SORjvUTyzTElmbJqJosYbJ+uaBiuFSIkj8KqgZ7VLLvbgnIqNAeDzwelADoU3MM+taY6gL0xiqEbHO7uDVyLJOTzQBej52gdabIuQelT25RjyBn1qSVAI/b6UAZTDBNXIhuRW61UYfM31q/ZITanBx83WgC1CGwBzmor75dqZyT1qzb/eGBzjmoNUz9oXIHCigDNVN3etvTl3WqD+IGsoLycd629LT/AEUE8YY0AWrdf3gU9RUHiVdht0GRxkir9rGDMmO/Wqvihc3ca9lFAGHCuW9gKSTG41Nt+cEcdsDvTGBVwDg5oAfbM0ZDD8Oa7DQ5ZXRWBPXOK5FR8uOBXZ+Dk80c9MdKAL10jSTAE4HcmqdywO0I3HIwa1dRjKJIx78CsOYHeoNADYQQzEkfL1xT2+Zc5Oeo96iGRCxUYJ4+tKpOEHfBoAoXDFBufGW6ViapjytxJLE1u3i/IXI4ArmdTmJbYOgoAxro/N9KzP2hf+Qt4P8A+xZs/wD0KStC5bBNZ/7Qgzq3g7/sWbP/ANCkpMGeVE5pKKQ0hF+0GIwe9asYwAB0rOgB2qO9akf3qY9ixCMyj2rV0xWN5FjJOaq6XaGdmbkAda6W2tBGySdxyKYLY6jwz4duPEWqCxtp7eGdkZl85iA2OoGAecZP4GtfxR8OtR8O6HJqF/dWDJGwXbHI5ZiTgAAqB79e1cxomp3Ok6va39uSZYJFk2n+L1H4jivTPjV4gg1C10iytHLwSxC9JB7MMJn3xu/OgDwWHJuZDjIyaJFaM7o+SxqwyrG7Lg5z+NN2jj26U7DsLaXBhuy6ncCuSPU1rQyz3bZUhUHQtWRjGABjnoK3LQbIEVBnIwpx09aQiyLNG/jOar3EE8cbNC+VHOO9attEWi+fA9GzUU8LJ5i4ycHpzQBzbMWJJOSa1fD0QkuW3jKhGP6VlyKQxGOAa2NFYqUTGGbg0rAXbZQjAAAnOMetW5VWRcINpUA8CoUQksARwcAHrV61hY4AIz/nrTAztYCTRQSLwyjYff3rPtYQ0gJ7Vqa0MQKB/fqhbnAPr1FAHcsDLsUDCpEBgcmp4IysbZyAcYBWq2iB7q1V0PzqArEfpWjtAyHAFAypcQYGVz9BWBrchkUKw4HTiuyKARBVOS3tXG63GzXWxRnHpQIXw9Zo0vnzgYHCg9Ca6W7sRiNowBnqRVfTLMBIY8BAo5Y1twLG8DR5JKnHHcUAY91axlYioy4PJArU0a03SR9Wj5470t5ETCM5wOgHatnw1EyJk856YHWmxnW6FZpGN+3AXhRWjqH/AB7sM9eKdZEGBflCnriq+qO23btGzBJpCOC8QJiZkfIQ8kg965SeMoHUAFRyK7LXYts6R4Mm45YjsOtcleKpkd1U7M4JOe9AGLdOckAAMehB6iuN8TSMYZEY5A6Cu4mjKowdAzqDyB2FcB4gOVkbjmgDi7jiU4oouf8AWmigGa94MTN9aIe9F9/rmoh6NQC3LK9RVy3XMgyOlUkNXrYc8elAkXYxkk+nOKlK5XHT2pkH3quIu4Ej8KBlBkIHNR1elU55qoRhj9aAGVagHyD2qDvVqy+Z2B7jNAGjbrxz2GasSruhkx2GajgG4ZI6cCrTkCzmHTigDCXpWvp0e7TnbsGxWVGu7jvXQ6VFnSnbHIbtQA20UE/NUWsKBdDH92r9lGPO7Adaq68mLkn0AoAy1XJwBzXRaVCRpwPXmsONfl5PWuq0yMf2Uvc56UAPsV+YbuKzPEgIv/bFb1lHllFYviNMXpz6UAY2PzoYZxxTiDUiIDGxPWgCEYrufh/GHjkJ5wa4ooemK9D+H0RFnI4HU9KALWuITIduPTmuelBGeORwTXT623z8nGKwX3MSTtXJ9KAM5VzgZxUrR7nJXGAAcU4qpfgEnGasLGC2CPl280Ac7rUwjiKjqTj6Vy855Ga2tel8y7YKSQvFYlx0HNAGZd96p/tBEf2n4O+XJ/4Rmz5/4FJVm5PX61V/aC/5Cng7n/mWbP8A9CkoYM8opU5YDsaSnwLukANShGraffH0rQtwXwoGSTjis+15cYrTt38t0cfwnPFUO51unxi3VIlwc9SR1rctIGkIEaiQ/wAXtWRp9xb3ARsnceTk1rPqsdkgitiDMwz8p5FAF59LmdVYRBSeMZqtcPtkCXAJZAFGTnA9PpWZPPe3I3SSH86Y13JGFEyMV9jzQAzVIkyX4LZ7VQXmp7ucTNwCoqGPG75uAaLjFTBrotKh/wCJW8jDJ3jZ9O9YBQKeK6CxlDWwRWwCoJz7elLqIuq4ZY0CfKe+OtK+5XDH5TuwPce9Oso8fMQfarhjDKwcjn1pgczqVusV220Kd3zccj6VFA7QyLIM5Vs8Vb1EbZFXv3qnTSGjq0VCiyoMowB3dwT2qxauFc9MHjNVNJO/RFOD8rbSfSptOybjGcknGRSEV/E0e2OFiBluRWdAAItwH51teK42WS3DEnjvWREoYMCOPYUAdF4LumFzLavjy5lO0nsRW5IpSVkLKcdhXJ+HlxrFoOeXH5V2F+oi1B4xyCMimhlnTk3ls8Dpiua1jbHrr8YVcZXpiut0VPMdQoGT3Ncd4nVl1mc8k9MdKQGykgDx/wC30ArUt5o1Qxg8E9MVylheoIAJByvrWxZajayeWMgEdSTyKBG3PGj267CRuPX09q2PDOG325PUgg+lc8t2L19qklI/utjGa3tDt5BPvXACfMWoGdxEBvID5AwMDtisnU52ZpoyMKc9TTTqscdnvdtsr9yKw77U47iRkjYooByf7xoAzNVuFa7ib5iFfZ8p6cVzV9KATGpOGfIPpitq5dArkgKoGce9Y91CSHI/iAI2+lAGTqkzJE3LEE4OT0Arz3X5g/mAdBXZa3MzhlDE4OM1wmuZWPB5Pc+tAjlbw/vfwoptwxMhooA3L05maiHoaW9GJW+tJD3oBblhemK0LTjP5VQXt9auQttbnpQCNKEqDxV6EoRx1ArNhxvBzx2q9CBzn14oAWZC2T6VQcYdvrWvsLjp25rJkB8xs+tAAgy3tVvT1C3KjrmoEGBgVd0tc30Q9TQBft4z5ZHYc1bijJhkU8DBqUwFWZR61ZihJjc4wB+tAHLquM4611Wlw40QHHJJNc8Y8yOOmCa6+xjxokA9qAKtjFiUYHFUdejxfHOcHtW3p0R3uSe3FZXiBf8ASyaAMpV4wB+FdlpkQ/s1MDHFckiE47V3enQ40mPI5wKAEsYyCxI4xWD4kH+mDPTFdRZrhMNxuNc54kGbpfl6jtQBglFOM/nSx4Ckds1KU4BprIEOB35oAQD9a9N8Bw7NDV/7xJ/WvN40LHAyfpXrugwi10KFeg8vdQBi64wMrDPWsK4k2kAdq0tRYSTMRnk8k1mMuMhvXvQBEgYuSoHJ6+tXZP3drI5XtVePAcGna6/laZKc4LDANAHB3j+ZK59Tms65OPwq9MecDHrWfcHOelAGXcjKs3GAemeeaqftBN/xM/Bo7f8ACM2Z/wDHpKmuzyag/aB/5Cfgz/sWLL/0KSkxM8rqW2H7zPYCoqmtfvn6UkBq2hwxxV6PhcVStuN/0q6gyAM8niq6Dexo2ztEqlDg4re0mHCmZ8l25yawFHAH4V0tmSbSIpyMYxTA04kAj34B781HPbtLBnAIP6VLaHB2tgnGBVtG2k8DB9aQHLMmDtOcilAGK0NWt1ilV4s7W6j0rPBzSYmPjTeQBgHOK0tHfDtEyjpgfWs6HO8ADLE9c9q0duyUHv1oQI6SxC7F3fjVyFTISFIx9M4qpHCyIknAVwOBV+xcCVVOQ+ccUxnPeI4gl+EXsi5rIYEHGK6LxfCy6yVOBlRg5rCYAMQW5FAXsdb4bKDw9cl0LMGBHp0qOxB+1gAAHPGO9afh6EDwlOynkvj61U05cXYyM4NAD/F8beTauRyRjJrn4GKo+BnntXXeKxnTYMjBBzXMQD904xnJ4oAueHuNTtyByJBj867vXYTHckoACwGTXE6JGf7Ss8ABt4GB616P4kiMTws2PmUZ4oAb4cA8xTjsce1cV4tXbrs/GS2MntXceG0xLgD+GuN8dRldbdkOB6nvQBzkynyzzgD070to20nd8wPT2qVlzg5z60wHjGfwoA6jwfIJLxos/ISMLXplvalEUIpCN94ivLfA0YbWY1VsE5IH0r2qJNmnfLnnrQBxviCQCVVQYCg4zWBAWLuzEY7j1PatnXN3m7nOdvAB61iKsnmdBgkdKAHI6zqySDbuyDiqVz/q26gqNv5VPHCyXCIMnc+QfWm6jEzNKxOAWKgDvg0AcXqieSHzICDziuD1mYSsQBxnrXWeKrvy5fKQfMeTx2rib9+MA8cmgDBuRulJzj6UUyRvm5BJooA6K+/1rUkPQ06+/wBa3402HoaAW5YHUetW14NVFPQirS880Ai5aNh9p71qW/PXoKyIflIbHIragXkFe54oAu2i5bjk9/asm6Qx3jrx1zWxbg7xkYyelVtbhCzqf+A0AZ45NXtKGb6EjswqmgIYcfhWnpSg6hAMfxChgdPPH+8OBjPJNSxxfuCwPBqa5UCVs881YghBh4xg0AcUVIkYEc7jXawwlNJhB7AVyMiZvGH+3j9a7uVCunRjpwKAIbCEBTmud1vDXrrgcetdXZoGQZ/OuX1gZv5Bjv1oApQLllBr0GGIJpsfHB7fhXD20WZowOpIBxXok0YWyjA6gUAU7deDn6VzniBMXQA9K6yzT5N2OBXNa+ubgD2oAwiuSKg25fnvWhswhGBn1oSAZBI+lADtNtiZ4gfmJYZH416jqLfZ9MKrx8oUe1cL4Wg+0a1CoGVQ7j712PiJyYkQeuTQBzVwCFyTyaoycOcDPH5VemDYJIGO1U9rb8nsetAEcS/OAelVvFsmLVEJ5OOKvoAJM849KxPFUm4xLnkc0AcrMQWOKzrrhT9a0ZxhiR+NZl2eTQBkXh+8ai/aA/5CXgz/ALFiy/nJTrs/KTTfj/zqHgs/9SvZfzkpMTPLKsWf32+g/nVerFn99voKSA1Lb+KrqnC5BwcVStej/WrqAEDPSq6D6F+PJ2jqSK69IwIIAqBSEHSuThxuQ44rrbe4ASMqAdwwCaB3LtrGcjoWPQVaKMvXqOOaitJm2ghQCOhxU+5inzZIBzQIoX6s9u23ORzWIwAOOhrp7qMrbysD8oXNc+6qUbb2OOnWgTI4F3EkHBFW4mIGSc1XhQEEjgg9aspyc4/KhDWx20BVNHtpH5LRDj3ptg37xCMZU5+tTzRk+GtPdhsJjxiq2lwt5oVTkHvQA3xrGJLmCVcEsOa53y1HBOee/auz8V2oXTreTIOM4xXJlMtzigDutDgH/CKk54OTj+tVNKiX7SgOPmOc1v6HCG8LOpOBs5I+tZVhGouSEBYKQBQBY8WW4XTYztzjrXJRDKYGdv0rvfGMZ/slTnbkA1w0LEqc9+OuKALuioPt9tjgrKDXp3iW38wWpK7soK4DQogdUtFHQyDNepa7BlbcpuO1cHNMZm+HLVlkdwCoAxiuL8fQhNSRj1Oa9H0KIh5FGCcZri/iPb/6XERg9RmkI4RuDj14prKAAABu9fWpZIyhGR71E6nORkUAdN4AhJ1qNs8gHgjrXtqrttgo7LxXi/w5glOtLIG6D1zXtMjbISxGCBQBwOuW5WR1OT3NYQVlG1WO08AdcV2OtqogJGdx55NcrIpOM845pjIY1USIFOGAHJ7c1JqkYSB2Y7VXcQR6nmpokzKjKoPIpnjYi28OSnhXOTmkI8R1yYzXkj5yCSc/0rnNQPzH2FbF22+Rgeg6H1rDv2+/27UAYN05Diior1sSCigDq538za/qMmiHv60z/lkmadB96gCyvSrS9uaqr0q1H0WgEWIR1NdDpuWtgc57fSufiA5PvXRaAd8MiAZIOaANG0QllJ54603XIP3JI7YNWoYsPGOQPWrOpQ/6M49RQBySrkjmtPSVzqNv/viqIQD/ABrU0SMnULdv9oUAdneQfvfqeKsxR/uTjqKkuk+YVNbr/oz4/GgDhlQNqoBHG/8ArXbXS4gjU+lcrYx+ZrYH/TQ11+oKBsB6gUAOs4wIT6YrktTX/T5ewBrtLQD7I4I5FclqCg3cwOetAEWlxb7+EY4LCvQrpP3KgdhXF+Hoi2pxDrzn6V3N6uAATyRQBFbxn7K3oa5LxAuLwAeldpEAtt1rkvESg3gAznHNAGPEm4t6CiYBFA/iP6VPAoXk96ilQ7+SSSe1AHSeA7cm4nnPRRtFamtPvkYg5xxT/DdsbLRQTw0nzHNVrjLuenqM8UAZjqCPeq7oV6nrV6QHuD1qtcDAzQBVUjzMDsK5rxFJvvSF6AYrpiAMscjiuR1JhJPI49eKAMe4PzH0xWTdkBTjpWpOeW9Kx708UAZF43ykUvx+/wCP/wAFf9ivZfzkqC+brU/x+/4//BX/AGK9l/OSkwZ5bVm0HXHXNVqt2gwM+ppISNG24D/hVxcbPfFVLcfIfc1cX7tV0DoXkzsXPXFaum3RiZEckx9vasi3fcg9V61bUhSCegOTTKO4tGHlEE8j9c1MGctluB+lQaMwn04ODygCkVZBI3AHA70hGgkXnWcw6nZxxXJso+YDvXZ6WCwKk5O0ZHrkVyl1F5N08TdQxBpoCuihQFUdqlAKjIpdoBOKcOopNg2enQWwuPBdkSpLBcVl6dC5l2qMHdgsO9dTosW3wRCuQTtHP1rK0uFhd7cHBagBnjG22aPGM5IYflXDgZPSvTfGMe/SWBGNp/HpXnYi2zIq85bPTnFAHqOhxb/DDKMhvLHas7SYF+1qz/3ua6DRYguisMHBjxVOwtxHfKAuQGoAb41h/wCJfjAC4BGa4OGNQOxYHn2Nej+NV3WTA5wMVwCptHAwaYzS8PKW1m0x1DivWdSjzBDkexrzLwpEG1iFufl/KvVNQUNbRgj5uopCKmiD99IOCPeuP+I6AyROF55FdtpEeyVyTxiuY+IUAaFSGxhu4pgeaNFuc7icelCQrJ8qoM9PerBTLYP3s9K0rK2WOJ5JBt4+9/SjQDoPhtZMl5JK8fy5wK9IvMmBgOp965nwHblbESFcBua3b2TLkDOAMUgOW1Vd7srk7gOmKxzAwjOcZJwK27+IieRt554wR1rOuAxK/wAKgYwO9OwEFrGjSKOS+QPpzWP8XZWg02OIHlmwfpW/okRe5ZXOOQBjuRXHfGW4Y3dvGOV2kn60gPJbrh2+tYGpkZb61vXn3+1c7qPOSeuaAOd1CQibAoqtfEmc0UCudyxzGlLD96mYxGlOg+/QMtr92rMIAxjpVVelW4+goAtRcqtdB4X4umUdxmsCEfKOK2/DZ26gnvkUAdOqnzORyDmrrxmWCQEdAeKJIthye47VftIRJHIc8laAOBVcFkZedxxWpoS51O3H+0Kr3KGO8lBHRzg1f0AY1W3OO9AHeXSfKDnrxU9lGDA49elE6fu1ycc5qeyT924z78UAcjpUJPiIgjoxNdHqKZl9qpaRbga5cuRnaa0brc8pJ6ZoANPH7uQZNcxqCgX8vYZrsLGPhvTH51yuqoRqMoxyDQBe8LQH7dvI4FdfeLnr+FYPhGL5nbHHFdDOAx6dKAEVMQMD0x1rj9ez9q/Cu3VP3GAO1cZrybrvigDJQFsYHFWdOtDd30ceOAcmnRoFHHGBXR+GbIIGmYctzzQBrXQEdsqLwoGKyHAwMg7m9a2LpC5Pp2PpWZcxnnByRQBmyEZGQeO9VLhD15q7OTnAGRnrVZ1O3kcmgDPuPlikPpXG3RLbj2Jrr9Vk2Wkg9eK464zigDMuCSGzWLfHrW1dcZ71hX5oAw7s5fFXPj9/x/8Agr/sV7L+clULg5krQ+Pgzf8Agr/sV7L+clJgeWDqKt2nT8aqd6t2n3fxoQkadt9w1bX7oqpb/wCr/Gra/doewdC1AuADjB9at5GBj+VVIG3DAGMdTVpOVxnGafQGdn4MkWW3uIQDkDcD9KvtlSQwOazPAh26osYGQ6Gt2/hAnZlHVsYoGaGk4JQjOfX1rH8U25h1QsAQrjJrZ0XO9CRjpxTPG8RPkyjpkjgUActEgfOTjFWFjC44B/rUVtyxGOoq3EoZlHvihArHsmlxIPCOw8kIOvasbTIcXK4Yna2frXS2FtjwttzxtGaydOi3TAAAemKAJ/GMIOjOxU5IrzWBM3UWOcsMfnXrHjOPZobBuWCc15rpMQn1ODKg8g4oA9T04bNFkJ4OKz9NXfqahuPm/CtllEWjsD95uAaq6RADdRs543dAKAIfGa/6BISeh5NeeKucY7CvSvHEeNNcH1Ga87aIqqlM5zzmgZ0PgiINrMRPXnINelakv7uNgSCprhvAUG/UjLjOxQc/Wu/vVLRDHY0CI9PUbWfua53x+mbEcg85xiuptV2QgVg+NIw+nMeMjmgDze1tfMlJVRgfM2fSpLpgZFhHCswO0Vctl8uHqAOrZpNHtzfazAFUn5wT7Cncdz0vQYPs2lwpjHy55pt/li+35QB19atXEvkRqg5OKznd2hYtuCkkZx14pBYw7kEzsxZyvGMdc4rMuCRv4ycZOa25Y8yI2/A4P14rOnCSvkgAdzQINGBjljZucZIH4V5n8VLlZ9YUDqq9K9Os124MZBdc8HoR614949kEuv3BGCBxnNAHF3JBZjjFc1qR49+eK6O9x8xBB4zXLaocIxJ7UAcvM4Mzn1opj/MxJ9aKm5J6AeIo/pREcODVKTVtN8tANQszgf8APZf8aauraduH/EwtP+/y/wCNUUba1aQ8Cs+zuYLpGktZopkBxujcMAfTitCL7o+lAFyHoK2dC41CDPXNY0Q+XPStjRzi/gJ9aAO9YbkVmHA54q/p+CTxgYqBVzCD1q3YLyMjGQaAOQ1uIR6lKAOCc1Y0Bf8AiZ24x/FVvxPEEvEbGdw60zw+oOpQ+ueOKAO7vBiNcdetTaf9xlbGccU+SPco44PSltU2OFzyaAKdlAYbud8DLUTD94xHTpWrcxhGVugI7Cs9oiQQBkk0AWtNQeWR3xn61z2q2+NQlLfMeuBXS2cPluATwf1rI16AtqajOFfHOO9AGh4ciEVvnpxWnI2DtK5+tRabHst6kb5wCARzigCxFyg4x7Vz+oWSS37ZJPHTtXRKPlxWFq5Auyu7AA5xQBRTTx5iAgE55rpbWFYoQijB71U063yBIw57AnpWkBgUAMZO4zWZcjDswAwa1mGRWfMv3gR70AYsgO4g5znmqkoIyDkCtSaPgnoOn1qhdKNgOCPrQBz2vHbCi55NctP90/Wuj8QMfNX0Arm7jpmgDJvDjPNYF+3X8a377qa5y/b72OKAMaTlya0fj9/x/wDgsf8AUr2X85Kz8kk8Ve/aBlij1HwWJJEQ/wDCL2XDMB3kpMTPL6t2v3fxNZ/2mD/ntF/32KuWVxC5CJNGzEnChgSaECNe1+6c1aXpVW15Q/WrS9KOgdCa2J8zGeKvpzx6mqVqBvJzzjpV6BvmHHQ0dA6HV+DpRFr1oe2cfnXa6lbBJJJCOA3FcDoJ26xa46+YuPzr1TXozJGm0AYxu461QzNsFMRXvuxg96teMrYHSXfoAV6UlmFe4WMZwBx7VteKLYNocwBBA+bP0pDPLrdcYIzyOh7VoWKbrmGPGCzDNVV6jP51qaKoOq2wPPzjpQI9v0uMjw7I20fdrK0yAGdAvrkmuhsIidCYKOdvH5VkaSgS4Ckck4oGL47G3R5vTH51574Wg3auhABHb6V6d46j/wCJNMcDha4XwTEZdRBIyMCnYDv9Si2aUh6cgCofD+5pwvpzVzWsi0ijVgQeQKpaPm3uUIOdxwfagCLxwubJieBmvPYm3R859K9N8bQ7tNc/Q9OtechBsBUHGaLgdh8OVP2m7OeABmu5lAK81ynw8i22dxJjlmA/KutNIQKMCsfxNGHsn46KeTWzWdr4B02U+1AHl+ots2qP4uuK6HwFafv3unPyKMA1kNbm6kRFHfjiu7tbQWGkxRRAKTyfemMmkmM8rHB2dAMc1Wlk+6rcqc8VZjDx4k4weKosWLKM7SpI+bpRsAixFoy20Yzx9Ky7hQDgrjnv3BrcimKR4kIyAcis+XGM7R68ikIz7UlDINpwq8eprxDxI+/V7s88yN1+teyXU7RwzOSQAp7+1eKaqweVi3Ukk0Ac7qOPnxheO3SuS1p8RtnHTFdVqJ4fHrXH643yH2oA56iiipJOf0jT7jVtVs9OsU8y7u5kghT+87MFA/Miu1+MXw0u/hprNlZz38Wo213C0kd1FHsXcrlXTGTypAzz/EKqfB/xJo/hDx1Z69r1tdXUNikkkENuisWn2kJu3MMKMk5GTkDiuj8ffFCx8dfDu303VtJjsvEFlqUl1bSWERFuYpfmlDF5GcMzkscZBwOnNUUUvhn/AMgOf/r5b/0Fa7aIfKtcT8M/+QHcH/p5b/0Fa7ePotAF2EYQA1raawW7iI/vCsiL7grVsRieM/7QoA9PtFzB/wABzVm0GZFPamaYm+1B/wBnFWbddpUUAZfiy3JWOUYODis7QEI1SDHA3V0uuwCXTnwM4wwFYOgLm/RsgBfWgD0CIDZ/wKmE7JgfelbKAbScHkU4xksrHjPUUAS6jh7PdzkVQVSSvXI5FaUgBt2XPPTNVo4GUhgNw65oGWFUhgT6Uk1ut2VZuCPu+1TSAiPcOMVJbr8intQIcgEceGPA4p+B2xj0pHAdSMc0Iu3igB1c5rwJv9vqAa6Ss3UbcPcwy7ScZBoAu267IUHfAqWo45EZAVIxT85oAWopohIuBxUtFAGXcWpUcdD2rJvVIHzAjHXNdLMrkErz7Vl3KBmKtnJ9aAOC1sBtrY4GRXOXPCmuo8Q4WXyh1Xk49a5q54zwCKAMO+/irmtR4D1018OtcvqZwGoAyhVb9pr/AJDfgj/sVLH/ANClqz689OtVv2mf+Q14I/7FSx/9ClpAW5vgQiubOHxVAdWOlDVhBLYSJF5e3OGmyVXv1ryHQf8AkLQf8C/9BNfRD/Hfw0t3Y3pbxVdQ22mLZPoUscAsLlwhUtJl2OOc52/wj6V886MwfWo2ChAzMQq9BweBTA7e3/1Y9yatL90VWtz+7+hqyOKTDoWbQDLHHPrmrsIBKg9zVS1A257k1ftgNy5Pemtg6G3o2RqdrjO4SDr9a9ovIGmsVPJxzn8K8W0n/kIWxwM+Yv8AOveHP/EoJAA+XNAzlrYbbqMqOQeT7V2Ot2/m6A7Z5eLOMdDXNIqKd/B7V210DLocS42kRdvQ0AeHooGQw5zW74chV9VtiBjDA1lOmbqRM9HP866HwohfWYRjkc0CPbbH5dKI6/L0H0rJtY8XisvGSMn0rZtwE0tm7bfyrLsmDzocdGxmgCTxxGD4fuDuxhe1cv8AD+1AiaVscniuy8XLu0C6x/drI8E25jtIywAGM89qANXVsbU24O3jNUdPRRdocHls81evlyilnBDE4o0yENMpI6HOadx3JPE6B9Lkz2HFebmICMrzgHt1r07xAu/SpxjtXnMWJPlY7R60Ajs/AkezSGPrIa6Ssvw1CINHhUHOctn6mtSkIKralEJrKVT/AHSRVmkYBlIYZB4IoA5fwppoEjXUgBYZArblUS3BjboBwRVuKJIkCRKFUdAKasQEpfGWPWgCpLDmMBhjbngVQmQ5UKOpznHpW44JDAAc1XeIugUEAr2x3p7jMiVDC3OCDyfrVW5Ul32nAOevNa7rtDYYYJ79ayb4MsbjIO4dB1oEc14gf7PoV1KeWAKgfpXit7kyHkn2r2HxzIbfQsLIfm+U5rx+9JON3SkBzmotwcdCfriuM1tuWHWuv1M4TA4GTXGaqThs9RQBk0UUVIjlKKKKoZ6X8M/+QJP/ANfDf+grXbQ9FoooAuw/dFalr/rU+tFFAHrOi/8AHnH9Ksx/62iigC1ej/Qn/wCuZrl9E/16fSiigDu3Pyj6VJacvFnng0UUAWB/rT9KdD9wUUU0MfL/AKs/Wpk+6PpRRSEOpooooAdUco+Q0UUAJbgeX0FSDqaKKAA0tFFABWdf9H+lFFAHnWr83MmfWsG76n6UUUAYd5/HXLat1NFFAGJdOyyWoViA8hVgD94bW4PqKj/aYULrPgdVACjwpYgAdB80tFFZw3ZnH4meO1oaD/yFoP8AgX/oJoorQ0O5t/8AV/jVof0oopMXRFu2+5+NaFj940UUyuhtaV/x/wBr/wBdF/nXvkAzphz/AM86KKaA5mPknP8Atf0rvo/+QQP9yiikI8aYA31xkfxn+ddH4K/5C6UUUAe2ED+y24/hrH0j/j7x/t0UUAaHir/kA3X+7UHhMD7COO3+FFFA0Wr5Rs6D7zVDoxP2hufWiigRd1j/AJBtx/uGvMl+/RRT6D6HpWg/8gi2/wB2r9FFIQUUUUAFIPvGiigBaa33TRRQBmS8lyevrWRcf6xT3waKKfQZxvj/AJ0q3z715Jfff/OiihiZy+pfdH1NcZqn/LSiikBlHqaKKKgR/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On the AP view (panel A), two separate fracture lines can be seen (black arrows), indicating this is a comminuted fracture (ie, at least three fracture fragments). On the oblique view (panel B), the fracture fragment at the lateral base of the phalanx can be seen to include more than 25 percent of the joint surface, with a small step-off on the joint surface (white arrow). The presence of a step-off makes this fracture more prone to complications and referral should be considered. Note also the presence of calcified arteries between the first and second metatarsal: the patient is a diabetic with peripheral neuropathy, who did not realize she had broken her toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39024=[""].join("\n");
var outline_f38_7_39024=null;
var title_f38_7_39025="Koilonychia 2";
var content_f38_7_39025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Koilonychia (spoon nail) associated with iron deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39025=[""].join("\n");
var outline_f38_7_39025=null;
var title_f38_7_39026="MRI in normal versus SpA";
var content_f38_7_39026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Comparison of magnetic resonance imaging findings in a normal subject and in a spondyloarthritis patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a STIR sequence. Bone edema is seen in the SpA but not in the normal subject. Bone edema indicated by arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Herne, Germany.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39026=[""].join("\n");
var outline_f38_7_39026=null;
var title_f38_7_39027="Prenatal ultrasound image of jejunal atresia";
var content_f38_7_39027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of jejunal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) T2w coronal magnetic resonance image at 33 weeks of gestation shows a single high signal dilated loop of bowel in the mid abdomen.",
"    <br>",
"     (B) T1w coronal magnetic resonance image shows the dilated loop is low signal. The distal bowel was collapsed with normal appearing meconium in the colon and rectum.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Dorothy I Bulas, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39027=[""].join("\n");
var outline_f38_7_39027=null;
var title_f38_7_39028="Arachnoid cyst";
var content_f38_7_39028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 635px\">",
"   <div class=\"ttl\">",
"    Arachnoid cyst at 26 postmenstrual weeks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 615px; height: 185px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A, axial section showing the sonolucent defect (arrow), which does not communicate with the ventricles. Panels B and C are transvaginal scans. Panel B is a coronal section showing the cyst (arrow), which pushes the brain parenchyma to one side. However, there is no hydrocephaly. Panel C, more precisely shows the location of the cyst, which is in the quadrigeminal cistern, just inferior and posterior to the corpus callosum. No hydrocephaly is evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39028=[""].join("\n");
var outline_f38_7_39028=null;
var title_f38_7_39029="Sulfadiazine: Pediatric drug information";
var content_f38_7_39029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfadiazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"    see \"Sulfadiazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/25/43412?source=see_link\">",
"    see \"Sulfadiazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Sulfonamide Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Congenital toxoplasmosis:",
"     </b>",
"     100 mg/kg/day divided every 12 hours for 12 months in conjunction with pyrimethamine and supplemental leucovorin (CDC, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Consult pyrimethamine monograph for additional dosing information.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"      see \"Sulfadiazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Manufacturer&rsquo;s recommendation: Infants &ge;2 months and Children: Initial: 75 mg/kg/dose or 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once followed by maintenance: 150 mg/kg/day or 4000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 4-6 hours; maximum dose: 6000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Toxoplasmosis",
"     </b>",
"     (CDC, 2009):",
"     <b>",
"      Note:",
"     </b>",
"     Consult pyrimethamine monograph for additional dosing information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Congenital: Infants: 100 mg/kg/day divided every 12 hours for 12 months in conjunction with pyrimethamine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Acquired: Infants &ge;2 months and Children: 100-200 mg/kg/day divided every 6 hours in conjunction with pyrimethamine (maximum dose: 6000 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Secondary prophylaxis (HIV-exposed/-positive): 85-120 mg/kg/day divided every 6-12 hours (maximum: 4000 mg/day) in conjunction with pyrimethamine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rheumatic fever prophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &le;30 kg: 500 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;30 kg: 1000 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing guidelines:",
"     </b>",
"     Oral: 2000-4000 mg/day in 3-6 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Toxoplasma gondii",
"      </i>",
"      encephalitis (HIV-exposed/-positive patients):",
"     </b>",
"     To be used in conjunction with pyrimethamine (CDC, 2009);",
"     <b>",
"      Note:",
"     </b>",
"     Consult pyrimethamine monograph for additional dosing information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Acute therapy: Duration of treatment &ge;6 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;60 kg: 1000 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &ge;60 kg: 1500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Secondary prophylaxis/chronic maintenance therapy: 2000-4000 mg/day in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rheumatic fever prophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;30 kg: 500 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;30 kg: 1000 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with water on an empty stomach",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment in toxoplasmosis with pyrimethamine [FDA approved in ages &ge;2 months and adults (may be used in ages &lt;2 months for treatment of congenital toxoplasmosis)]; treatment of urinary tract infections; nocardiosis (not first line); rheumatic fever prophylaxis in penicillin-allergic patient; uncomplicated attack of malaria due to chloroquine-resistant",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     (FDA approved in ages &ge;2 months and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       SulfADIAZINE may be confused with sulfaSALAzine, sulfiSOXAZOLE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F223807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Allergic myocarditis, periarteritis nodosa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, chills, convulsions, depression, fever, hallucinations, headache, insomnia, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Epidermal necrolysis, erythema multiforme, exfoliative dermatitis, photosensitivity, pruritus, purpura, rash, skin eruptions, Stevens-Johnson syndrome, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, thyroid function disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, pancreatitis, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Crystalluria, stone formation, toxic nephrosis with oliguria and anuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytopenia, aplastic anemia, hemolytic anemia, hypoprothrombinemia, leukopenia, methemoglobinemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, peripheral neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctival/scleral injection, periorbital edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, lupus erythematosus, serum sickness-like reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any sulfa drug or any component; porphyria; infants &lt;2 months of age due to competition with bilirubin for protein-binding sites (unless indicated for the treatment of congenital toxoplasmosis); pregnant women during third trimester and during the breast-feeding period",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired hepatic function or impaired renal function, urinary obstruction, blood dyscrasia, severe allergy or bronchial asthma, G-6-PD deficiency; dosage modification required in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13715394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities associated with sulfonamides, although rare, have occurred due to severe reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias; discontinue use at first sign of rash or any sign of adverse reaction, including sore throat, fever, arthralgia, pallor, purpura, jaundice, cough, shortness of breath, and pulmonary infiltrates. Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid); potential for crossreaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. In an established infection, sulfonamides do not eradicate streptococcus nor prevent sequelae, such as rheumatic fever, and should not be used for the treatment of group A beta-hemolytic streptococcal infection. Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Sulfa antibiotics have been shown to displace bilirubin from protein binding sites which may potentially lead to hyperbilirubinemia and kernicterus in neonates and young infants; do not use in neonates; avoid use in infants &lt;2 months unless other options are not available.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F223797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Sulfonamide Derivatives may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Sulfonamide Derivatives may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Sulfonamide Derivatives may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Sulfonamide Derivatives may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procaine: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Sulfonamide Derivatives may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonamide Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplemental leucovorin calcium should be administered to reverse symptoms or prevent problems due to folic acid deficiency; avoid large quantities of vitamin C or acidifying agents (cranberry juice) to prevent crystalluria",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8774446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies sulfadiazine as pregnancy category C. Sulfadiazine crosses the placenta. Available studies and case reports have failed to show an increased risk for congenital malformations after use. Sulfadiazine is indicated for use in children &lt;2 months of age for the treatment of congenital toxoplasmosis and may be used in pregnancy for the maternal treatment of",
"     <i>",
"      Toxoplasmic gondii",
"     </i>",
"     encephalitis and as an alternative agent for the secondary prevention of rheumatic fever. Because of the theoretical increased risk for hyperbilirubinemia and kernicterus, sulfadiazine is contraindicated by the manufacturer for use near term. Neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, renal function tests, urinalysis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Excreted in breast milk; diffuses into CSF with higher concentrations reached when meninges are inflamed; distributed into most body tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 32% to 56%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized by N-acetylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine as metabolites (15% to 40%) and as unchanged drug (43% to 60%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/25/43412?source=see_link\">",
"      see \"Sulfadiazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink plenty of fluids; limit alcohol; notify physician if rash, sore throat, fever, arthralgia, shortness of breath, or jaundice occurs. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F13225872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfadiazine plus pyrimethamine confers protection against",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     so additional PCP prophylaxis not required (CDC, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11448585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 200 mg/mL oral suspension may be made with sulfadiazine powder and sterile water. Place 50 g sulfadiazine powder in a glass mortar. Add small portions of sterile water and mix to a uniform paste; mix while incrementally adding sterile water to",
"     <b>",
"      almost",
"     </b>",
"     250 mL; transfer to a calibrated bottle, rinse mortar with sterile water, and add sufficient quantity of sterile water to make 250 mL. Label \"shake well\" and \"refrigerate\". Stable for 3 days refrigerated.",
"     <b>",
"      Note:",
"     </b>",
"     Suspension may also be prepared by crushing one-hundred 500 mg tablets; however, it is stable for only 2 days.",
"    </p>",
"    <div class=\"reference\">",
"     Pathmanathan U, Halgrain D, Chiadmi F, et al, \"Stability of Sulfadiazine Oral Liquids Prepared From Tablets and Powder,\"",
"     <i>",
"      J Pharm Pharm Sci",
"     </i>",
"     , 2004, 7(1):84-7.",
"     <span class=\"pubmed-id\">",
"      15144740",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39029/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frenkel JK, &ldquo;Toxoplasmosis,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1985, 32(4):917-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39029/abstract-text/3895139/pubmed\" id=\"3895139\" target=\"_blank\">",
"        3895139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmidt DR, Hogh B, Andersen O, et al, \"Treatment of Infants With Congenital Toxoplasmosis: Tolerability and Plasma Concentrations of Sulfadiazine and Pyrimethamine,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2006, 165(1):19-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39029/abstract-text/16133245/pubmed\" id=\"16133245\" target=\"_blank\">",
"        16133245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12814 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-947418B5B9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39029=[""].join("\n");
var outline_f38_7_39029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050008\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445119\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050001\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223759\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223745\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050011\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050004\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050010\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223809\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223807\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050015\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050000\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13715394\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223797\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223754\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050017\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223756\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774446\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050007\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049999\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050014\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050006\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225872\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11448585\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12814\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12814|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=related_link\">",
"      Sulfadiazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/25/43412?source=related_link\">",
"      Sulfadiazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_7_39030="Wrist ligaments";
var content_f38_7_39030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Ligaments of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure shows the volar surface of the wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39030=[""].join("\n");
var outline_f38_7_39030=null;
var title_f38_7_39031="Cilazapril: Drug information";
var content_f38_7_39031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cilazapril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/62/8165?source=see_link\">",
"    see \"Cilazapril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cilazapril&reg;;",
"     </li>",
"     <li>",
"      CO Cilazapril;",
"     </li>",
"     <li>",
"      Inhibace&reg;;",
"     </li>",
"     <li>",
"      Mylan-Cilazapril;",
"     </li>",
"     <li>",
"      Novo-Cilazapril;",
"     </li>",
"     <li>",
"      PHL-Cilazapril;",
"     </li>",
"     <li>",
"      PMS-Cilazapril",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F151399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F151367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 0.5 mg once daily; if tolerated, after 5 days increase to 1 mg/day (lowest maintenance dose); may increase to usual maximum of 2.5 mg once daily. (",
"     <b>",
"      Note:",
"     </b>",
"     Some additional benefit has been observed with doses up to 5 mg/day in a few patients.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 2.5 mg once daily; titrate to response at  intervals of at least 2 weeks. Usual dose: 2.5-5 mg once daily (maximum dose: 10 mg/day).",
"     <b>",
"      Note:",
"     </b>",
"     May administer total daily dose in 2 divided doses if antihypertensive effect diminishes over 24-hour dosing interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Combination therapy with diuretic:",
"     </i>",
"     Initial: 0.5 mg once daily; titrate slowly as tolerated",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F151368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 0.5 mg once daily; if tolerated, after 5 days increase to 1 mg/day (lowest maintenance dose); may increase to maximum of 2.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Elderly patients with heart failure on high diuretic dosage:",
"     </i>",
"     Do not initiate with doses &gt;0.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: &le;1.25 mg once daily; titrate slowly as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Combination therapy with diuretic:",
"     </i>",
"     Initial: 0.5 mg once daily; titrate slowly as tolerated",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F151369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Heart failure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;40 mL/minute: Initial 0.5 mg once daily (maximum dose: 2.5 mg once daily).",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer labeling does not define the estimated creatinine clearance value at which a dosage adjustment is not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-40 mL/minute: Initial: 0.25-0.5 mg once daily (maximum dose: 2.5 mg once daily).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 0.25-0.5 mg once or twice weekly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypertension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;40 mL/minute: Initial: 1 mg once daily (maximum dose: 5 mg once daily).",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer labeling does not define the estimated creatinine clearance value at which a dosage adjustment is not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-40 mL/minute: Initial: 0.5 mg once daily (maximum dose: 2.5 mg once daily).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 0.25-0.5 mg once or twice weekly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer on nondialysis days; titrate to response.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F151370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: &le;0.5 mg once daily (with caution)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhibace&reg;, Novo-Cilazapril: 1 mg, 2.5 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F151341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F151340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension; treatment of heart failure",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F151397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (up to 1%), hypotension (symptomatic, up to 1% in HF patients), orthostatic hypotension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 5%), dizziness (3% to 8%), fatigue (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (2% in hypertension, up to 8% in HF patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal vision, angina, angioedema, arrhythmia, atrial fibrillation, AV block, bradycardia, bronchospasm, cardiac decompensation, cardiac failure, cardiogenic shock, depression, dyspnea, extrasystoles, GI bleed, hemolytic anemia, hyperglycemia, hyperkalemia, MI, neutropenia, pancreatitis, paresthesia, rash, renal failure, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenic purpura, visual hallucinations (Doane, 2013), vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F151344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cilazapril, any other ACE inhibitor, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; ascites",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F151329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising the airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts.  Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers: Concurrent use of angiotensin receptor blockers may increase the risk of clinically-significant adverse events (eg, renal dysfunction, hyperkalemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diuretics: Concomitant use of diuretics may increase the risk of hypotension; initiate cilazapril with caution. The manufacturer recommends discontinuation of diuretic therapy 2-3 days prior to cilazapril initiation or initiation with a lower dose ; monitor closely for hypotension if concomitant therapy cannot be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [Canadian Boxed Warning]:  Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Contains lactose; avoid use in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F151359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Cilazapril serum concentrations may be decreased if taken with food (no apparent effect on activity). Long-term use of ACE inhibitors may result in a zinc deficiency which can result in a decrease in taste perception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice (may worsen hypertension). Avoid black cohosh, california poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F151347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [Canadian Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F151372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F151348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6155486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN, electrolytes, serum creatinine, LFT (at baseline and periodically thereafter in patients with pre-existing hepatic impairment), CBC with differential (in patients with renal impairment and/or collagen vascular disease); blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F151349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cilaril (IL);",
"     </li>",
"     <li>",
"      Cilazil (HR);",
"     </li>",
"     <li>",
"      Dynorm (DE);",
"     </li>",
"     <li>",
"      Inhibace (AR, AT, AU, BE, BG, CH, CL, CN, CO, CZ, EE, ES, FI, GR, HK, HN, HU, IT, JP, KP, NL, NZ, PE, PK, PL, PT, SE, SG, TR, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Inibace (LU);",
"     </li>",
"     <li>",
"      Inocar (ES);",
"     </li>",
"     <li>",
"      Justor (FR);",
"     </li>",
"     <li>",
"      Vascace (BR, GB, IE, PH);",
"     </li>",
"     <li>",
"      Zapril (NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F151328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cilazapril is a prodrug that is rapidly converted to cilazaprilat (active metabolite), a competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F151343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antihypertensive: ~1-2 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Therapeutic effect: Up to 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Cilazapril (prodrug) hydrolyzed to active metabolite (cilazaprilat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 57%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Cilazaprilat: Terminal: 36-49 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Cilazaprilat: Urine (53% unchanged)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doane J and Stults B, &ldquo;Visual Hallucinations Related to Angiotensin-Converting Enzyme Inhibitor Use: Case Reports and Review,&rdquo;",
"      <i>",
"       J Clin Hypertens (Greenwich)",
"      </i>",
"      , 2013 [epub ahead pf print].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dossegger L, Nielsen T, Preston C, et al, &ldquo;Heart Failure Therapy With Cilazapril: An Overview,&rdquo;",
"      <i>",
"       J Cardiovasc Pharmacol",
"      </i>",
"      , 1994, 24(Suppl 3):38-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, &ldquo;Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DR, Oliveria SA, Berlowitz DR, et al, &ldquo;Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2008, 51(6):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/18413488/pubmed\" id=\"18413488\" target=\"_blank\">",
"        18413488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/10587334/pubmed\" id=\"10587334\" target=\"_blank\">",
"        10587334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenthal JH, &ldquo;Therapeutic Experience With Cilazapril,&rdquo;",
"      <i>",
"       J Cardiovasc Pharmacol",
"      </i>",
"      , 1994, 24(Suppl2):65-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Song JC and White CM, &ldquo;Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors: An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2002, 41(3):207-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/11929321/pubmed\" id=\"11929321\" target=\"_blank\">",
"        11929321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/7/39031/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8715 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39031=[""].join("\n");
var outline_f38_7_39031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151363\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151399\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151367\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151368\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151369\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151370\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076208\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217376\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151341\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151340\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151397\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151344\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151329\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299043\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151333\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151359\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151347\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151372\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151348\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6155486\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151349\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151328\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151343\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8715\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8715|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/62/8165?source=related_link\">",
"      Cilazapril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_7_39032="Treatment and prevention of avian influenza";
var content_f38_7_39032=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of avian influenza",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/7/39032/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39032/contributors\">",
"     Iain Stephenson, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/7/39032/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39032/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/7/39032/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39032/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/7/39032/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been five influenza pandemics during the past 100 years, and each has been caused by the emergence of a novel virus. In the 1957 and 1968 pandemics, the new viruses contained components of previous human as well as avian influenza viruses. The origin of the influenza virus responsible for the 1918 pandemic, which killed more people in a single year than the bubonic plague, remains uncertain, but it appears to have been an adapted avian influenza strain. The emergence of a novel H1N1 human-swine-avian reassortant virus in 2009 in North America started a new pandemic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sporadic transmission of avian influenza H5N1 to more than 600 humans since 2003 has prompted concerns that conditions are suitable for emergence of the next pandemic; the case-fatality rate is approximately 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/1\">",
"     1",
"    </a>",
"    ]. Estimates of potential global mortality related to pandemic avian influenza are as high as 62 million deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and prevention of avian influenza will be reviewed here. The possible role of avian influenza vaccines, and the epidemiology, transmission, pathogenesis, clinical manifestations, and diagnosis of avian influenza are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=see_link\">",
"     \"Avian influenza vaccines\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=see_link\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22599?source=see_link\">",
"     \"Clinical manifestations and diagnosis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THERAPEUTIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classes of drugs are effective against influenza: adamantanes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    , also known as M2 ion channel inhibitors) and neuraminidase inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    ). H5N1 viruses isolated in Thailand and Vietnam have amino acid substitutions within the M2 protein that confer resistance to amantadine and rimantadine&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, these viruses are susceptible to the neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of a registry that included 308 human cases of H5N1 influenza from 12 countries suggested that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    was associated with a significant reduction in mortality (hazard ratio 0.51, 95% CI 0.34-0.77) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/6\">",
"     6",
"    </a>",
"    ]. The mortality benefit was greatest when treatment was started within the first two days following symptom onset, but some benefit persisted for up to six to eight days following symptom onset. In a later registry analysis, the case-fatality rate among patients who received treatment &le;2 days after symptom onset was 18 versus 63 percent for those receiving treatment later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/7\">",
"     7",
"    </a>",
"    ]. In this study, early initiation of oseltamivir was particularly effective in individuals without respiratory failure. Patients who required ventilatory support at the time of oseltamivir initiation were more likely to die from the episode of H5N1 influenza infection than patients who did not. In another study of H5N1 influenza infections in children, there was an increased risk of death for each day of delay in initiating oseltamivir (odds ratio 1.75, 95% CI 1.17-2.61) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal dose and duration of antiviral therapy for H5N1 influenza have not been established. In an animal study, mice were given various doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    four hours before inoculation with a H5N1 variant strain that had been isolated from a patient with fatal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/3\">",
"     3",
"    </a>",
"    ]. Mice who were treated for eight days had significantly improved survival rates in all dose ranges compared with animals that only received five days of treatment. Prior animal studies had demonstrated that five days of oseltamivir was effective against another H5N1 variant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the above study suggested that this specific avian strain may be more pathogenic than others previously tested and that virulence may be a factor in determining treatment duration and dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Experimental regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;An experimental treatment for H5N1 influenza that has been tested in mice involves the use of H5-specific monoclonal antibodies that are capable of broadly neutralizing a range of H5 influenza viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Monoclonal antibodies that can neutralize both avian and human influenza A viruses have also been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another experimental approach involves the use of nanobodies that target H5N1 hemagglutinin; nanobodies are single-domain immunoglobulins engineered from the antibodies of camelids composed only of heavy chains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/14\">",
"     14",
"    </a>",
"    ]. When administered intranasally to mice prior to a lethal challenge of H5N1 influenza virus, nanobodies derived from llamas reduced virus replication in the lungs and reduced morbidity and mortality. When given after a lethal challenge of H5N1 influenza, nanobody therapy reduced viral replication in the lungs and delayed the time to death.",
"   </p>",
"   <p>",
"    An approach that has been proposed for optimizing the use of limited supplies of antivirals during a pandemic involves combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    in order to reduce renal clearance of the former drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/15\">",
"     15",
"    </a>",
"    ]. In a pharmacokinetic study of oseltamivir prophylaxis in humans, alternate daily dosing of oseltamivir in combination with probenecid (four times a day) resulted in adequate trough concentrations of the active metabolite of oseltamivir to achieve neuraminidase inhibition in vitro.",
"   </p>",
"   <p>",
"    Another potential treatment strategy involves the use of an intravenous formulation of a neuraminidase inhibitor, such as peramivir or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    , but neither agent has been approved for the treatment of H5N1 influenza by the US Food and Drug Administration or other regulatory agencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other investigational agents for the treatment of influenza are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Investigational approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In March 2006, the World Health Organization (WHO) convened a panel of experts to develop guidelines for the treatment of avian influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/17\">",
"     17",
"    </a>",
"    ]. These guidelines were updated in August 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18\">",
"     18",
"    </a>",
"    ]. The following recommendations were based on small observational case series, data in animal models, and controlled trials of seasonal influenza:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with confirmed or highly suspected avian influenza, treatment should be initiated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      since it has proven benefit against human seasonal influenza infection and may decrease viral shedding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/17\">",
"       17",
"      </a>",
"      ]. Although the efficacy of oseltamivir for H5N1 influenza has not been assessed in clinical trials, limited data have suggested a possible mortality benefit when compared with no antiviral therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. In addition, some studies have suggested that early initiation of oseltamivir may prevent severe H5N1 influenza infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reduce mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/6,7,19,21,22\">",
"       6,7,19,21,22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Therapeutic agents'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The standard dosing and duration of oseltamivir is 75 mg twice daily for five days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/17\">",
"       17",
"      </a>",
"      ], but a higher dose of 150 mg twice daily and a longer duration of 10 days may be considered, especially in patients with pneumonia or clinical progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Oseltamivir should be administered as early as possible but should be initiated even in patients who present late because viral replication is more prolonged than with uncomplicated seasonal influenza (for which only early therapy is indicated) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18,23\">",
"       18,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      should not be used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Intravenous zanamivir and peramivir, which are both in clinical development, have been shown to have activity in animal models, including activity against",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      -resistant isolates, and are well tolerated in humans. Thus, these intravenous agents may be alternatives to oral oseltamivir for treatment of human influenza A (H5N1) infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adamantanes (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      ) should not be used as first-line therapy due to the high rate of resistance of H5N1 influenza to this class and the rapid emergence of resistance when used as monotherapy for seasonal influenza [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combination therapy with a neuraminidase inhibitor and an adamantane may be considered if infection occurs in a region where the isolate is likely to be adamantane-susceptible (eg, Clades 2.2 and 2.3, which have caused disease in parts of Asia) in a patient with pneumonia or clinical progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. All data on this approach should be collected prospectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High-dose glucocorticoids have not been shown to be beneficial and can result in serious harm in influenza A (H5N1) virus-infected patients, including secondary infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18\">",
"       18",
"      </a>",
"      ]. Thus, glucocorticoids should only be considered in patients with septic shock and suspected adrenal insufficiency requiring vasopressors.",
"     </li>",
"     <li>",
"      Antibiotic chemoprophylaxis should not be used, although patients with pneumonia should be treated initially according to published guidelines until a diagnosis is established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monitoring of oxygen saturation should be performed and supplemental oxygen provided to correct hypoxemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Therapy of avian influenza-associated acute respiratory distress syndrome should be based upon published guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=see_link\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=see_link\">",
"       \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance testing has been investigated for both M2 ion channel-blocking adamantanes and neuraminidase inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adamantane resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of genetic mutations associated with resistance to adamantane derivatives,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    , was studied in viral isolates from multiple countries in Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/25\">",
"     25",
"    </a>",
"    ]. More than 95 percent of the viruses from Vietnam, Thailand, and Cambodia contained a dual mutation (Leu26Ile-Ser31Asn) associated with amantadine resistance.",
"   </p>",
"   <p>",
"    However, resistant mutants were much less commonly isolated in Indonesia and China (6 to 8 percent of isolates). These results suggest that the dual mutant viruses may have been separately introduced and generated into this geographic region, apart from the rest of Asia. Furthermore,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    may retain some therapeutic efficacy in certain parts of Asia, in the event of a pandemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neuraminidase inhibitor resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two mechanisms of resistance against neuraminidase inhibitors have been described for influenza virus, which involve mutations in either the neuraminidase or the hemagglutinin genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    was predicted by structural analysis of the drug; the inhibitor molecules mimic the substrate of the influenza neuraminidase and bind to the active site, preventing neuraminidase from cleaving host-cell receptors and releasing progeny virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/30\">",
"     30",
"    </a>",
"    ]. Mutations in neuraminidase prevent molecular rearrangements in the virus that must occur for binding to oseltamivir leading to drug resistance; however,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    binding and drug activity are unaffected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link&amp;anchor=H2#H2\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Neuraminidase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    following treatment has been documented in H5N1 avian influenza infections in humans, both in children and adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H5N1 virus with an amino acid substitution in neuraminidase (H274Y) conferring high-level resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      was isolated from two of eight Vietnamese patients during treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/31\">",
"       31",
"      </a>",
"      ]. Both patients died of influenza infection despite early initiation of treatment in one patient. In the patients who survived, measurements of viral RNA in sequential throat specimens demonstrated rapid declines to undetectable levels; in contrast, viral RNA was still detectable at the completion of therapy in the two patients who died.",
"      <br/>",
"      <br/>",
"      These observations suggest that treatment with the recommended dosage of oseltamivir incompletely suppresses viral replication in a subset of patients and may be associated with clinical failure and development of drug resistance.",
"     </li>",
"     <li>",
"      The isolation of an H5N1 influenza virus resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      was demonstrated in a Vietnamese girl who had received prophylaxis for three days after diagnosis of H5N1 infection in her brother [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/32\">",
"       32",
"      </a>",
"      ]. Prophylactic doses were increased to therapeutic doses after the patient began to exhibit symptoms of disease and she subsequently recovered. Direct sequencing after amplification by PCR demonstrated a histidine to tyrosine substitution at position 274 of the neuraminidase protein. Additional investigation demonstrated that this resistant clone was identical to a clone found in the source patient.",
"      <br/>",
"      <br/>",
"      The timing of the infection in these two patients, and the lack of poultry exposure of the girl, suggests the possibility of human-to-human transmission. Vigilant surveillance for drug resistance will be needed for avian influenza cases. Additional studies in ferrets found zanamivir reduced viral titers of oseltamivir sensitive and resistant virus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher rates of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    resistance have been observed with seasonal influenza virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of avian influenza includes infection control measures, postexposure prophylaxis, and advice for travelers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infection control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;When avian influenza outbreaks occur in poultry, quarantine and depopulation (or culling) and surveillance around affected flocks is the preferred control and eradication option. For workers involved in control of poultry outbreaks of avian influenza, personal protective equipment should be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/33\">",
"     33",
"    </a>",
"    ]. This may include the use of gloves and gowns, frequent and thorough hand hygiene with soap and water or alcohol-based hand rubs, appropriate respiratory protection (N95 mask), antiviral prophylaxis (neuraminidase inhibitors), and vaccination with the seasonal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    to reduce the risk of coinfection and potential reassortment between avian and circulating human strains.",
"   </p>",
"   <p>",
"    For both hospitalized patients and those managed in the outpatient setting, isolation precautions similar to those used for SARS-infected patients should be implemented. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=see_link&amp;anchor=H23#H23\">",
"     \"Severe acute respiratory syndrome (SARS)\", section on 'Infection control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other precautionary measures that have been implemented include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 2004, the CDC and the Department of Agriculture issued an order for an immediate ban on the import of all birds and bird products from Southeast Asia.",
"     </li>",
"     <li>",
"      Specific policies have been established for the management of passengers who have a respiratory illness and are traveling from an area where avian influenza has been reported. The captain of the airliner is required by law to report the illness to the nearest US Quarantine Station prior to arrival, so that appropriate medical assistance and quarantine procedures can be implemented.",
"     </li>",
"     <li>",
"      An executive order was signed on April 3, 2005 authorizing the United States government to impose a quarantine in case of an outbreak of avian influenza.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the risk of transmission from person to person appears low, it has been suggested that social distancing measures may help reduce transmission rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/19\">",
"     19",
"    </a>",
"    ]. The World Health Organization has developed a protocol for containment of pandemic influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following measures have been proposed for improving infection control in the setting of an avian influenza outbreak in healthcare facilities in the developing world: improved health care administrative support, the development of practical surveillance strategies, the early involvement of specialists (eg, infectious diseases, pulmonary, and emergency medicine), and the creation of a temporary isolation ward during an epidemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Postexposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization recommends that household contacts of patients with avian influenza should receive postexposure prophylaxis with 75 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    once daily for seven to ten days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Individuals who have been exposed to a proven or potential case of avian influenza should monitor their temperature.",
"   </p>",
"   <p>",
"    The optimal dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    for prophylaxis of avian influenza has not been studied in humans. The recommendation above is based on studies of prophylaxis for seasonal influenza.",
"   </p>",
"   <p>",
"    In a study of 92 close contacts of a patient who acquired fatal H5N1 infection after visiting a poultry market, only the patient's father acquired infection; the father only began antivirals after developing symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/36\">",
"     36",
"    </a>",
"    ]. Eighty-six percent of the other contacts received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    prophylaxis and two developed mild illness, although both were found to be negative for H5N1 virus by reverse-transcriptase PCR. All close contacts (excluding the father of the index case) remained negative for H5N1 antibodies. One cannot conclude whether or not the recommended regimen of oseltamivir prophylaxis was beneficial based on this study, since only limited human-to-human transmission has been observed.",
"   </p>",
"   <p>",
"    In an animal model of avian influenza infection, higher dosing and more frequent administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    were more effective at preventing clinical and pathological signs of infection and reducing mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/37\">",
"     37",
"    </a>",
"    ]. Clinical trials will need to be done to assess the possible benefit of an increased dose or multiple daily doses of oseltamivir to prevent avian influenza.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Categories of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) has categorized individuals with potential exposure into various assignments of risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk &mdash; Household or family contacts of a documented or suspected case.",
"     </li>",
"     <li>",
"      Moderate risk &mdash; Personnel involved in handling sick animals or decontaminating affected environments without appropriate protection; individuals in contact with sick animals infected with avian influenza or implicated in human cases; health care workers with close exposure (eg, intubation) to a patient with diagnosed avian influenza or a suspected case; laboratory workers with unprotected exposure to a virus-containing sample.",
"     </li>",
"     <li>",
"      Low risk &mdash; Health care workers or animal workers who used protective equipment or who have no known exposures to H5N1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In high risk individuals,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    should be administered;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    can be considered as an alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/17\">",
"     17",
"    </a>",
"    ]. Adamantanes should not be administered as first-line prophylaxis unless neuraminidase inhibitors are not available and local sensitivity testing suggests susceptibility.",
"   </p>",
"   <p>",
"    In moderate risk individuals, prophylaxis can be considered. In low risk groups, prophylaxis is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Travel advice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers to countries where avian influenza is endemic in bird populations should avoid contact with poultry; this includes visits to markets where live birds are sold. Freezing and refrigeration do not substantially reduce the concentration or virulence of viruses in meat, so it is essential to follow safe food-handling procedures and to cook food thoroughly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention has not recommended that the general public avoid travel to any particular area with documented cases of avian influenza. Travelers can check the latest bulletins on the CDC website (",
"    <a class=\"external\" href=\"file://www.cdc.gov/travel\">",
"     www.cdc.gov/travel",
"    </a>",
"    ) prior to departure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of avian influenza vaccination in the prevention of infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=see_link\">",
"     \"Avian influenza vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PUBLIC HEALTH PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) and governments across the globe are actively preparing for the possibility of an H5N1 pandemic by investing in vaccine development, stockpiling neuraminidase inhibitor antiviral drugs, and planning for care of large numbers of ill persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strategies to combat H5N1 in poultry markets have included mass slaughter of birds during outbreaks, removal of ducks, geese and quail (species thought to introduce avian influenza viruses into poultry) and improvements in sanitation.",
"   </p>",
"   <p>",
"    The use of inactivated H5N1 vaccine in chickens is an additional strategy, but must be used with caution. Inactivated H5N2 and H5N3 vaccines prevent signs of infection with highly pathogenic avian influenza (HPAI) viruses and decrease virus shedding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/42\">",
"     42",
"    </a>",
"    ]. However, since standardization and potency testing of agricultural vaccines are not rigorous, the use of suboptimal or subpotent vaccines in birds that protect against clinical illness, but do not reduce virus shedding and excretion, may become a significant concern. The persistence of undetected H5 infection in a partially immune flock may accelerate virus evolution and pose threats to human health.",
"   </p>",
"   <p>",
"    Vaccine for widespread clinical use may not be available until six to eight months after the emergence of a novel virus, leaving influenza antiviral agents as a first response. Neuraminidase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    may be of benefit if given prophylactically to an exposed population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Postexposure prophylaxis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=see_link\">",
"     \"Avian influenza vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To curb pandemic influenza, unrealistic quantities of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    would have to be stockpiled, but realistic quantities could be used to protect workers in essential services while waiting for an effective vaccine.",
"   </p>",
"   <p>",
"    It has been suggested that mobile stockpiles of antivirals could be flown to the epicenter of an emerging pandemic in an attempt to limit spread, but this would require countries that are able to afford the purchase of a stockpile to share their drugs. National and international authorities are starting to stockpile antiviral drugs for use according to pandemic plans. We and others do not recommend prescribing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    on patient request for personal stockpiling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As rapid deployment of vaccine is critical to ameliorating the impact of the next pandemic, advanced production and vaccine stockpiling have been suggested to address manufacturing delays and shortfalls in production capacity. Several countries have purchased H5N1 vaccines for stockpiling. Another approach that has been proposed is pre-pandemic vaccination. Pre-pandemic stockpiling and vaccination are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=see_link&amp;anchor=H18#H18\">",
"     \"Avian influenza vaccines\", section on 'Pre-pandemic stockpiling and vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns have been expressed that resources will be concentrated in developed countries where vaccines and antiviral medications are owned and manufactured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This could have a devastating effect on resource-poor countries. Furthermore, improved surveillance in developing countries is important for early detection and containment of outbreaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Planning for a pandemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the event of a pandemic, three major interventions for controlling person-to-person transmission include use of vaccine, antiviral agents, and social distancing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. A model based on analysis of the 1918 influenza pandemic estimates that in the United States, one-third of transmissions will occur in the household, one-third in workplaces and schools, and one-third in the general community [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/51\">",
"     51",
"    </a>",
"    ]. Thus, an important containment strategy will target antiviral agents combined with school and business closings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/47,51-53\">",
"     47,51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether hospitals would be able to have the surge capacity to take care of the large numbers of sick patients is seriously questioned, since the average proportion of open beds currently is only about 5 percent. Plans to close this gap need to be addressed at the regional level by local providers and public health authorities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/40\">",
"     40",
"    </a>",
"    ]. Other identified needs include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clear guidelines for overriding standard procedures for confidentiality and patient consent in the interest of public health.",
"     </li>",
"     <li>",
"      Clear and fair infection control measures that do not create barriers to care.",
"     </li>",
"     <li>",
"      Planning for health care in alternative, non-hospital settings.",
"     </li>",
"     <li>",
"      Creation of appropriate infrastructure, reliable communication systems, and leadership at national and local planning levels to coordinate a public health response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gaps persist in preparedness planning for pandemic influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. A survey of 21 countries in Europe in 2005 found substantial variation in national plans for planning and coordination, surveillance, public health interventions, communication, and implementation of essential services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39032/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/58/6050?source=see_link\">",
"       \"Patient information: Bird flu (avian influenza) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although no outcome trials have been performed in humans infected with avian influenza, in vitro and animal model studies, as well as analysis of data in a registry of human cases, suggest that neuraminidase inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , may be of benefit. We recommend treatment with oseltamivir for suspected cases since it has proven benefit against human influenza infection and may decrease viral shedding (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the optimal dose and duration are unknown,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      is typically administered to patients with uncomplicated disease at a dose of 75 mg twice daily for five days. Patients with pneumonia or clinical worsening on the lower dose should be given 150 mg twice daily for 10 days. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best way to monitor the efficacy of therapy is not known. It may be useful to assess viral RNA levels in throat specimens toward the end of treatment to document clearance; if virus is still present, longer duration or increased dosing of therapy may be required. However, this approach has not been validated and it is possible that residual viral RNA may not equate with infectious virus. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination therapy with a neuraminidase inhibitor and an adamantane may be considered in patients with pneumonia or clinical progression if infection occurs in a region where the isolate is likely to be adamantane-susceptible (eg, Clades 2.2 and 2.3, which have caused disease in parts of Asia). However, the utility of this approach has not been demonstrated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When suspecting highly pathogenic avian influenza, specimens must be handled and processed using appropriate biosafety precautions.",
"     </li>",
"     <li>",
"      For both hospitalized patients and those managed in the outpatient setting, we use isolation precautions similar to those used for SARS-infected patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=see_link\">",
"       \"Severe acute respiratory syndrome (SARS)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of avian influenza vaccination is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=see_link\">",
"       \"Avian influenza vaccines\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. file://www.who.int/influenza/human_animal_interface/EN_GIP_20130215CumulativeNumberH5N1cases.pdf (Accessed on February 20, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/2\">",
"      Murray CJ, Lopez AD, Chin B, et al. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet 2006; 368:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/3\">",
"      Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005; 192:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States and worldwide, 2003-04 season, and composition of the 2004-05 influenza vaccine. MMWR Morb Mortal Wkly Rep 2004; 53:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/5\">",
"      Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/6\">",
"      Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis 2010; 202:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/7\">",
"      Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/8\">",
"      Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis 2012; 55:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/9\">",
"      Govorkova EA, Leneva IA, Goloubeva OG, et al. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001; 45:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/10\">",
"      Chen Y, Qin K, Wu WL, et al. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 2009; 199:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/11\">",
"      Zheng Q, Xia L, Wu WL, et al. Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses. Antimicrob Agents Chemother 2011; 55:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/12\">",
"      Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/13\">",
"      Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/14\">",
"      Iba&ntilde;ez LI, De Filette M, Hultberg A, et al. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. J Infect Dis 2011; 203:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/15\">",
"      Holodniy M, Penzak SR, Straight TM, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008; 52:3013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/16\">",
"      Couch RB, Davis BR. Has oseltamivir been shown to be effective for treatment of H5N1 influenza? J Infect Dis 2010; 202:1149.",
"     </a>",
"    </li>",
"    <li>",
"     WHO rapid advice guildelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. Available online at: www.who.int/entity/medicines/publications/WHO_PSM_PAR_2006.6.pdf (Accessed on July 7, 2006).",
"    </li>",
"    <li>",
"     WHO. Clinical management of human infection with avian influenza A (H5N1) virus file://www.who.int/influenza/resources/documents/clinical_management_h5n1_15_08_2007/en/index.html (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/19\">",
"      Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/20\">",
"      Liem NT, Tung CV, Hien ND, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 2009; 48:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/21\">",
"      Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 2009; 49:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/22\">",
"      Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 2008; 372:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/23\">",
"      de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/24\">",
"      Tsiodras S, Mooney JD, Hatzakis A. Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ 2007; 334:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/25\">",
"      Cheung CL, Rayner JM, Smith GJ, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 2006; 193:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/26\">",
"      Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006; 355:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/27\">",
"      Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1:i5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/28\">",
"      Ong AK, Hayden FG. John F. Enders lecture 2006: antivirals for influenza. J Infect Dis 2007; 196:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/29\">",
"      Mihajlovic ML, Mitrasinovic PM. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV). Biophys Chem 2008; 136:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/30\">",
"      Moscona A. Oseltamivir resistance--disabling our influenza defenses. N Engl J Med 2005; 353:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/31\">",
"      de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/32\">",
"      Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108.",
"     </a>",
"    </li>",
"    <li>",
"     WHO diseases alert: 16 July 2004. Avian Influenza - Necessary precautions to prevent human infection of H5N1, need for virus sharing. www.who.int/csr/don/2004_07_16/en/ (Accessed December 12, 2005).",
"    </li>",
"    <li>",
"     WHO interim protocol: rapid operations to contain the initial emergence of pandemic influenza. Updated October 2007. file://www.who.int/csr/disease/avian_influenza/guidelines/draftprotocol/en/ (Accessed February 1, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/35\">",
"      Apisarnthanarak A, Warren DK, Fraser VJ. Issues relevant to the adoption and modification of hospital infection-control recommendations for avian influenza (H5N1 infection) in developing countries. Clin Infect Dis 2007; 45:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/36\">",
"      Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008; 371:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/37\">",
"      Boltz DA, Rehg JE, McClaren J, et al. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J Infect Dis 2008; 197:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/38\">",
"      Sampathkumar P, Maki DG. Avian H5N1 influenza--are we inching closer to a global pandemic? Mayo Clin Proc 2005; 80:1552.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. National Strategy for Pandemic Influenza. Available at: file://www.whitehouse.gov/homeland/pandemic-influenza.html (Accessed May 23, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/40\">",
"      American College of Physicians, Barnitz L, Berkwits M. The health care response to pandemic influenza. Ann Intern Med 2006; 145:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/41\">",
"      Monto AS, Whitley RJ. Seasonal and pandemic influenza: a 2007 update on challenges and solutions. Clin Infect Dis 2008; 46:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/42\">",
"      Liu M, Wood JM, Ellis T, et al. Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics. Virology 2003; 314:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/43\">",
"      Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004; 159:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/44\">",
"      Brett AS, Zuger A. The run on tamiflu--should physicians prescribe on demand? N Engl J Med 2005; 353:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/45\">",
"      Gostin LO. Medical countermeasures for pandemic influenza: ethics and the law. JAMA 2006; 295:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/46\">",
"      Fedson DS. Meeting the challenge of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2009; 15:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/47\">",
"      Bartlett JG. Planning for avian influenza. Ann Intern Med 2006; 145:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/48\">",
"      Provisional guidelines from the British Infection Society, British Thoracic Society and Health Protection Agency in collaboration with the Department of Health. Thorax 2007; 62:i1.",
"     </a>",
"    </li>",
"    <li>",
"     WHO interim protocol: rapid operations to contain the initial emergence of pandemic influenza. Updated October 2007. file://www.who.int/csr/disease/avian_influenza/guidelines/draftprotocol/en/ (Accessed May 23, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/50\">",
"      Monto AS. The risk of seasonal and pandemic influenza: prospects for control. Clin Infect Dis 2009; 48 Suppl 1:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/51\">",
"      Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006; 442:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/52\">",
"      Markel H, Lipman HB, Navarro JA, et al. Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic. JAMA 2007; 298:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/53\">",
"      Democratis J, Pareek M, Stephenson I. Use of neuraminidase inhibitors to combat pandemic influenza. J Antimicrob Chemother 2006; 58:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/54\">",
"      Whitley RJ, Bartlett J, Hayden FG, et al. Seasonal and pandemic influenza: recommendations for preparedness in the United States. J Infect Dis 2006; 194 Suppl 2:S155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/55\">",
"      Mounier-Jack S, Coker RJ. How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet 2006; 367:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/56\">",
"      Bartlett JG, Borio L. Healthcare epidemiology: the current status of planning for pandemic influenza and implications for health care planning in the United States. Clin Infect Dis 2008; 46:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39032/abstract/57\">",
"      Oshitani H, Kamigaki T, Suzuki A. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2008; 14:875.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7003 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-714CE7359B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39032=[""].join("\n");
var outline_f38_7_39032=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THERAPEUTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Experimental regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adamantane resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neuraminidase inhibitor resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infection control measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Categories of risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Travel advice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PUBLIC HEALTH PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Planning for a pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=related_link\">",
"      Antiviral drug resistance among seasonal influenza viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=related_link\">",
"      Avian influenza vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22599?source=related_link\">",
"      Clinical manifestations and diagnosis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=related_link\">",
"      Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/58/6050?source=related_link\">",
"      Patient information: Bird flu (avian influenza) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=related_link\">",
"      Pharmacology of antiviral drugs for influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=related_link\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_7_39033="Buruli ulcer (Mycobacterium ulcerans infection)";
var content_f38_7_39033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Buruli ulcer (Mycobacterium ulcerans infection)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/7/39033/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39033/contributors\">",
"     Tjip S van der Werf, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39033/contributors\">",
"     Ymkje Stienstra, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/7/39033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39033/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/7/39033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39033/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/7/39033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buruli ulcer is a disabling skin infection caused by Mycobacterium ulcerans. It is named for the Buruli district in Uganda, a region where many of the early cases in the literature were described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Buruli ulcer begins as localized skin lesions that progress to extensive ulceration, leading to functional disability, loss of economic productivity, and social stigma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Since the 1998 World Health Organization (WHO) Buruli ulcer initiative, there has been increased attention to research efforts for treatment and control of Buruli ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterium ulcerans is the third most common mycobacterial infection worldwide (after tuberculosis and leprosy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Buruli ulcer due to M. ulcerans mainly affects individuals in humid, rural, tropical regions with limited access to medical care. It has been reported in about 30 tropical countries, with the greatest frequency in Africa, particularly in the West African countries of C&ocirc;te d'Ivoire, Ghana, and B&eacute;nin (20 to 158 cases per 100,000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. Cases have also been described in other locales including Mexico, South America, Papua New Guinea, and Australia (where the disease is known as Bairnsdale ulcer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peak age group in West Africa studies is 5 to 15 years, although Buruli ulcer can affect any age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/20,27,28\">",
"     20,27,28",
"    </a>",
"    ]. In Australia, the median age is 50 to 66 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/24\">",
"     24",
"    </a>",
"    ]. The disease has a low mortality rate, but its disabling sequelae have an enormous physical and socioeconomic impact on affected individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mode of M. ulcerans transmission is not fully understood, although the disease is known to be linked to contaminated water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/29-35\">",
"     29-35",
"    </a>",
"    ]. Areas affected by Buruli ulcer disease are located near stagnant or slow-moving water, and outbreaks appear to be related to environmental changes (deforestation, agriculture, hydraulic installations) involving surface water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/17,29,34,36\">",
"     17,29,34,36",
"    </a>",
"    ]. Buruli ulcers have been observed more frequently during the rainy season in Africa, and exposure may occur in muddy farming fields [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/23,37,38\">",
"     23,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission of the organism is probably via skin trauma, although insects also may play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Water insects (Naucoris and Belostoma spp) have been implicated in laboratory transmission of infection, but their potential role as vectors have been questioned by studies in West Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In Australia, salt marsh mosquitoes appear to have positive PCR signals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/31,33,43,44\">",
"     31,33,43,44",
"    </a>",
"    ]. Intermediate hosts including aquatic animals may also play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/32,33,45,46\">",
"     32,33,45,46",
"    </a>",
"    ]. Human-to-human transmission is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buruli ulcer is caused by Mycobacterium ulcerans, a slow-growing mycobacterium that can be cultured in vitro at 29 to 33&ordm;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. M. ulcerans is closely related to M. marinum (98 percent DNA homology), but M. ulcerans is unique among human pathogens in that it is capable of producing mycolactone, a potent cytotoxin that induces necrosis and ulceration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The molecular structure of the mycolactones is well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. Mycolactones A and B are associated with African strains of M. ulcerans, while Mycolactone C is associated with the Australian strains. Mycolactones A and B are more potent toxins than Mycolactone C, but whether this reflects the clinical differences in disease severity is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Further understanding of the mycolactone production mechanisms and other aspects of M. ulcerans pathogenesis could facilitate development of a protective vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buruli ulcer usually begins as a painless nodule less than 5 cm in diameter. Less common forms of initial skin lesions include papules (described in Australia), plaques, and edematous lesions (",
"    <a class=\"graphic graphic_picture graphicRef85471 \" href=\"mobipreview.htm?36/38/37472\">",
"     picture 1",
"    </a>",
"    ). The limbs are the most frequently involved areas; other involved areas include the head, neck, trunk and genital regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/4,5,64\">",
"     4,5,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial lesion usually breaks down after days to weeks, forming an ulcer with characteristic undermined edges (",
"    <a class=\"graphic graphic_picture graphicRef77733 graphicRef65909 graphicRef53970 graphicRef77234 \" href=\"mobipreview.htm?41/12/42186\">",
"     picture 2A-D",
"    </a>",
"    ). Ulceration tends to progress slowly and painlessly, and systemic symptoms are characteristically absent unless secondary bacterial infection occurs.",
"   </p>",
"   <p>",
"    Patients with an initial edematous lesion (a less common presentation) tend to demonstrate relatively rapid progression, with tissue swelling leading to massive ulceration within a few days. They also tend to have associated pain and low-grade fever. Excess mycolactone production may play an important role in the pathophysiology of this form of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial M. ulcerans infection can progress to involve deeper tissues including tendons, joints, and bones. Contiguous or hematogenous spread leads to osteomyelitis in up to 15 percent of cases, while involvement of other organs is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/15,65-67\">",
"     15,65-67",
"    </a>",
"    ]. Disseminated disease in association with HIV has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Coinfection with schistosomiasis has also been described, although schistosomiasis does not appear to enhance susceptibility to Buruli ulcer disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of Buruli ulcer includes spontaneous healing in up to one-third of cases; the mechanisms by which this occurs are poorly understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/14,72\">",
"     14,72",
"    </a>",
"    ]. Such healing is quite slow; it can take months and lead to deep scarring and retractions. Contractures can develop when the lesion is close to a joint, and more than half of patients have persistent functional disability years following acute infection (",
"    <a class=\"graphic graphic_picture graphicRef77234 \" href=\"mobipreview.htm?15/30/15840\">",
"     picture 2D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/6,7,27,73-75\">",
"     6,7,27,73-75",
"    </a>",
"    ]. In addition, extensive tissue destruction may warrant amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/15,21\">",
"     15,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buruli ulcers are readily recognized in endemic regions given their chronicity and characteristic appearance of undermined edges. Other diseases that can mimic this appearance include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onchocerciasis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20970?source=see_link\">",
"       \"Onchocerciasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Filariasis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15241?source=see_link\">",
"       \"Diagnosis, treatment, and prevention of lymphatic filariasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Leishmaniasis (see",
"      <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Madura foot (chronic skin infection due to Actinomycetes or fungi)",
"     </li>",
"     <li>",
"      Bacterial soft tissue infection, notably tropical (phagedenic) ulcer (see related topics)",
"     </li>",
"     <li>",
"      Pyoderma gangrenosum (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2328?source=see_link\">",
"       \"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Kaposi's sarcoma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Squamous cell carcinoma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=see_link\">",
"       \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lipoma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=see_link\">",
"       \"Ganglia and nodules\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sebaceous (epidermal) cyst (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=see_link\">",
"       \"Overview of benign lesions of the skin\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ulcers in sickle cell disease, diabetes",
"     </li>",
"     <li>",
"      Venous insufficiency (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/43/33462?source=see_link\">",
"       \"Diagnostic evaluation of chronic venous insufficiency\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Buruli ulcer is frequently based upon clinical manifestations and is often not confirmed because of limited access to laboratory services. Laboratory diagnostic tools include staining for acid-fast bacilli, histopathology, mycobacterial culture, and polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acid fast staining &mdash; The most readily available laboratory technique is acid fast staining of a swab taken from the undermined edge of an ulcer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/78\">",
"       78",
"      </a>",
"      ]. In the setting of an endemic area with a strong clinical suspicion for Buruli ulcer, this test is only about 40 percent sensitive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. In addition, the presence of acid-fast bacilli does not rule out other related infections such as M. tuberculosis or other environmental mycobacteria.",
"     </li>",
"     <li>",
"      Culture &mdash; M. ulcerans grows slowly in the laboratory on Lowenstein-Jensen or liquid media (positive results require at least six weeks); the sensitivity of culture diagnosis is usually low but may approach 60 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/79\">",
"       79",
"      </a>",
"      ]. Specimens can be obtained by punch biopsy or fine needle aspiration of the edge of ulcerated lesions or the center of non-ulcerated lesions. Alternatively, specimens can be obtained by cotton swab from undermined ulcer edges. Culture yield is highest from plaque specimens and lowest from edematous lesions. The optimal transport medium is Liquid Middlebrook 7H9 broth supplemented with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , nalidixic acid,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      and azlocillin (PANTA); specimens in this medium can be stored and transported at room temperature.",
"     </li>",
"     <li>",
"      Histology &mdash; Histology has the highest sensitivity of the conventional diagnostic methods (82 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/13\">",
"       13",
"      </a>",
"      ]. Diagnostic features of early lesions (eg, within six months of infection) include coalescent necrosis, vascular occlusion, hemorrhage, and large numbers of extracellular acid-fast bacilli. In later disease, granuloma formulation is more prominent and fewer acid fast bacilli may be observed.",
"     </li>",
"     <li>",
"      PCR &mdash; PCR for M. ulcerans utilizes the insertion sequence 2404, one of two multicopy insertion sequences in the M. ulcerans genome. The sensitivity of this technique is high; most series report between 70 to 80 percent sensitivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/80\">",
"       80",
"      </a>",
"      ]. This tool has been implemented clinically in endemic areas, and it is an important research tool for studying environmental sources of infection, with a growing interest in quantitative real-time (multiplex) PCR technology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/79,81\">",
"       79,81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most experience with PCR has been in the setting of surgical and punch biopsy specimens, although the test may also be used for swabs taken from the undermined edges of ulcers. In edematous forms of the disease, the diagnostic yield of PCR is usually relatively low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/79\">",
"     79",
"    </a>",
"    ]. Fine needle aspiration is the preferred specimen for PCR evaluation of non-ulcerated lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/82-85\">",
"     82-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    typically turns positive during the course of disease, although skin testing is not recommended for a number of reasons. Skin testing may be negative early in the course of infection and, when positive, cannot differentiate between mycobacterial infections. Serological tests are also not helpful, nor have interferon gamma release assays for Buruli ulcer been developed for diagnostic purposes.",
"   </p>",
"   <p>",
"    If osteomyelitis is suspected, radiological imaging is useful for further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy is the cornerstone of treatment, with a very low recurrence rate and high cure rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/86\">",
"     86",
"    </a>",
"    ]. The role of surgery remains uncertain; it was previously assumed to be the only chance for cure, despite frequent recurrence of disease following excision and associated disability. Treatment practices may therefore vary depending upon the available resources and the stage of clinical presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/80\">",
"     80",
"    </a>",
"    ]. In affluent settings such as Australia, antimicrobial treatment has been combined with surgery to establish rapid cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/26,87\">",
"     26,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Approach by WHO category",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment differs slightly depending upon the size and stage of the lesion, as outlined by the following WHO classification categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Category I &mdash; Single nodules, papules, plaques and ulcers &le;5 cm in diameter; up to one-third of early nodules may heal spontaneously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Category II &mdash; Single plaques and ulcers 5 to 15 cm in diameter; edematous lesions; any lesion in the head and neck region, particularly the face",
"     </li>",
"     <li>",
"      Category III &mdash; Single plaques and ulcers &gt;15 cm in diameter; multiple lesions; joint involvement or osteomyelitis; any lesion at critical sites such as genital organs or the eye.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antimicrobial therapy is the initial therapy of choice. For lesions that require some form of surgery, delayed surgical intervention is preferred, since deterioration during antimicrobial treatment is uncommon and extensive early debridement leaves more tissue damage than necessary. Progression of lesion size on antimicrobial therapy may reflect a paradoxical reaction. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Category II'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Category I",
"    </span>",
"    &nbsp;&mdash;&nbsp;For preulcerative lesions and clean ulcers that are smaller than 5 cm, four weeks of antibiotic therapy may be combined with simple surgical excision followed by immediate closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/26,89\">",
"     26,89",
"    </a>",
"    ]. Some data suggest that simple excision may be curative for category I lesions; others have described recurrence rates of up to 18 percent with surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/72,80,90-92\">",
"     72,80,90-92",
"    </a>",
"    ]. Therefore, antimicrobial therapy should be administered in conjunction with surgery to optimize the likelihood of recurrence-free cure.",
"   </p>",
"   <p>",
"    In regions where surgical expertise is not available, we favor eight weeks of antibiotic therapy. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Systemic antibiotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Category II",
"    </span>",
"    &nbsp;&mdash;&nbsp;For lesions larger than 5 cm, or lesions at critical sites, antibiotic therapy should be initiated with close follow up to evaluate for recovery of potentially viable tissue. If the lesion appears unchanged or is improving, antibiotics should be continued for eight weeks, with ongoing supportive care.",
"   </p>",
"   <p>",
"    Accumulating observations suggest that many category II ulcers gradually heal with antimicrobial therapy alone, although ulcer healing may not necessarily be observed during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/86,93-95\">",
"     86,93-95",
"    </a>",
"    ]. Category II lesions appear to heal more slowly than smaller category I lesions and therefore are more likely to require skin grafting.",
"   </p>",
"   <p>",
"    Paradoxical deterioration can occur during antimicrobial therapy or in the two to four weeks following completion of therapy, reflecting antimicrobial killing accompanied by enhanced immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/96\">",
"     96",
"    </a>",
"    ]. This likely occurs because of decreasing concentrations of cytotoxic mycolactone that causes immune paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/96,97\">",
"     96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the lesion appears to be worsening (eg, the swelling has increased or the surface area is larger), surgical intervention with debridement of superimposed bacterial infection or for skin grafting to accelerate healing of large ulcers may be warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Generous excision margins including healthy tissue are not necessary, although in the past this was felt to be needed for cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/6,86,90\">",
"     6,86,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Edematous lesions appear to be highly amenable to antimicrobial therapy, which can reduce the surface area of ulceration. This may be a result of direct antibiotic activity against mycolactone production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/93,100\">",
"     93,100",
"    </a>",
"    ]. In such cases it is important to monitor for clinical response to antimicrobial therapy; surgery should be limited to removal of necrotic tissue and skin grafting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In regions where surgical expertise is not available, we favor eight weeks of antibiotic therapy. Extending antibiotics beyond eight weeks is of no proven benefit and increases the risk of adverse effects. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Category III",
"    </span>",
"    &nbsp;&mdash;&nbsp;For lesions larger than 15 cm, we favor initial treatment with antibiotic therapy. In some cases, limited surgical debridement of necrotic tissue followed by skin grafting is helpful for acceleration of healing. Reconstruction should be combined with physiotherapy to reduce the likelihood of disability. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Supportive care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surgery should be avoided for lesions at critical sites such as orbital, facial, and genital lesions.",
"   </p>",
"   <p>",
"    No reports have been published on the optimal management of complications such as joint involvement and osteomyelitis; the approach to these cases must be tailored to individual patient circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/100\">",
"     100",
"    </a>",
"    ]. A general approach to osteomyelitis is outlined in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of antimicrobial therapy for the treatment of early, limited Buruli ulcer disease is well described. The benefit of antibiotics in the setting of irreversible tissue necrosis with impaired immune response and impaired drug penetration at the site of infection is more difficult to discern. However, antimicrobials in the right combination for the appropriate duration likely reduce healing time, recurrence rate, and reduce the need for debridement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/86,101,102\">",
"     86,101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several antimicrobial agents have been evaluated in the treatment of Buruli ulcer. The most effective regimens appear to be those that combine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    with an additional agent such as an aminoglycoside, fluoroquinolone, macrolide, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. Since M. ulcerans has a slow replication rate, most favor a once-daily dosing regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rifampin and streptomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely accepted regimen for treatment of Buruli ulcer is the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    . In a study of 21 patients with Buruli ulcer, four weeks of rifampin (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally once daily) with streptomycin (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intramuscularly once daily) demonstrated inhibition of M. ulcerans growth in nodules and plaques by culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/102\">",
"     102",
"    </a>",
"    ]. As a result of this study, the WHO issued guidelines suggesting an eight week course of rifampin with streptomycin; surgical intervention was reserved only for lesions that continue to enlarge despite four weeks of antibiotic therapy, for debridement of superimposed bacterial infection, or for skin grafting to accelerate healing of large ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/88,99\">",
"     88,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the implementation of the WHO provisional guidelines, accumulating observations in West Africa suggest that many ulcers heal with antimicrobial therapy alone, although improvement may not necessarily be observed during therapy and healing may not be complete until after finishing treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/86,93,94\">",
"     86,93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a report of 224 patients treated with eight weeks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ; about half were also managed with surgical excision and skin grafting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/94\">",
"     94",
"    </a>",
"    ]. Treatment success was observed in 96 percent of cases, and recurrent disease was observed in less than 2 percent of the 208 patients evaluated at one-year followup. Antibiotics alone were curative in 47 percent of cases and were particularly effective against ulcers of less than 5 cm in diameter.",
"   </p>",
"   <p>",
"    A subsequent randomized trial including 151 patients demonstrated that the number of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    injections can be reduced by employing a regimen of four weeks of streptomycin and rifampicin followed by four weeks of rifampicin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ; the efficacy of this approach was comparable to eight weeks of streptomycin and rifampicin (96 versus 91 percent healed after one year, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/86\">",
"     86",
"    </a>",
"    ]. Surgery was avoided in the majority of patients. Category I lesions healed after median 20 weeks, while category II and III lesions healed after median 30 weeks.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    appear to have a dramatically beneficial effect among patients with edematous M. ulcerans disease; this may be a result of antibiotic activity against mycolactone production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/93,100\">",
"     93,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of an oral regimen consisting of eight weeks of rifampicin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    appears promising; randomized trial data are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    with a fluoroquinolone (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ) has been effective in vitro and in animal models, but clinical trials are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/104,108-110\">",
"     104,108-110",
"    </a>",
"    ]. The combination of rifampin with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally once daily) has also been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/86,111\">",
"     86,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    demonstrated some reduction in ulcer size in a small study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/112\">",
"     112",
"    </a>",
"    ]. It has also been suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    combined with rifampin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    may improve blood circulation and antibiotic penetration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/98,113\">",
"     98,113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment for pregnant women should not include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    . A reasonable alternative is the combination of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily) combined with rifampicin (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily); further study is needed to evaluate the response to oral therapy.",
"   </p>",
"   <p>",
"    Monotherapy with clofazamine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    or other agents should not be used for treatment of Buruli ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/72,110,114\">",
"     72,110,114",
"    </a>",
"    ]. Resistant strains have been demonstrated after rifampin monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on long-term antimicrobial therapy are at risk for adverse effects. Aminoglycosides pose risk for ototoxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nephrotoxicity, and long-term injectable administration is not practical for many regions where Buruli ulcer is endemic. Patients who develop signs of aminoglycoside toxicity before the end of treatment should be switched to an alternative regimen such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or rifampin with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Fluoroquinolones are favorable agents in that they can be administered orally and have good bone penetration, although they are contraindicated for pregnant women and young children. In addition, the antimycobacterial activity of fluoroquinolones requires exclusion of concomitant active tuberculosis to avoid emergence of resistant organisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Topical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical treatment of ulcerative lesions should include wet dressing materials. Topical therapies including nitrogen oxide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    powder, and local heat have been suggested for treatment of Buruli ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/115-117\">",
"     115-117",
"    </a>",
"    ]. Nitric oxide kills M. ulcerans in vitro, while phenytoin powder appears to promote healing through acceleration of fibrogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Local heat application to 40&ordm;C takes advantage of the temperature sensitivity of M. ulcerans (whose optimal growth conditions are 29 to 33&ordm;C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/10,117-119\">",
"     10,117-119",
"    </a>",
"    ]. Topical modalities require further study before they should be considered for routine use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to wound care with clean dressings can prevent life-threatening secondary bacterial infection. Fever, acute inflammatory changes, copious purulent discharge, and foul smelling pus suggest secondary polymicrobial bacterial infection. Tetanus immunization is also critical. In addition, physiotherapy is important for prevention of fixed joint deformities, and this intervention can be administered by health workers with minimal training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Water exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A better understanding of transmission mechanisms is needed for development of effective approaches to Buruli ulcer prevention. Limiting exposure to contaminated water sources may be helpful, although this is difficult to achieve in endemic areas where farming activities require close contact with waterways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/24\">",
"     24",
"    </a>",
"    ]. Other prevention strategies such as wearing protective clothing while farming and prompt cleansing of traumatic skin injuries may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Transmission'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;BCG vaccination appears to offer limited protection against Buruli ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/120-122\">",
"     120-122",
"    </a>",
"    ]. This was illustrated in a randomized trial of over 8000 individuals in which BCG vaccination had a 47 percent short-term protective effect against Buruli ulcer (6 to 12 months); the trial did not determine whether BCG provided long-lasting protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/120\">",
"     120",
"    </a>",
"    ]. Two other studies have suggested that BCG may have a protective effect against severe disease (osteomyelitis and multiple lesions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/65,121\">",
"     65,121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further study of the mycolactone production mechanisms and other aspects of M. ulcerans pathogenesis may facilitate development of a more effective vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39033/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Buruli ulcer is a disabling skin infection due to Mycobacterium ulcerans that affects individuals in humid, rural, tropical regions with limited access to medical care. Transmission is related to contaminated water; inoculation probably occurs via skin trauma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Microbiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Buruli ulcer usually begins as a small painless papule that breaks down after days to weeks, forming an ulcer with characteristic undermined edges. Sequelae may include osteomyelitis, scarring, retractions, and contractures. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most widely available laboratory diagnostic technique is acid fast staining of a swab taken from the undermined edge of an ulcer. However, in endemic areas the diagnosis of Buruli ulcer is frequently based upon clinical manifestations and rarely confirmed because of limited access to laboratory services. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For category I, II, and III disease, we suggest antibiotic therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Dosing is rifampin 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally once daily with streptomycin 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intramuscularly once daily. The number of streptomycin injections can be reduced by employing a regimen of four weeks of streptomycin and rifampicin followed by four weeks of rifampicin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      . For category I disease, four weeks of therapy may be sufficient; for category II and III disease the preferred duration of antibiotic therapy is eight weeks. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach by WHO category'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild paradoxical deterioration may occur during antimicrobial therapy or in the two to four weeks following completion of therapy, reflecting antimicrobial killing accompanied by enhanced immune response. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach by WHO category'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for pregnant women should not include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      ; a reasonable alternative is the combination of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily) combined with rifampicin (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Other regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery may or may not be needed. Any debridement should be limited to removal of necrotic tissue and delayed for at least four weeks following initiation of antibiotic therapy. Once the wound surface is clean and granulating, skin grafting should be planned. Surgery should be avoided for lesions at critical sites such as orbital, facial, and genital lesions. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach by WHO category'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications including joint deformities and secondary bacterial infection and may be diminished with physiotherapy and attention to wound care. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention measures may include limiting exposure to contaminated water sources but a better understanding of transmission mechanisms is needed. BCG vaccination appears to afford limited protection, although mycolactone may be a good target for a more effective vaccine. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/1\">",
"      LUNN HF, CONNOR DH, WILKS NE, et al. BURULI (MYCOBACTERIAL) ULCERATION IN UGANDA. (A NEW FOCUS OF BURULI ULCER IN MADI DISTRICT, UGANDA): REPORT OF A FIELD STUDY. East Afr Med J 1965; 42:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/2\">",
"      CLANCEY JK, DODGE OG, LUNN HF, ODUORI ML. Mycobacterial skin ulcers in Uganda. Lancet 1961; 2:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/3\">",
"      CLANCEY JK. MYCOBACTERIAL SKIN ULCERS IN UGANDA: DESCRIPTION OF A NEW MYCOBACTERIUM (MYCOBACTERIUM BURULI). J Pathol Bacteriol 1964; 88:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/4\">",
"      Barker DJ. Buruli disease in a district of Uganda. J Trop Med Hyg 1971; 74:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/5\">",
"      Barker DJ. The distribution of Buruli disease in Uganda. Trans R Soc Trop Med Hyg 1972; 66:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/6\">",
"      Stienstra Y, van Roest MH, van Wezel MJ, et al. Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Trop Med Int Health 2005; 10:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/7\">",
"      Ellen DE, Stienstra Y, Teelken MA, et al. Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli ulcer functional limitation score. Trop Med Int Health 2003; 8:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/8\">",
"      Asiedu K, Etuaful S. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg 1998; 59:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/9\">",
"      Stienstra Y, van der Graaf WT, Asamoa K, van der Werf TS. Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg 2002; 67:207.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organizations: Global Buruli Ulcer Initiative (GBUI). Available at: www.who.int/buruli/en/ (Accessed on February 12, 2008).",
"    </li>",
"    <li>",
"     5th WHO Advisory Group Meeting on Buruli ulcer; Geneva, Switzerland; March 11-14,2002.",
"    </li>",
"    <li>",
"     WHO. Report of the 6th WHO Advisory Group Meeting on Buruli ulcer.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/13\">",
"      van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 1999; 354:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/14\">",
"      Johnson PD, Stinear T, Small PL, et al. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2005; 2:e108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/15\">",
"      Debacker M, Aguiar J, Steunou C, et al. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis 2004; 10:1391.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Buruli ulcer disease. 2007. Available at: file://www.who.int/mediacentre/factsheets/fs199/en/print.html (Accessed on April 30, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/17\">",
"      Amofah G, Bonsu F, Tetteh C, et al. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis 2002; 8:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/18\">",
"      Darie H, Le Guyadec T, Touze JE. [Epidemiological and clinical aspects of Buruli ulcer in Ivory Coast. 124 recent cases]. Bull Soc Pathol Exot 1993; 86:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/19\">",
"      Kanga JM, Kacou ED. [Epidemiologicl aspects of Buruli ulcer in C&ocirc;te d'Ivoire: results of a national survey]. Bull Soc Pathol Exot 2001; 94:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/20\">",
"      van der Werf TS, van der Graaf WT, Groothuis DG, Knell AJ. Mycobacterium ulcerans infection in Ashanti region, Ghana. Trans R Soc Trop Med Hyg 1989; 83:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/21\">",
"      Muelder K, Nourou A. Buruli ulcer in Benin. Lancet 1990; 336:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/22\">",
"      Buruli ulcer disease. Wkly Epidemiol Rec 2004; 79:194.",
"     </a>",
"    </li>",
"    <li>",
"     Asiedu K, Scherpbier R, Raviglione M. Buruli ulcer: Mycobacterium ulcerans infection. Geneva: WHO, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/24\">",
"      Veitch MG, Johnson PD, Flood PE, et al. A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect 1997; 119:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/25\">",
"      Johnson PD, Veitch MG, Leslie DE, et al. The emergence of Mycobacterium ulcerans infection near Melbourne. Med J Aust 1996; 164:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/26\">",
"      Johnson PD, Hayman JA, Quek TY, et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007; 186:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/27\">",
"      Marston BJ, Diallo MO, Horsburgh CR Jr, et al. Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire. Am J Trop Med Hyg 1995; 52:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/28\">",
"      Debacker M, Aguiar J, Steunou C, et al. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health 2004; 9:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/29\">",
"      Buruli ulcer disease. Mycobacterium ulcerans infection. Wkly Epidemiol Rec 2002; 77:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/30\">",
"      Johnson RC, Sopoh GE, Boko M, et al. [Distribution of Mycobacterium ulcerans (Buruli ulcer) in the district of Lalo in Benin]. Trop Med Int Health 2005; 10:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/31\">",
"      Marsollier L, Robert R, Aubry J, et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 2002; 68:4623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/32\">",
"      Eddyani M, Ofori-Adjei D, Teugels G, et al. Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol 2004; 70:5679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/33\">",
"      Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007; 13:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/34\">",
"      Ross BC, Johnson PD, Oppedisano F, et al. Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol 1997; 63:4135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/35\">",
"      Raghunathan PL, Whitney EA, Asamoa K, et al. Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis 2005; 40:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/36\">",
"      Marsollier L, Stinear T, Aubry J, et al. Aquatic plants stimulate the growth of and biofilm formation by Mycobacterium ulcerans in axenic culture and harbor these bacteria in the environment. Appl Environ Microbiol 2004; 70:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/37\">",
"      Barker DJ. Epidemiology of Mycobacterium ulcerans infection. Trans R Soc Trop Med Hyg 1973; 67:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/38\">",
"      Revill WD, Barker DJ. Seasonal distribution of mycobacterial skin ulcers. Br J Prev Soc Med 1972; 26:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/39\">",
"      Portaels F, Meyers WM, Ablordey A, et al. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2008; 2:e178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/40\">",
"      Meyers WM, Shelly WM, Connor DH, Meyers EK. Human Mycobacterium ulcerans infections developing at sites of trauma to skin. Am J Trop Med Hyg 1974; 23:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/41\">",
"      Williamson HR, Benbow ME, Nguyen KD, et al. Distribution of Mycobacterium ulcerans in buruli ulcer endemic and non-endemic aquatic sites in Ghana. PLoS Negl Trop Dis 2008; 2:e205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/42\">",
"      Benbow ME, Williamson H, Kimbirauskas R, et al. Aquatic invertebrates as unlikely vectors of Buruli ulcer disease. Emerg Infect Dis 2008; 14:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/43\">",
"      Marsollier L, Aubry J, Coutanceau E, et al. Colonization of the salivary glands of Naucoris cimicoides by Mycobacterium ulcerans requires host plasmatocytes and a macrolide toxin, mycolactone. Cell Microbiol 2005; 7:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/44\">",
"      Portaels F, Elsen P, Guimaraes-Peres A, et al. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 1999; 353:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/45\">",
"      Marsollier L, S&eacute;v&eacute;rin T, Aubry J, et al. Aquatic snails, passive hosts of Mycobacterium ulcerans. Appl Environ Microbiol 2004; 70:6296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/46\">",
"      Marsollier L, Aubry J, Saint-Andr&eacute; JP, et al. [Ecology and transmission of Mycobacterium ulcerans]. Pathol Biol (Paris) 2003; 51:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/47\">",
"      Exner K, Lemperle G. [Buruli ulcer--necrotizing infection of the hand of a plastic surgeon]. Handchir Mikrochir Plast Chir 1987; 19:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/48\">",
"      Debacker M, Zinsou C, Aguiar J, et al. First case of Mycobacterium ulcerans disease (Buruli ulcer) following a human bite. Clin Infect Dis 2003; 36:e67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/49\">",
"      MacCALLUM P, TOLHURST JC. A new mycobacterial infection in man. J Pathol Bacteriol 1948; 60:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/50\">",
"      Palomino JC, Obiang AM, Realini L, et al. Effect of oxygen on growth of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol 1998; 36:3420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/51\">",
"      Palomino JC, Portaels F. Effects of decontamination methods and culture conditions on viability of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol 1998; 36:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/52\">",
"      Chemlal K, Huys G, Fonteyne PA, et al. Evaluation of PCR-restriction profile analysis and IS2404 restriction fragment length polymorphism and amplified fragment length polymorphism fingerprinting for identification and typing of Mycobacterium ulcerans and M. marinum. J Clin Microbiol 2001; 39:3272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/53\">",
"      Chemlal K, Huys G, Laval F, et al. Characterization of an unusual Mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans. J Clin Microbiol 2002; 40:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/54\">",
"      Stinear TP, Jenkin GA, Johnson PD, Davies JK. Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol 2000; 182:6322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/55\">",
"      van der Werf TS, Stinear T, Stienstra Y, et al. Mycolactones and Mycobacterium ulcerans disease. Lancet 2003; 362:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/56\">",
"      Benowitz AB, Fidanze S, Small PL, Kishi Y. Stereochemistry of the core structure of the mycolactones. J Am Chem Soc 2001; 123:5128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/57\">",
"      Fidanze S, Song F, Szlosek-Pinaud M, et al. Complete structure of the mycolactones. J Am Chem Soc 2001; 123:10117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/58\">",
"      Song F, Fidanze S, Benowitz AB, Kishi Y. Total synthesis of the mycolactones. Org Lett 2002; 4:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/59\">",
"      van Summeren RP, Feringa BL, Minnaard AJ. New approaches towards the synthesis of the side-chain of mycolactones A and B. Org Biomol Chem 2005; 3:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/60\">",
"      Judd TC, Bischoff A, Kishi Y, et al. Structure determination of mycolactone C via total synthesis. Org Lett 2004; 6:4901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/61\">",
"      Mve-Obiang A, Lee RE, Portaels F, Small PL. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 2003; 71:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/62\">",
"      Evans MR, Thangaraj HS, Wansbrough-Jones MH. Buruli ulcer. Curr Opin Infect Dis 2000; 13:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/63\">",
"      Huygen K, Adjei O, Affolabi D, et al. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol 2009; 198:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/64\">",
"      Hospers IC, Wiersma IC, Dijkstra PU, et al. Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. Trans R Soc Trop Med Hyg 2005; 99:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/65\">",
"      Noeske J, Kuaban C, Rondini S, et al. Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg 2004; 70:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/66\">",
"      Portaels F, Aguiar J, Debacker M, et al. Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol 2002; 9:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/67\">",
"      Pszolla N, Sarkar MR, Strecker W, et al. Buruli ulcer: a systemic disease. Clin Infect Dis 2003; 37:e78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/68\">",
"      Bafende AE, Lukanu NP, Numbi AN. Buruli ulcer in an AIDS patient. S Afr Med J 2002; 92:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/69\">",
"      Johnson RC, Ifebe D, Hans-Moevi A, et al. Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. AIDS 2002; 16:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/70\">",
"      Scott JT, Johnson RC, Aguiar J, et al. Schistosoma haematobium infection and Buruli ulcer. Emerg Infect Dis 2004; 10:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/71\">",
"      Stienstra Y, van der Werf TS, van der Graaf WT, et al. Buruli ulcer and schistosomiasis: no association found. Am J Trop Med Hyg 2004; 71:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/72\">",
"      Revill WD, Morrow RH, Pike MC, Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 1973; 2:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/73\">",
"      Stienstra Y, Dijkstra PU, Gu&eacute;d&eacute;non A, et al. Development of a questionnaire assessing Buruli ulcer-induced functional limitation. Am J Trop Med Hyg 2004; 70:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/74\">",
"      Stienstra Y, Dijkstra PU, Van Wezel MJ, et al. Reliability and validity of the Buruli ulcer functional limitation score questionnaire. Am J Trop Med Hyg 2005; 72:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/75\">",
"      Schunk M, Thompson W, Klutse E, et al. Outcome of patients with buruli ulcer after surgical treatment with or without antimycobacterial treatment in Ghana. Am J Trop Med Hyg 2009; 81:75.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Buruli ulcer &mdash; diagnosis of Mycobacterium ulcerans disease &mdash; a manual for health care providers. Geneva: WHO, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/77\">",
"      Herbinger KH, Adjei O, Awua-Boateng NY, et al. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis 2009; 48:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/78\">",
"      Portaels F, Agular J, Fissette K, et al. Direct detection and identification of Mycobacterium ulcerans in clinical specimens by PCR and oligonucleotide-specific capture plate hybridization. J Clin Microbiol 1997; 35:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/79\">",
"      Phillips R, Horsfield C, Kuijper S, et al. Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an Assay using punch biopsy specimens for diagnosis of Buruli ulcer. J Clin Microbiol 2005; 43:3650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/80\">",
"      Ross BC, Marino L, Oppedisano F, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol 1997; 35:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/81\">",
"      Fyfe JA, Lavender CJ, Johnson PD, et al. Development and application of two multiplex real-time PCR assays for the detection of Mycobacterium ulcerans in clinical and environmental samples. Appl Environ Microbiol 2007; 73:4733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/82\">",
"      Cassisa V, Chauty A, Marion E, et al. Use of fine-needle aspiration for diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol 2010; 48:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/83\">",
"      Yeboah-Manu D, Danso E, Ampah K, et al. Isolation of Mycobacterium ulcerans from swab and fine-needle-aspiration specimens. J Clin Microbiol 2011; 49:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/84\">",
"      Eddyani M, Fraga AG, Schmitt F, et al. Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol 2009; 47:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/85\">",
"      Phillips RO, Sarfo FS, Osei-Sarpong F, et al. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J Clin Microbiol 2009; 47:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/86\">",
"      Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/87\">",
"      O'Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186:58.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/89\">",
"      Clinical features and treatment of pre-ulcerative Buruli lesions (Mycobacterium ulcerans infection). Report II of the Uganda Buruli Group. Br Med J 1970; 2:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/90\">",
"      Amofah G, Asamoah S, Afram-Gyening C. Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana. Trop Doct 1998; 28:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/91\">",
"      Debacker M, Aguiar J, Steunou C, et al. Buruli ulcer recurrence, Benin. Emerg Infect Dis 2005; 11:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/92\">",
"      Rondini S, Mensah-Quainoo E, Troll H, et al. Development and application of real-time PCR assay for quantification of Mycobacterium ulcerans DNA. J Clin Microbiol 2003; 41:4231.",
"     </a>",
"    </li>",
"    <li>",
"     Chauty A. Treatment of Buruli ulcer with the commbination rifampicin and streptomycin in Benin. 8th WHO Advisory Group Meeting on Buruli ulcer; Geneva, Switzerland; Mar 14-17, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/94\">",
"      Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007; 51:4029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/95\">",
"      Radford AJ. The surgical management of lesions of ulcerans infections due to Mycobacterium ulcerans, revisited. Trans R Soc Trop Med Hyg 2009; 103:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/96\">",
"      Nienhuis WA, Stienstra Y, Abass KM, et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012; 54:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/97\">",
"      O'Brien DP, Robson ME, Callan PP, McDonald AH. \"Paradoxical\" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 2009; 191:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/98\">",
"      Sizaire V, Nackers F, Comte E, Portaels F. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis 2006; 6:288.",
"     </a>",
"    </li>",
"    <li>",
"     Etuaful, S, Carbonnelle, B, Grosset, J, et al. Bactericidal activity of rifampicin and streptomycin treatment for early human M ulcerans lesions. 6th WHO Advisory Group Meeting on Buruli ulcer 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/100\">",
"      Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. Lancet 2006; 367:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/101\">",
"      Evans MR, Phillips R, Etuaful SN, et al. An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease. Trans R Soc Trop Med Hyg 2003; 97:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/102\">",
"      Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005; 49:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/103\">",
"      Havel A, Pattyn SR. Activity of rifampicin on Mycobacterium ulcerans. Ann Soc Belg Med Trop 1975; 55:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/104\">",
"      Thangaraj HS, Adjei O, Allen BW, et al. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 2000; 45:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/105\">",
"      Portaels F, Traore H, De Ridder K, Meyers WM. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother 1998; 42:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/106\">",
"      Stanford JL, Phillips I. Rifampicin in experimental Mycobacterium ulcerans infection. J Med Microbiol 1972; 5:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/107\">",
"      Chauty A, Ardant MF, Marsollier L, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011; 52:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/108\">",
"      Dhople AM, Namba K. In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans. J Antimicrob Chemother 2002; 50:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/109\">",
"      Dhople AM, Namba K. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice. J Chemother 2003; 15:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/110\">",
"      Marsollier L, Honor&eacute; N, Legras P, et al. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob Agents Chemother 2003; 47:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/111\">",
"      Drummond C, Butler JR. Mycobacterium ulcerans treatment costs, Australia. Emerg Infect Dis 2004; 10:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/112\">",
"      Espey DK, Djomand G, Diomande I, et al. A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis 2002; 6:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/113\">",
"      Kanga JM, Dion-Laine M, Kacou DE, Menan EI. [Contribution of heparin therapy in the medical treatment of Buruli ulcer apropos of 1 case]. Bull Soc Pathol Exot 2001; 94:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/114\">",
"      Fehr H, Egger M, Senn I. Cotrimoxazol in the treatment of Mycobacterium ulcerans infection (Buruli ulcer) in west Africa. Trop Doct 1994; 24:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/115\">",
"      Phillips R, Kuijper S, Benjamin N, et al. In vitro killing of Mycobacterium ulcerans by acidified nitrite. Antimicrob Agents Chemother 2004; 48:3130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/116\">",
"      Adjei O, Evans MR, Asiedu A. Phenytoin in the treatment of Buruli ulcer. Trans R Soc Trop Med Hyg 1998; 92:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/117\">",
"      Meyers WM, Shelly WM, Connor DH. Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg 1974; 23:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/118\">",
"      Buruli ulcer. Br Med J 1970; 2:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/119\">",
"      Junghanss T, Um Boock A, Vogel M, et al. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis 2009; 3:e380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/120\">",
"      Smith PG, Revill WD, Lukwago E, Rykushin YP. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 1976; 70:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/121\">",
"      Portaels F, Aguiar J, Debacker M, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39033/abstract/122\">",
"      BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet 1969; 1:111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5349 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39033=[""].join("\n");
var outline_f38_7_39033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Approach by WHO category",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Category I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Category II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Category III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rifampin and streptomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Topical therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Water exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5349\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5349|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/38/37472\" title=\"picture 1\">",
"      Buruli ulcer edematous lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/36/11847\" title=\"picture 2A\">",
"      Buruli ulcer thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/59/28597\" title=\"picture 2B\">",
"      Buruli ulcer lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/51/42806\" title=\"picture 2C\">",
"      Long standing Buruli ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/30/15840\" title=\"picture 2D\">",
"      Buruli ulcer foot",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=related_link\">",
"      Clinical manifestations and diagnosis of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15241?source=related_link\">",
"      Diagnosis, treatment, and prevention of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/43/33462?source=related_link\">",
"      Diagnostic evaluation of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=related_link\">",
"      Ganglia and nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20970?source=related_link\">",
"      Onchocerciasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2328?source=related_link\">",
"      Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_7_39034="Risks and side effects associated with estrogen-progestin contraceptives";
var content_f38_7_39034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risks and side effects associated with estrogen-progestin contraceptives",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/7/39034/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39034/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39034/contributors\">",
"     Pamela S Douglas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/7/39034/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39034/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39034/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/7/39034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/7/39034/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/7/39034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives (OCs) are a reliable form of contraception with a theoretical failure rate of 0.1 percent and, due to problems with compliance, an actual failure rate of 2 to 3 percent. They also have noncontraceptive benefits, being useful in the treatment of a variety of disorders including hyperandrogenism, dysmenorrhea, and menorrhagia. Currently available preparations are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef69223 \" href=\"mobipreview.htm?10/59/11184\">",
"     table 1",
"    </a>",
"    ). There are, however, several contraindications to their use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concern about toxicity (such as thromboembolic events and cardiovascular disease) initially limited the long-term use of these drugs. However, the decrease in both estrogen and progestin content since the introduction of the pill in 1960 has led to a reduction in both side effects and cardiovascular complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, these preparations are a reasonable contraceptive option for most women.",
"   </p>",
"   <p>",
"    While the Food and Drug Administration had previously set upper age limits for OC use as 35 years for smokers and 40 years for nonsmokers, the age limit was removed in 1989 for healthy, nonsmoking women. Thus, OCs can be given until menopause in such women. Caution is still needed in prescribing OCs for women who smoke and an effort to induce smoking cessation should be made first.",
"   </p>",
"   <p>",
"    Certain forms of toxicity remain a concern. This topic will review the side effects and major potential risks associated with OC administration. The noncontraceptive benefits of estrogen-progestin contraceptives and other types of contraception are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Noncontraceptive benefits'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early side effects of OCs include bloating, nausea, and breast tenderness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/2\">",
"     2",
"    </a>",
"    ]. Although they may be bothersome enough to lead to discontinuation of the OC, these side effects usually subside in several months. Abnormal bleeding is a common problem that often resolves. Weight gain is not a consistent finding with low-dose pills. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Weight'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Breakthrough bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breakthrough bleeding is the most common side effect of OCs. Its occurrence does not indicate a decrease in efficacy, but reflects tissue breakdown as the endometrium adjusts to a new thin state in which it is fragile and atrophic. Breakthrough bleeding is more of a problem with lower doses of estrogen because estrogen stabilizes the endometrium. In addition, bleeding is more common with extended and continuous regimens, although most women eventually develop amenorrhea.",
"   </p>",
"   <p>",
"    The most common cause of breakthrough bleeding is thought to be missed pills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/3\">",
"     3",
"    </a>",
"    ]. Women should be cautioned that missing pills results in an increase in breakthrough bleeding as well as a decrease in contraceptive efficacy.",
"   </p>",
"   <p>",
"    Follicular development with increased estrogen concentrations may also occur with the lower dose preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/4\">",
"     4",
"    </a>",
"    ]. Other causes include smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/5\">",
"     5",
"    </a>",
"    ] and drug interactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although contraceptive efficacy appears to be similar for different progestins, limited data suggest that the third-generation progestins may be associated with less intermenstrual bleeding than earlier progestins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/6\">",
"     6",
"    </a>",
"    ]. However, we do not consider this to be a reason to choose third-generation progestins over earlier ones.",
"   </p>",
"   <p>",
"    Our approach to treatment of bleeding starts with patient reassurance and encouragement to take the OC for at least three cycles before making any changes. If the bleeding does not stop, a cervical examination pelvic ultrasound to rule out structural causes of bleeding, such as uterine fibroids or polyps, should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Amenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amenorrhea is the goal with the continuous and extended estrogen-progestin regimens. However, amenorrhea may also occur with the standard preparations containing 21 days of hormone and seven days of placebo, most commonly with the lower dose pills containing 20 mcg. Amenorrhea is the desired outcome with the extended regimens, but it is a bothersome problem with the standard cyclic regimens because of the monthly concern that pregnancy might have occurred.",
"   </p>",
"   <p>",
"    If the woman is on a low dose (20 mcg OC), switching to a 30 to 35 mcg preparation often restores menses. Our most common approach is to simply reassure the patient that the amenorrhea is not a sign of a new endocrine problem, nor does it mean that she is not getting reliable contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Post-pill amenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;It had previously been thought that women who used oral contraceptives were at risk of developing subsequent irregular menses or amenorrhea. However, data suggest that the incidence and endocrinologic findings in women with amenorrhea occurring after the use of cyclic oral contraceptive regimens are the same as in women with spontaneous amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/7\">",
"     7",
"    </a>",
"    ]. This appears to be true for continuous pill regimens, as well, as illustrated in a report of 187 women using the continuous pill for one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/8\">",
"     8",
"    </a>",
"    ]. After stopping the pill, the median time to return to menses was 32 days, and spontaneous menses or pregnancy occurred at day &le;90 in 185 of 187 women (98.9 percent).",
"   </p>",
"   <p>",
"    Thus, women who do not menstruate three months after discontinuing an OC should undergo the same evaluation for amenorrhea as any woman with amenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism of OCs is accelerated by any drug that increases liver microsomal enzyme activity such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H807323864\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute and relative contraindications to the use or estrogen-progestin contraceptives are reviewed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H3033285#H3033285\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest concern surrounding the use of estrogen-progestin contraceptives has been the increase in cardiovascular morbidity and mortality that occurred with the early high-dose pills. However, the reduction in estrogen content has increased safety substantially. Because myocardial infarction is an extremely rare event in otherwise healthy women of reproductive age, even a doubling of the risk would result in an extremely low attributable risk. Risk in older women who smoke outweighs the risk of an unwanted pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much of what is known about the potential risks of OCs comes from four large cohort studies: the Royal College of General Practitioners (RCGP) Study, the Oxford Family Planning Association Study, the Walnut Creek Contraceptive Drug Study, and the Group Health Cooperative of Puget Sound Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of epidemiologic studies have reported an increase in myocardial infarction, thought to be related to a thrombotic mechanism rather than the development of atherosclerotic plaques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/12\">",
"     12",
"    </a>",
"    ], and an increase in cardiovascular mortality in estrogen-progestin contraceptive users over age 35 who smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These studies included women who used both high (&ge;50 mcg EE) and low-dose (&le;35 mcg EE) OCs. However, the absolute risk of a myocardial infarction in a nonsmoker using a pill containing 20 to 40 mcg of ethinyl estradiol is very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/12,15\">",
"     12,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer \"third-generation\" OCs (eg, those containing desogestrel, norgestimate, or gestodene) have more favorable effects on the lipid profile than second generation preparations, but this did not translate into a lower risk of myocardial infarction in two case-control studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a third study, the risk of myocardial infarction appeared to be lower in women using third rather than second generation (RR 2.5) oral contraceptives (RR 1.3 versus 2.5, respectively), but the difference was not significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 10 studies calculated an overall doubling of cardiovascular mortality risk (due to CHD) in women using oral contraceptives with less than 50 mcg ethinyl estradiol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/19\">",
"     19",
"    </a>",
"    ]. However, because myocardial infarction is an extremely rare event in otherwise healthy women of reproductive age, even a doubling of the risk would result in an extremely low attributable risk.",
"   </p>",
"   <p>",
"    The largest cohort study of hormonal contraception and arterial thrombosis risk was published after the meta-analysis, and included the entire population of Danish women, ages 15 to 49 years of age, followed from 1995 to 2009, with nearly 500 myocardial infarctions and over 1000 strokes in current users of hormonal contraception. In an analysis adjusted for differences in progestin type and age, oral contraceptives containing ethinyl estradiol doses of 20 mcg or 30 to 40 mcg were associated with an increased risk of myocardial infarction (MI) (RR 1.4 and 1.88, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/12\">",
"     12",
"    </a>",
"    ]. Risks did not differ significantly between type of progestin. In spite of the apparent excess risk of MI, the absolute risk of an event with oral contraceptives is very low; the authors estimated that among 10,000 women who use a pill containing ethinyl estradiol 20 mcg with desogestrel for one year, two will have arterial thrombosis (myocardial infarction or thrombotic stroke) (versus 6.8 with venous thrombosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Stroke'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Venous thromboembolic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The numbers of myocardial infarctions were too low to estimate risk for the contraceptive patch and vaginal ring. No excess risk was seen with any of the progestin-only formulations.",
"   </p>",
"   <p>",
"    Theoretically, the increase in myocardial infarction risk may be more clinically relevant in women with polycystic ovary syndrome (who are thought to be at higher risk of cardiovascular disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/19\">",
"     19",
"    </a>",
"    ]. However, there are no clinical data on the risk of myocardial infarction with oral contraceptive use in this group of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A consensus panel reviewing the issue of oral contraceptives in women over 35 who smoke suggested that OCs should not be given to those who smoke more than 15 cigarettes per day, but they can be considered in women who smoke fewer than 15 cigarettes per day, since the risks of pregnancy in this age group are greater than the risks associated with OC use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/20\">",
"     20",
"    </a>",
"    ]. WHO guidelines agree with this approach. However, patients often underreport the number of cigarettes smoked per day and, therefore, we agree with ACOG that the risk of OC use is unacceptable for women over 35 who smoke at all.",
"   </p>",
"   <p>",
"    On the other hand, for younger women, the benefits of OCs appear to outweigh the risks, even among heavy smokers, as long as there is no family history of thromboembolic disease.",
"   </p>",
"   <p>",
"    Women who have taken an OC are",
"    <strong>",
"     not",
"    </strong>",
"    at increased risk for coronary heart disease later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, some, but not all, studies report that oral contraceptives may be associated with an increased risk of myocardial infarction. However, because myocardial infarction is an extremely rare event in otherwise healthy women of reproductive age, even a doubling of the risk would result in an extremely low attributable risk. Risk in older women who smoke outweighs the risk of an unwanted pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCs frequently cause a mild elevation in blood pressure within the normal range; however, overt hypertension can occur. Early reports suggesting an incidence of hypertension of 5 percent involved preparations containing at least 50 mcg of estrogen and 1 to 4 mg of progestin. The effect of current low-dose OCs was assessed in a report from the Nurses' Health Study, which prospectively evaluated almost 70,000 nurses aged 25 to 42 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/23\">",
"     23",
"    </a>",
"    ]. After adjustment for age, weight, smoking, family history, and other risk factors, the relative risk of hypertension compared with women who never used OCs was 1.8 for current users and 1.2 for previous users. Overall, only 41.5 cases per 10,000 person-years could be attributed to OC use; this risk rapidly declined with cessation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=see_link\">",
"     \"Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although oral contraceptive-induced hypertension is not common, its recognition is important, as hypertensive oral contraceptive users appear to be at increased risk of myocardial infarction and stroke relative to nonusers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptive use has been associated with a small but significant increase in ischemic stroke risk in many [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/28-30\">",
"     28-30",
"    </a>",
"    ], studies. This was a particular concern with early OC preparations that contained high doses of estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/31\">",
"     31",
"    </a>",
"    ]. Newer OC preparations containing less than 50 mcg of ethinyl estradiol are associated with a lower risk of stroke than high-dose preparations. Of note is that in otherwise healthy young women (non-smokers without hypertension), the attributable risk is extremely low because baseline risk of ischemic stroke is so low in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/32\">",
"     32",
"    </a>",
"    ]. In all of these studies, the",
"    <strong>",
"     absolute",
"    </strong>",
"    risk of stroke was very low in young women (11.3 per 100,000 patients per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Stroke risk appears to be similar across different progestins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/27,33\">",
"     27,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 16 epidemiologic studies found that a nonsmoking, normotensive woman's annual stroke risk would be expected to increase from 4.4 to 8.5 per 100,000 with use of low estrogen oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, treatment of 24,000 women would lead to one additional ischemic stroke each year.",
"   </p>",
"   <p>",
"    A second meta-analysis of 20 studies (four cohort and 16 case-control, including many of the studies described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]), reported an increased risk of thrombotic stroke in the case-control studies (OR 2.74, 95% CI 2.24-3.35), but not the cohort studies (OR 0.95, 95% CI 0.51-1.78) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/34\">",
"     34",
"    </a>",
"    ]. The authors argue that the association, if it exists, is very small, and perhaps nonexistent (due to heterogeneity of the studies, ORs less than 1.0 in the cohort studies, and methodological limitations including potential biases and confounders, which were not adequately addressed). Even if one assumes a 1.3-fold increase in stroke risk for a woman under age 35 years using oral contraceptives, the potential risk of stroke (three additional strokes per 100,000 women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/34\">",
"     34",
"    </a>",
"    ] needs to be balanced with the maternal mortality associated with unwanted pregnancy (9 per 100,000 live births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the large Danish cohort study described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/12\">",
"     12",
"    </a>",
"    ], use of combined oral contraceptives was associated with an excess risk of thrombotic stroke in addition to myocardial infarction when compared with nonuse (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Coronary heart disease'",
"    </a>",
"    above). In the analysis adjusted for differences in progestin type and age, preparations containing ethinyl estradiol doses of 20 mcg or 30 to 40 mcg, the relative risks of thrombotic stroke risk were 1.6 and 1.75, respectively. Risks did not differ significantly between type of progestin. As described above, the absolute risk of an arterial thrombosis (stroke or myocardial infarction) is very low (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Coronary heart disease'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The risk of thrombotic stroke also appeared to be increased for other routes of administration: for the contraceptive patch (RR 3.15 95% 0.79-12.6) and the vaginal ring (RR 2.49 95% CI 1.41-4.41). No excess risk was seen with any of the progestin-only formulations.",
"   </p>",
"   <p>",
"    Thus, low-dose oral contraceptives may be associated with a small increase in stroke risk. If present, the absolute increase in risk is extremely low, particularly in healthy women under age 35 (non-smokers without hypertension). Risk appears to be similar for different progestins, and the risk of hemorrhagic stroke does not appear to be increased.",
"   </p>",
"   <p>",
"    If a woman on an oral contraceptive has a stroke, the pill should be discontinued and not resumed. Although the pill does not appear to be associated with an increased risk of hemorrhagic stroke, we suggest alternate forms of contraception in women who have had such a stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOEMBOLIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in the risk of venous thromboembolic disease (VTE) is seen with both high and low dose estrogen OC preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Although the reduction in steroid content of oral contraceptives has improved the safety and side effect profile of the pill, the increased risk of venous thrombosis has not been eliminated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/37,40,41\">",
"     37,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pooled analysis of studies regarding the use of OCs found that the risk ratios for thromboembolism in women taking non-third generation OCs compared with women who did not take an OC ranged from 1.1 to 4.8 (depending upon the type of study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/40\">",
"     40",
"    </a>",
"    ]. However, the absolute risk of thromboembolism is very low in healthy women, and the potential risk of VTE with the use of oral contraceptives is far less than the risks associated with unintended pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity further increases risk. Among OC users in two case-control studies, obese women had a two- [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/42\">",
"     42",
"    </a>",
"    ] to 24-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/43\">",
"     43",
"    </a>",
"    ] higher risk of VTE as non-obese women. In a third case-control study of 454 consecutive patients with a first episode of objectively diagnosed DVT, the risk of thrombosis among those with both obesity and OC use was increased 10-fold compared with women with neither risk factor; the increase in risk was lower (2.3- to 4.6-fold) with either risk factor alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334461040\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing age is also associated with increased risk. In a pooled analysis of two case-control studies, the risk of venous thromboembolism rose sharply after age 39 years among women taking estrogen-progestin oral contraceptives. The estimated incidence in women over age 39, when compared with adolescents, was 100 versus 25 cases of VTE per 100,000 person-years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Type of progestin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334461085\">",
"    <span class=\"h3\">",
"     Third generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been concerns that newer progestins may be associated with a greater risk of venous thromboembolism (VTE) when compared with earlier progestins. A number of observational studies, initially published in the mid-1990s, reported that women taking oral contraceptives (OCs) containing third generation progestins (desogestrel and gestodene, but not norgestimate) were at greater risk for VTE when compared with women taking OCs containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    , a second generation progestin (odds ratios ranging from 1.5 to 2.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Similar results were later reported in a meta-analysis of seven studies that compared the effects of different OCs on VTE risk; the overall adjusted odds ratio for VTE with third versus second generation oral contraceptives was 1.7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not all epidemiologic studies have confirmed these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], a large 2011 registry-based cohort study reported an excess risk of VTE with OCs containing desogestrel or gestodene compared with those containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquired resistance to activated protein C has been suggested as one mechanism by which the third generation OCs could predispose to venous thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In addition, third generation and second generation progestins have different effects on the anticoagulant pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. It has been suggested that second generation progestins, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    , are more effective than third generation progestins, such as desogestrel, in counteracting the thrombotic effects of estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, most studies suggest that the third generation progestins, desogestrel and gestodene (but not norgestimate), may be associated with a higher risk of venous thromboembolism when compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    , a second generation progestin. However, the absolute excess risk is small, and may be outweighed by the many benefits of OCs, including prevention of an unwanted pregnancy, and a reduction in ovarian and endometrial cancer risk. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Ovarian cancer'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Endometrial cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334461099\">",
"    <span class=\"h3\">",
"     Antiandrogens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5943098\">",
"    <span class=\"h4\">",
"     Cyproterone acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the impact of oral contraceptives containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    , a progestin and antiandrogen, on the risk of venous thromboembolism (VTE) are conflicting. In two studies, a higher risk of VTE was seen when compared with contraceptives containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/59,60\">",
"     59,60",
"    </a>",
"    ], while a lower risk was reported in a report from the Danish National Register of Patients (absolute risk 4.2 and 3.1 per 10,000 woman-years for levonorgestrel and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"     cyproterone",
"    </a>",
"    acetate, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5943105\">",
"    <span class=\"h4\">",
"     Drospirenone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drospirenone, a progestin that also has antiandrogen and antimineralocorticoid properties, has been associated with a greater risk of VTE when compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    in some, but not all studies. In 2012, based upon available data, the US Food and Drug Administration (FDA) added revised labeling to all oral contraceptives containing drospirenone, stating that they may be associated with up to a threefold higher risk of VTE compared with OCs with levonorgestrel and some other progestins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FDA does not advise women to stop drospirenone-containing OCs, but does suggest that an individual&rsquo;s risk of VTE be assessed before starting one in a new OC user, or before considering using one in a woman who has been on an OC not containing drospirenone. Lastly, the warning notes that the VTE risk with drospirenone is small and still lower than the risk of VTE during pregnancy.",
"   </p>",
"   <p>",
"    The FDA based its decision on the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two initial observational studies reported that oral contraceptives containing drospirenone were associated with an excess risk of venous thromboembolism (similar in magnitude to the third generation progestins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/49,63\">",
"       49,63",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      Two subsequent large, prospective, surveillance studies of new users of drospirenone-containing oral contraceptives subsequently reported that the thromboembolism risk was no different from that for other OCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. It was estimated that 9000 women would need to be treated with a drospirenone OC to see one additional case of venous thromboembolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After the publication of the two surveillance studies, two additional case-control studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/66,67\">",
"       66,67",
"      </a>",
"      ] and a registry-based cohort study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/53\">",
"       53",
"      </a>",
"      ] reported a two- to threefold increased risk of VTE with OCs containing drospirenone compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      An FDA sponsored study published after the Drug Safety Communication utilized computerized data files from two integrated medical care programs and two state Medicaid programs to obtain data regarding the risk of several cardiovascular endpoints in combined hormonal contraceptives users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/68\">",
"       68",
"      </a>",
"      ]. The authors identified a final cohort that included 189,210 person-years of exposure to drospirenone. In adjusted analyses, drospirenone use was associated with a significantly higher risk of VTE relative to low-estrogen comparators (RR 1.74; 95% CI 1.42-2.14). When the analysis was restricted to new users only, drospirenone was associated with a higher risk of both arterial thrombotic events (RR 2.01; 95% CI 1.06-3.81) and VTE (RR 1.77; 95% CI 1.33-2.35).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2011, the European Medicines Agency also concluded that drospirenone-containing birth control pills carry a higher risk of venous thromboembolism, but noted the overall risk of blood clot from any birth control method remains small and stopped short of advising women to stop taking pills containing drospirenone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Contraceptive patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are conflicting on whether the risk of venous thromboembolism is higher in users of the transdermal contraceptive patch (Ortho Evra) than users of oral contraceptives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=see_link&amp;anchor=H16#H16\">",
"     \"Transdermal contraceptive patch\", section on 'Major adverse events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Injectables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral and injectable progestin-only preparations for contraception do not appear to be associated with an increased risk of thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of contraception\", section on 'Injectable contraceptives'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Thrombophilias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of oral contraceptives (OC) significantly increases the risk of thrombosis in women with hereditary thrombophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 155 consecutive premenopausal women with deep venous thrombosis, the risk of thrombosis among those with both OC use and the factor V Leiden mutation was increased more than 30-fold compared with women with neither risk factor; the increase in risk was lower (four- to eightfold) with either risk factor alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/70\">",
"       70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link&amp;anchor=H14#H14\">",
"       \"Activated protein C resistance and factor V Leiden\", section on 'Risk of DVT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a retrospective family cohort study, women with hereditary deficiencies of protein S, protein C, or antithrombin who were taking an oral contraceptive had an annual incidence of venous thromboembolism of 3.5 percent, increasing to 12 percent if an additional thrombophilic defect was present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Screening for thrombophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some have argued that all women should be screened for the Factor V mutation before pregnancy or OC therapy. However, the cost efficacy of this approach is questionable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/37,72\">",
"     37,72",
"    </a>",
"    ]. Over 500,000 women would need to be screened for Factor V Leiden to avoid one death from pulmonary embolism, as only 5 percent of women have the mutation, and venous thrombosis-related mortality is low in young women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/37\">",
"     37",
"    </a>",
"    ]. The World Health Organization does not recommend routine screening for thrombogenic mutations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20903?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\", section on 'Oral contraceptives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other risk factors for venous thromboembolism are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cerebral vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carriers of hereditary thrombophilias (Factor V Leiden, the prothrombin gene mutation, and deficiencies of protein S, protein C, and antithrombin) and subjects with hyperhomocysteinemia who take an OC are at higher risk of cerebral vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20743?source=see_link\">",
"     \"Prothrombin gene mutation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72308940\">",
"    <span class=\"h2\">",
"     Surgical risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential perioperative risk of venous thromboembolism due to oral contraceptives and the indications for stopping OCs prior to surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H20#H20\">",
"     \"Perioperative medication management\", section on 'Oral contraceptives'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, even low dose OCs cause a modest increase in risk of venous thromboembolism. Some studies suggest that the risk of venous thromboembolism is higher with OCs containing third generation progestins (desogestrel and gestodene), when compared with OCs containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/46-48,77\">",
"     46-48,77",
"    </a>",
"    ]. However, this area remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/50,52,78-80\">",
"     50,52,78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OCs containing drospirenone also appear to be associated with a higher risk of venous thromboembolism compared with OCs containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    . As of 2012, these OCs carry revised labeling to reflect this possible excess risk.",
"   </p>",
"   <p>",
"    It is important to take a careful personal and family history of deep venous thrombosis to detect those women who might be at high risk before prescribing an OC. Women with antiphospholipid antibodies or the nephrotic syndrome also may be at increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The World Health Organization strongly discourages the use of oral contraceptives or other hormonal contraception in women with either an underlying thrombophilia or a history of a previous venous thromboembolic event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/83\">",
"     83",
"    </a>",
"    ]. However, they do not recommend routine screening for underlying thrombogenic mutations.",
"   </p>",
"   <p>",
"    Although there are no data specifically addressing the risk of recurrent deep venous thrombosis with oral contraceptives, data in postmenopausal women suggest that even low dose estrogen use increases risk of a recurrent event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RISK OF CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Overall cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptive use has been associated with an increased risk of certain types of cancer and a decrease in others. However, it appears that the pill is",
"    <strong>",
"     not",
"    </strong>",
"    associated with an overall increased risk of cancer. This was illustrated in the Royal College of General Practitioners' cohort study, which included nearly 50,000 women followed for a mean of 24 years. In pill users compared with nonusers, risks were significantly lower for colorectal, uterine, and ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/85\">",
"     85",
"    </a>",
"    ]. The incidence of breast cancer was similar in pill users and never users, but there were significant trends of increasing risk of cervical and central nervous system cancer in pill users. Depending upon the data set used, there was either a nonsignificant or significant reduction in overall cancer risk among users compared with nonusers, with an estimated absolute risk reduction between 10 and 45 per 100,000 woman-years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available data on breast cancer risk with OC use are conflicting.",
"   </p>",
"   <p>",
"    Epidemiologic studies have generally not demonstrated an association between OC use and the risk of breast cancer later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/86-91\">",
"     86-91",
"    </a>",
"    ]. This can be illustrated by the results of three of the largest series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Nurses' Health Study, in women over age 40 years, neither long-term past OC use, nor use prior to a first full-term pregnancy was associated with an increased breast cancer risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population-based, case-control study evaluated women ages 35 to 64 (4574 women with breast cancer and 4682 controls), over 75 percent of whom were using or had used OCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/89\">",
"       89",
"      </a>",
"      ]. The relative risks of breast cancer for current or previous oral contraceptive use were 1.0 (95% CI 0.8-1.2) and 0.9 (95% CI 0.8-1.0), respectively. Breast cancer risk was not associated with estrogen dose, duration of use, initiation at a young age (&lt;age 20), or race.",
"     </li>",
"     <li>",
"      In the Royal College of General Practitioners' study described above, the risk of breast cancer was similar in users compared with never users of the pill (RR 0.98, 95% CI 0.87-1.10) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, an increase in risk has been reported in some pooled and meta-analyses. In one pooled analysis published before the observational studies noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/88,89\">",
"     88,89",
"    </a>",
"    ], there was a small but significant increase in the overall relative risk of breast cancer (RR = 1.07) in forever versus never users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/92\">",
"     92",
"    </a>",
"    ]. However, because pill users are young, this represented a very small rise in absolute risk. In addition, concerns have been raised about this meta-analysis because a low percentage of women had ever used oral contraceptives (40 percent), and it lacked the follow-up necessary to determine whether there were long-term effects of OC use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on breast cancer risk in OC users with a family history of breast cancer are also conflicting. In the above case-control study, the risk was not increased in women with a family history of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/89\">",
"     89",
"    </a>",
"    ]. In contrast, a review of women taking OCs prior to 1975 (high dose formulations) found an increase in breast cancer risk in those who had a first-degree relative with breast cancer (RR = 3.3; 95% CI 1.6-6.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral contraceptive use may increase breast cancer risk in carriers of BRCA1 mutations, and possibly BRCA2 mutations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link&amp;anchor=H15#H15\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Cancer risk modifiers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cervical cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be an increased risk for developing cervical cancer among women who have taken OCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/85,91,94-96\">",
"     85,91,94-96",
"    </a>",
"    ]. A systematic review of 28 studies, including over 12,000 women with cervical cancer, found that the risk increased with increasing duration of oral OC use (",
"    <a class=\"graphic graphic_table graphicRef57084 \" href=\"mobipreview.htm?2/53/2907\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/97\">",
"     97",
"    </a>",
"    ]. Although there was considerable variation in study designs, the increased risk of cervical cancer was demonstrated after adjusting for the number of sexual partners, previous cervical smears, smoking, histology (adenocarcinoma or squamous cell), HPV status, and use of barrier methods. Adjustment for HPV status may not have been reliable since HPV testing at regular intervals was not routinely performed; thus, some HPV infections could have been missed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best available evidence comes from The Collaborative Group on Epidemiological Studies of Cervical Cancer, which reanalyzed and pooled individual participant data from 24 epidemiologic studies that included 16,573 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/98\">",
"     98",
"    </a>",
"    ]. The risk of invasive cervical cancer increased with increasing duration of use (RR for five or more years of use 1.90, 95% CI 1.69-2.13). The risk decreased after use ceased, returning to that of nonusers after 10 years.",
"   </p>",
"   <p>",
"    Similar patterns of risk were seen for invasive and in-situ cancer, and for women who tested positive for high-risk HPV. The absolute increase in risk is very low: the authors estimate that 10 years of use between ages 20 and 30 would increase the cumulative incidence of cervical cancer from 7.3 to 8.3 per 1000 and 3.8 to 4.5 per 1000 in less developed and more developed countries, respectively. It is still unclear whether the relationship between oral contraceptive use and cervical cancer is a causal one because their use is also associated with exposure to human papillomavirus, the known cause of cervical cancer.",
"   </p>",
"   <p>",
"    Some studies indicate HPV-negative OC users do not have an increased risk of cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/97,99\">",
"     97,99",
"    </a>",
"    ]. The mechanism for an increased cervical cancer risk in HPV-positive OC users noted in some studies may be related to a metabolite of estradiol, 16 alpha-hydroxyestrone, which can act as a cofactor with oncogenic HPV to promote cell proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/96,99-101\">",
"     96,99-101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have consistently shown that prolonged use of oral contraceptive pills (OCs) reduces the risk of ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/91\">",
"     91",
"    </a>",
"    ]. An analysis of 45 epidemiological studies from 21 countries found that, compared with women who had never used OCs, any use of OCs was associated with a significant reduction in risk of developing ovarian cancer (RR 0.73, 95% CI 0.70-0.76) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/102\">",
"     102",
"    </a>",
"    ]. Importantly, the protective effect persisted for 30 years after cessation of OCs. Low dose OCs are as effective as higher dose OCs. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of OCs to reduce the risk of ovarian cancer in women at high risk of this disease (BRCA1 or BRCA2 mutations) is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Endometrial cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of oral contraceptive pills decreases the risk of endometrial cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/85,91,103\">",
"     85,91,103",
"    </a>",
"    ]. In one study, women using combination oral contraceptive pills for at least 12 months had a relative risk of endometrial cancer of 0.6 (95% CI 0.3-0.9) compared with nonusers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/103\">",
"     103",
"    </a>",
"    ]. The protective effect of oral contraceptives persisted for at least 15 years after cessation of use. This benefit is likely related to the progestin effect of oral contraceptives, which suppress endometrial proliferation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of oral contraceptives on the risk of melanoma has been unclear. In a prospective cohort study of premenopausal Caucasian women, current oral contraceptive use was associated with a twofold increase in risk, particularly in current users with 10 or more years of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/104\">",
"     104",
"    </a>",
"    ]. However, a systematic meta-analysis that included 18 case-control studies showed no evidence for an increased risk of melanoma with the use of OCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H11#H11\">",
"     \"Risk factors for the development of melanoma\", section on 'Other factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OVERALL MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, oral contraceptive use in women over age 35 who smoke is associated with an increased risk of death from cardiovascular events. However, overall mortality rates are not increased, and may actually be decreased, among ever users of oral contraceptives compared with never users, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Oxford Family Planning cohort study of 17,032 women of reproductive age followed for 32 years, the rate ratio for death from any cause in those who had ever used oral contraceptives was 0.89 compared with never users (after adjusting for smoking, age, parity, social class, and duration of use) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Nurses&rsquo; Health Study, there was no adverse effect of oral contraceptive use on overall long-term mortality (relative risk [RR] of mortality 0.93 for ever users versus never users; RR 1.06 for &ge;10 years of use) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A possible mortality benefit was reported in the Royal College of General Practitioners' prospective cohort study of over 46,000 women followed for up to 39 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/108\">",
"       108",
"      </a>",
"      ]. Ever users of OCs had a significantly lower rate of death from any cause (RR 0.88). Lower rates of death were also seen for all cancers combined, individual cancers (colorectal, uterine, ovarian), cardiovascular disease, and coronary heart disease. The estimated absolute reduction in all cause mortality for ever users of OCs was 52 per 100,000 woman years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of women in this study had taken oral contraceptives containing higher doses of estrogen than are typically used today (&ge;50 mcg versus 20 to 35 mcg ethinyl estradiol). These data should reassure young, nonsmoking women that current use of oral contraceptives is not associated with an increased long-term risk of death, and may actually provide a small benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OTHER EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives have a variety of other effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Carbohydrate and lipid metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal glucose tolerance tests were fairly common in women taking high-dose OCs, but few women developed diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/109\">",
"     109",
"    </a>",
"    ]. Women taking low-dose OCs have normal glucose tolerance, but these pills do cause mild insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/109\">",
"     109",
"    </a>",
"    ]. In a study of Hispanic women with recent gestational diabetes who were breast feeding, the use of progestin-only OCs was associated with an increased risk of type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/110\">",
"     110",
"    </a>",
"    ]; the applicability of these findings to other women is unclear, but progestin-only OCs should be used with caution in breast-feeding women with a history of gestational diabetes mellitus. Other information on contraception options for diabetic women is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=see_link&amp;anchor=H14#H14\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\", section on 'Contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of OCs on serum lipid values depends upon the estrogen dose and the androgenicity of the progestin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .) In general, serum triglyceride concentrations rise slightly, but there are no consistent changes in serum high-density (HDL) or low-density (LDL) lipoprotein cholesterol concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estrogen component of OCs increases serum triglycerides and HDL concentrations and lowers serum LDL cholesterol concentrations.",
"     </li>",
"     <li>",
"      Oral but not transdermal preparations are associated with an increase in serum triglycerides [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/113-115\">",
"       113-115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The progestin usually increases serum LDL cholesterol and lowers serum HDL cholesterol concentrations, particularly the androgenic progestins (norgestrel and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Contraceptives with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      lower serum LDL cholesterol and raise serum HDL cholesterol concentrations because of the dominant effects of estrogen and the relatively low androgenicity of norethindrone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The newer progestins, such as desogestrel, tend to raise serum HDL cholesterol and lower LDL cholesterol concentrations. In a meta-analysis of 18 studies, administration of a desogestrel-containing OC increased the former by 5.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and reduced the latter by 4.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Increased binding proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estrogen component of OC pills, like any estrogen taken orally, raises the serum concentrations of thyroxine-binding globulin (TBG), cortisol-binding globulin (CBG), and sex hormone-binding globulin (SHBG). As a result, the serum concentrations of total thyroxine, triiodothyronine, cortisol, estradiol, and testosterone increase, but the serum concentrations of free thyroxine, triiodothyronine, cortisol, estradiol, and testosterone do not change. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/856?source=see_link\">",
"     \"Euthyroid hyperthyroxinemia and hypothyroxinemia\"",
"    </a>",
"    .) This effect of oral estrogen administration needs to be considered when evaluating tests of thyroid, adrenal, and gonadal function in women taking any estrogen orally.",
"   </p>",
"   <p>",
"    Low doses of estrogen administered transdermally or vaginally (eg, postmenopausal doses) do not cause such changes, although a transdermal contraceptive patch, which contains a much higher dose of estrogen, does increase SHBG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of contraception\", section on 'Transdermal contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Pregnancy and fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadvertent OC administration during early pregnancy has not been associated with an increase in risk of congenital anomalies. A possible exception is congenital urinary tract abnormalities, the frequency of which was increased in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When OCs are discontinued, several months may elapse before ovulatory cycles return, but there is no increased risk of infertility. To the contrary, the risk of primary infertility may be reduced in women who have taken an OC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Use during lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization and the American College of Obstetricians and Gynecologists (ACOG) have made recommendations for nonhormonal and hormonal contraception during lactation. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=see_link&amp;anchor=H20#H20\">",
"     \"Principles of medication use during lactation\", section on 'Contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625745963\">",
"    <span class=\"h2\">",
"     Sexual function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the impact of estrogen-progestin contraceptives on female sexuality are conflicting. Although OCs suppress serum testosterone concentrations, there are no definitive data that they have a negative impact on libido. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H17#H17\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Hormonal contraceptives'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Uterine fibroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of low dose OCs does not cause fibroids to grow; therefore, administration of these drugs is not contraindicated in women with fibroids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link&amp;anchor=H5291214#H5291214\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Hormonal contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Liver disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of liver disorders have been thought to be associated with oral contraceptive use. Evidence for an association with hepatic adenoma is good, while evidence for an association with focal nodular hyperplasia and hepatocellular carcinoma is inconclusive. Estrogen-progestin contraceptives containing &le;35 mcg of ethinyl estradiol have not been shown to have an adverse effect on liver function tests; this includes pills containing early generation progestins, third generation progestins, and drospirenone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/118-120\">",
"     118-120",
"    </a>",
"    ]. The eligibility criteria for women with known liver disease (or past disease) are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Focal nodular hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of oral contraceptives is not required for the development of focal nodular hyperplasia (FNH), but they may be a risk factor, although data are inconsistent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22791?source=see_link\">",
"     \"Focal nodular hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Hepatic adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives are associated with the development of hepatic adenomas; risk correlates with dose and duration of use. Most of the available incidence data are based upon early OC preparations with high estrogen and progestin content; the incidence is thought to be decreasing with lower dose OC preparations, but data are limited. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15352?source=see_link\">",
"     \"Hepatic adenoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating whether oral contraceptives increase the risk of hepatocellular carcinoma (HCC) have produced mixed results. No significant relationship was detected in a meta-analysis of 12 studies (OR 1.45; 95% CI 0.93&ndash;2.27) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/121\">",
"     121",
"    </a>",
"    ]. Six of the 12 studies reported a possible increased risk of HCC in women using OCs long-term (&gt;5 years; OR range 2 to 20), but the studies had potentially important methodologic limitations. Thus, any association between long-term OC use and HCC remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83166920\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral exogenous estrogen raises serum triglyceride concentrations, and has been associated with hypertriglyceridemia-induced acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/122\">",
"     122",
"    </a>",
"    ]. We recommend against the use of oral contraceptives in women whose serum triglyceride levels are &gt;500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    due to a heightened risk of this complication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31064?source=see_link&amp;anchor=H4#H4\">",
"     \"Hypertriglyceridemia-induced acute pancreatitis\", section on 'Secondary hypertriglyceridemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women and their clinicians believe that oral contraceptives cause weight gain. However, available data suggest that this is not the case. As an example, in a study of 49 healthy women initiating treatment with an oral contraceptive containing 30 mcg ethinyl estradiol plus 75 mcg gestodene, anthropometric measurements before and after the initiation of OC use were compared with those in 31 age-and-weight matched women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/123\">",
"     123",
"    </a>",
"    ]. Baseline BMI, percent fat, percent water, and waist-to-hip (WHR) ratio did not change significantly after six cycles in the OC users. A similar number of women gained weight in both groups (30.6 percent of users, 35.4 percent of controls); the typical weight gain in the OC group was only 0.5 kg. The weight gain in these women was due to accumulation of fat, not body water. Approximately 20 percent of women in both groups lost weight.",
"   </p>",
"   <p>",
"    In a systematic review of 44 trials (only three of which had a placebo group), there was no evidence to support a causal relationship between combination oral contraceptive use and weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/124\">",
"     124",
"    </a>",
"    ]. The majority of trials that compared pills of variable types and doses (ethinyl estradiol doses 20 to 50 mcg) showed no significant difference in weight between groups. The authors concluded that the available data exclude a large, but not a small, effect of oral contraceptives on weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is among the most common side effects that are reported with oral contraceptive use, and is a frequently cited reason for discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/125\">",
"     125",
"    </a>",
"    ]. In a systematic review of oral contraceptives and headache, quantitative analysis was not possible because of differences in study populations, pill formulations, trial endpoints, and trial durations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/126\">",
"     126",
"    </a>",
"    ]. However, the authors made several conclusions, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There does not appear to be a strong relationship between oral contraceptive use and headache for most women. In controlled trials, increases in headache frequency were sometimes seen in early cycles of pill use, with improvement in subsequent cycles.",
"     </li>",
"     <li>",
"      Women with a strong personal or family history of troublesome headaches (in particular, migraine) did appear to be at higher risk for new-onset headache related to oral contraceptive use. However, most women with this history reported no change in overall headache history.",
"     </li>",
"     <li>",
"      The dose or type of progestin did not appear to affect headache risk. The effect of estrogen dose was unclear.",
"     </li>",
"     <li>",
"      Regardless of cause, when headaches started or worsened with oral contraceptive use, they tended to improve despite continued use. The authors estimated that women who experience headache in the first cycle of pill use have a one in three and 1 in 10 chance of experiencing headache in the second and third cycle, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, it appears that concerns about headache should not be a major factor in the decision about whether to use oral contraceptives. However, oral contraceptives should not be used in women with pseudotumor cerebri (idiopathic intracranial hypertension) or migraines with focal symptoms. The association of pseudotumor cerebri with prothrombotic abnormalities (antithrombin III deficiency and antiphospholipid antibodies), and an increased risk of cerebral vein thrombosis, represents an unacceptable risk for using combined estrogen-progestin contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/127\">",
"     127",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Migraine headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine headaches have been reported to worsen, improve, or not change in women taking an OC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/128-131\">",
"     128-131",
"    </a>",
"    ]. If migraines occur during OC therapy, it is typically during the hormone-free interval. Use of extended cycle OC regimens or OCs with a shortened pill-free interval (four days) appear to result in fewer and less severe migraines when compared with standard OCs with a seven-day pill-free interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=see_link\">",
"     \"Estrogen-associated migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral contraceptive use has been associated with a small but significant increase in ischemic stroke risk. The absolute increase in risk, however, is extremely low. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Stroke'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Migraine headaches appear to be an independent risk factor for ischemic stroke in women. Although there are concerns that studies of stroke risk in women with migraine headaches have significant methodological limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/1\">",
"     1",
"    </a>",
"    ], the best evidence for an association comes from a meta-analysis of 11 case-control studies and three cohort studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/134\">",
"     134",
"    </a>",
"    ]. The pooled relative risk for ischemic stroke among women with any type of migraine was 2.16. In a pooled analysis of three of the studies, the relative risk among women with migraines who were also taking oral contraceptives was 8.72 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/134\">",
"     134",
"    </a>",
"    ]. Migraine with aura appears to be associated with a greater risk of stroke than migraine without aura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=see_link&amp;anchor=H19#H19\">",
"     \"Headache, migraine, and stroke\", section on 'Migraine and ischemic stroke risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The World Health Organization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/136\">",
"     136",
"    </a>",
"    ] and American College of Obstetricians and Gynecologists (ACOG) conclude from the literature that women with a history of migraine headaches who take oral contraceptives are at increased risk for cerebral thromboembolism, and that the risks of OC use usually outweigh the benefits in women over age 35 with migraines. In addition, they suggest that for women of any age with migraines associated with aura or focal symptoms, the risk of OC use is unacceptable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=see_link&amp;anchor=H19#H19\">",
"     \"Headache, migraine, and stroke\", section on 'Migraine and ischemic stroke risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with migraines without aura, other modifiable risk factors for stroke such as smoking, hypertension, and dyslipidemia should be identified and treated before considering using an OC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/137,138\">",
"     137,138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 25 percent of women with migraine headaches have auras, which are usually visual. The International Headache Society&rsquo;s definition of aura is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H21674127#H21674127\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migraine with aura'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with migraines",
"    <strong>",
"     with",
"    </strong>",
"    aura but no other risk factors, the frequency and severity of the aura is likely to be important. For example, a patient who experienced only one to two aura in the distant past may be a reasonable candidate for an OC, while a patient who experiences a prolonged aura with every migraine would not be [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature is conflicting with regard to a possible role of OCs in predisposing to the development of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/140\">",
"     140",
"    </a>",
"    ]. Given the uncertainty, it is reasonable to continue the OC in women with inflammatory bowel disease who are doing well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/140\">",
"     140",
"    </a>",
"    ]. However, cessation should be considered in those women who remain symptomatic despite conventional drug therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7450?source=see_link&amp;anchor=H10#H10\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\", section on 'Oral contraceptives and hormone replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential risk of developing or worsening of systemic lupus erythematosus is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16646?source=see_link\">",
"     \"Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives or postmenopausal hormone therapy appear to induce or exacerbate symptoms of hereditary angioedema in some patients. In a study of 516 women with recurrent angioedema, 228 (44 percent) had used one of the two hormone therapies. Of these 228 patients, postmenopausal hormone therapy led to angioedema attacks in 46 (20 percent), including 20 of 32 (63 percent) and 24 of 39 (64 percent) of the women with hereditary angioedemas types I and III, respectively. Only 2 of 50 women with idiopathic angioedema were affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/7/39034/abstract/141\">",
"     141",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18707?source=see_link\">",
"       \"Patient information: Hormonal birth control (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=see_link\">",
"       \"Patient information: Choosing birth control (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=see_link\">",
"       \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=see_link\">",
"       \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"       \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1385889034\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early side effects of oral contraceptives (OCs) include bloating, nausea, and breast tenderness. Although they may be bothersome enough to lead to discontinuation of the OC, these side effects usually subside in several months. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breakthrough bleeding is the most common side effect of OCs. The most common cause of breakthrough bleeding is thought to be missed pills, but it is common in women who do not miss pills. Its occurrence does not indicate a decrease in efficacy, but reflects tissue breakdown as the endometrium adjusts to a new thin state in which it is fragile and atrophic. Breakthrough bleeding is more of a problem with lower doses of estrogen because estrogen stabilizes the endometrium. In addition, bleeding is more common with extended and continuous regimens, although most women eventually develop amenorrhea. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Breakthrough bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral contraceptive use does not cause subsequent menstrual cycle disorders, including amenorrhea. Women who do not menstruate three months after discontinuing an OC should undergo the same evaluation for amenorrhea as any woman with amenorrhea. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Post-pill amenorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most data suggest that weight gain is not a consistent finding with oral contraceptives. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Weight'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral contraceptives may be associated with an increased risk of myocardial infarction. However, because myocardial infarction is an extremely rare event in otherwise healthy women of reproductive age, even a doubling of the risk would result in an extremely low attributable risk. Risk in older women who smoke outweighs the risk of an unwanted pregnancy. Low-dose oral contraceptives may be associated with a small increase in stroke risk. If present, the absolute increase in risk is extremely low, particularly in healthy women under age 35 (non-smokers without hypertension). Risk appears to be similar for different progestins, and the risk of hemorrhagic stroke does not appear to be increased. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cardiovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increase in the risk of venous thromboembolic disease (VTE) is seen with both high and low dose estrogen OC preparations. Although the reduction in steroid content of oral contraceptives has improved the safety and side effect profile of the pill, the increased risk of venous thrombosis has not been eliminated. Risk is affected by patient age, weight, and thrombophilia status. The type of progestin also affects risk. A pooled analysis of studies regarding the use of OCs found that the risk ratios for thromboembolism in women taking non-third generation OCs compared with women who did not take an OC ranged from 1.1 to 4.8 (depending upon the type of study). However, the absolute risk of thromboembolism is very low in healthy women, and the potential risk of VTE with the use of oral contraceptives is far less than the risks associated with unintended pregnancy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Venous thromboembolic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of ovarian and endometrial cancer are both reduced with oral contraceptive use. The risk of cervical cancer appears to be increased, while data on breast cancer are conflicting. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Risk of cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The World Health Organization and American College of Obstetricians and Gynecologists (ACOG) conclude from the literature that women with a history of migraine headaches who take oral contraceptives are at increased risk for cerebral thromboembolism, and that the risks of OC use usually outweigh the benefits in women over age 35 with migraines. In addition, they suggest that for women of any age with migraines associated with aura or focal symptoms, the risk of OC use is unacceptable. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Migraine headaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/1\">",
"      Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/2\">",
"      Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/3\">",
"      ESHRE Capri Workshop Group, Collins J, Crosignani PG. Endometrial bleeding. Hum Reprod Update 2007; 13:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/4\">",
"      Endrikat J, Gerlinger C, Plettig K, et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecol Endocrinol 2003; 17:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/5\">",
"      Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol 1996; 174:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/6\">",
"      Lawrie TA, Helmerhorst FM, Maitra NK, et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011; :CD004861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/7\">",
"      Jacobs HS, Knuth UA, Hull MG, Franks S. Post-\"pill\" amenorrhoea--cause or coincidence? Br Med J 1977; 2:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/8\">",
"      Davis AR, Kroll R, Soltes B, et al. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril 2008; 89:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/9\">",
"      Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998; 128:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/10\">",
"      Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981; 305:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/11\">",
"      Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study. Lancet 1981; 1:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/12\">",
"      Lidegaard &Oslash;, L&oslash;kkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/13\">",
"      Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989; 298:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/14\">",
"      Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001; 161:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/15\">",
"      Petitti DB. Hormonal contraceptives and arterial thrombosis--not risk-free but safe enough. N Engl J Med 2012; 366:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/16\">",
"      Lewis MA, Spitzer WO, Heinemann LA, et al. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/17\">",
"      Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999; 318:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/18\">",
"      Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/19\">",
"      Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005; 90:3863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/20\">",
"      Schiff I, Bell WR, Davis V, et al. Oral contraceptives and smoking, current considerations: recommendations of a consensus panel. Am J Obstet Gynecol 1999; 180:S383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/21\">",
"      Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/22\">",
"      Merz CN, Johnson BD, Berga S, et al. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Fertil Steril 2006; 85:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/23\">",
"      Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/24\">",
"      Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol 2002; 99:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/25\">",
"      Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/26\">",
"      Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/27\">",
"      Heinemann LA, Lewis MA, Thorogood M, et al. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from International Study on Oral Contraceptives and Health of Young Women. BMJ 1997; 315:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/28\">",
"      Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/29\">",
"      Schwartz SM, Siscovick DS, Longstreth WT Jr, et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997; 127:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/30\">",
"      Siritho S, Thrift AG, McNeil JJ, et al. Risk of ischemic stroke among users of the oral contraceptive pill: The Melbourne Risk Factor Study (MERFS) Group. Stroke 2003; 34:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/31\">",
"      Oral contraceptives and stroke in young women. Associated risk factors. JAMA 1975; 231:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/32\">",
"      Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000; 284:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/33\">",
"      Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/34\">",
"      Chan WS, Ray J, Wai EK, et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004; 164:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/35\">",
"      Hoyert DL, Arias E, Smith BL, et al. Deaths: final data for 1999. Natl Vital Stat Rep 2001; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/36\">",
"      Porter JB, Hunter JR, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/37\">",
"      Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/38\">",
"      Kujovich JL. Hormones and pregnancy: thromboembolic risks for women. Br J Haematol 2004; 126:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/39\">",
"      Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/40\">",
"      Douketis JD, Ginsberg JS, Holbrook A, et al. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997; 157:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/41\">",
"      Bloemenkamp KW, Rosendaal FR, B&uuml;ller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/42\">",
"      Sidney S, Petitti DB, Soff GA, et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004; 70:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/43\">",
"      Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/44\">",
"      Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/45\">",
"      Nightingale AL, Lawrenson RA, Simpson EL, et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/46\">",
"      Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/47\">",
"      Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/48\">",
"      Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/49\">",
"      Lidegaard &Oslash;, L&oslash;kkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339:b2890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/50\">",
"      Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/51\">",
"      Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/52\">",
"      Farmer RD, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/53\">",
"      Lidegaard &Oslash;, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343:d6423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/54\">",
"      Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/55\">",
"      Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/56\">",
"      Middeldorp S, Meijers JC, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/57\">",
"      Kemmeren JM, Algra A, Meijers JC, et al. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost 2002; 87:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/58\">",
"      Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 2004; 103:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/59\">",
"      Seaman HE, de Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod 2003; 18:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/60\">",
"      Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/61\">",
"      Lidegaard &Oslash;. Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol. J Obstet Gynaecol Can 2003; 25:575.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Birth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm299605.htm (Accessed on April 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/63\">",
"      van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/64\">",
"      Dinger JC, Heinemann LA, K&uuml;hl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007; 75:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/65\">",
"      Seeger JD, Loughlin J, Eng PM, et al. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007; 110:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/66\">",
"      Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342:d2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/67\">",
"      Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 342:d2151.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Office of Surveillance and Epidemiology. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. file://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf (Accessed on February 03, 2012).",
"    </li>",
"    <li>",
"     European Medicines Agency. PhVWP Monthly report on safety concerns, guidelines and general matters, January 2012 - Issue number: 1201. file://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/01/WC500121387.pdf (Accessed on April 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/70\">",
"      Vandenbroucke JP, Koster T, Bri&euml;t E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/71\">",
"      van Vlijmen EF, Brouwer JL, Veeger NJ, et al. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007; 167:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/72\">",
"      Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/73\">",
"      de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 1998; 316:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/74\">",
"      Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/75\">",
"      Martinelli I, Battaglioli T, Pedotti P, et al. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 2003; 102:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/76\">",
"      Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006; 73:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/77\">",
"      Leblanc ES, Laws A. Benefits and risks of third-generation oral contraceptives. J Gen Intern Med 1999; 14:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/78\">",
"      Johannisson E. Safety of modern oral contraceptives. The International Committee for Research in Reproduction. Lancet 1996; 347:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/79\">",
"      Barbieri RL, Speroff L, Walker AM, McPherson K. Therapeutic controversy: The safety of third-generation oral contraceptives. J Clin Endocrinol Metab 1999; 84:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/80\">",
"      Vandenbroucke JP, Rosendaal FR. End of the line for \"third-generation-pill\" controversy? Lancet 1997; 349:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/81\">",
"      Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991; 20:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/82\">",
"      Julkunen HA, Kaaja R, Friman C. Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol 1993; 32:227.",
"     </a>",
"    </li>",
"    <li>",
"     Contraceptive Technology Update June 2004; 25:61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/84\">",
"      H&oslash;ibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/85\">",
"      Hannaford PC, Selvaraj S, Elliott AM, et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/86\">",
"      Long-term oral contraceptive use and the risk of breast cancer. The centers for Disease Control Cancer and Steroid Hormone Study. JAMA 1983; 249:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/87\">",
"      Oral-contraceptive use and the risk of breast cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1986; 315:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/88\">",
"      Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control 1997; 8:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/89\">",
"      Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/90\">",
"      Davidson NE, Helzlsouer KJ. Good news about oral contraceptives. N Engl J Med 2002; 346:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/91\">",
"      Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006; 95:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/92\">",
"      Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996; 347:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/93\">",
"      Grabrick DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000; 284:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/94\">",
"      Ursin G, Peters RK, Henderson BE, et al. Oral contraceptive use and adenocarcinoma of cervix. Lancet 1994; 344:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/95\">",
"      Thomas DB, Ray RM. Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol 1996; 144:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/96\">",
"      Moreno V, Bosch FX, Mu&ntilde;oz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/97\">",
"      Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/98\">",
"      International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/99\">",
"      de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2003; 103:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/100\">",
"      Auborn KJ, Woodworth C, DiPaolo JA, Bradlow HL. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int J Cancer 1991; 49:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/101\">",
"      Newfield L, Bradlow HL, Sepkovic DW, Auborn K. Estrogen metabolism and the malignant potential of human papillomavirus immortalized keratinocytes. Proc Soc Exp Biol Med 1998; 217:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/102\">",
"      Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/103\">",
"      Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 1987; 257:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/104\">",
"      Feskanich D, Hunter DJ, Willett WC, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999; 81:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/105\">",
"      Pfahlberg A, Hassan K, Wille L, et al. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev 1997; 25:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/106\">",
"      Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/107\">",
"      Colditz GA. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses' Health Study. Ann Intern Med 1994; 120:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/108\">",
"      Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010; 340:c927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/109\">",
"      Krauss RM, Burkman RT Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992; 167:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/110\">",
"      Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/111\">",
"      Lobo RA, Skinner JB, Lippman JS, Cirillo SJ. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril 1996; 65:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/112\">",
"      LaRosa JC. Effects of oral contraceptives on circulating lipids and lipoproteins: maximizing benefit, minimizing risk. Int J Fertil 1989; 34 Suppl:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/113\">",
"      Greenlund KJ, Webber LS, Srinivasan S, et al. Associations of oral contraceptive use with serum lipids and lipoproteins in young women: the Bogalusa Heart Study. Ann Epidemiol 1997; 7:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/114\">",
"      Foulon T, Payen N, Laporte F, et al. Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. Contraception 2001; 64:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/115\">",
"      Kiriwat O, Petyim S. The effects of transdermal contraception on lipid profiles, carbohydrate metabolism and coagulogram in Thai women. Gynecol Endocrinol 2010; 26:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/116\">",
"      Li DK, Daling JR, Mueller BA, et al. Oral contraceptive use after conception in relation to the risk of congenital urinary tract anomalies. Teratology 1995; 51:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/117\">",
"      Bagwell MA, Thompson SJ, Addy CL, et al. Primary infertility and oral contraceptive steroid use. Fertil Steril 1995; 63:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/118\">",
"      Dickerson J, Bressler R, Christian CD. Liver function tests and low-dose estrogen oral contraceptives. Contraception 1980; 22:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/119\">",
"      Paseka J, Unzeitig V, Cibula D, Chroust K. [Liver function tests during administration of triphasic contraceptives containing Norgestimate]. Ceska Gynekol 2000; 65:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/120\">",
"      Szlendak-Sauer K, Radowicki S, Sk&oacute;rzewska K. [The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function]. Ginekol Pol 2009; 80:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/121\">",
"      Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 2007; 47:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/122\">",
"      Goldenberg NM, Wang P, Glueck CJ. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin Chim Acta 2003; 332:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/123\">",
"      Reubinoff BE, Grubstein A, Meirow D, et al. Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril 1995; 63:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/124\">",
"      Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2006; :CD003987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/125\">",
"      Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/126\">",
"      Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 2005; 193:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/127\">",
"      Walsh J, Smith C. The clinical enquiry service; benign intracranial hypertension. Br J Fam Plann 2000; 26:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/128\">",
"      Granella F, Sances G, Zanferrari C, et al. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993; 33:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/129\">",
"      Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003; 23:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/130\">",
"      Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/131\">",
"      Aegidius K, Zwart JA, Hagen K, et al. Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology 2006; 66:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/132\">",
"      Sulak P, Willis S, Kuehl T, et al. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 2007; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/133\">",
"      De Leo V, Scolaro V, Musacchio MC, et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 2011; 96:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/134\">",
"      Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005; 330:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/135\">",
"      MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 2007; 38:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/136\">",
"      Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999; 318:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/137\">",
"      Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 1995; 102:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/138\">",
"      Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives &amp; Hormone Replacement Therapy. Cephalalgia 2000; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/139\">",
"      Loder EW, Buse DC, Golub JR. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache 2005; 45:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/140\">",
"      Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterology 1990; 99:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/7/39034/abstract/141\">",
"      Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003; 114:294.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7399 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39034=[""].join("\n");
var outline_f38_7_39034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1385889034\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Breakthrough bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Post-pill amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H807323864\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VENOUS THROMBOEMBOLIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H334461040\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Type of progestin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H334461085\">",
"      - Third generation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H334461099\">",
"      - Antiandrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5943098\">",
"      Cyproterone acetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5943105\">",
"      Drospirenone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Contraceptive patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Injectables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Screening for thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cerebral vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72308940\">",
"      Surgical risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RISK OF CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Overall cancer risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OVERALL MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OTHER EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Carbohydrate and lipid metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Increased binding proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Pregnancy and fertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Use during lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625745963\">",
"      Sexual function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Uterine fibroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Liver disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Focal nodular hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Hepatic adenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83166920\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Headaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Migraine headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1385889034\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/59/11184\" title=\"table 1\">",
"      Estrogen and progestin types and doses in hormonal contraceptive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/13/12506\" title=\"table 2\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/53/2907\" title=\"table 3\">",
"      Cervical cancer risk with OCs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=related_link\">",
"      Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=related_link\">",
"      Estrogen-associated migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/856?source=related_link\">",
"      Euthyroid hyperthyroxinemia and hypothyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22791?source=related_link\">",
"      Focal nodular hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=related_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15352?source=related_link\">",
"      Hepatic adenoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=related_link\">",
"      Hereditary angioedema: Prevention of attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31064?source=related_link\">",
"      Hypertriglyceridemia-induced acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16646?source=related_link\">",
"      Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=related_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18707?source=related_link\">",
"      Patient information: Hormonal birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=related_link\">",
"      Transdermal contraceptive patch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_7_39035="Narrow QRS complex tachycardia classification by anatomy";
var content_f38_7_39035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of narrow QRS complex tachycardias by structures required for initiation and maintenance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Atrial tissue only",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sinus tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inappropriate sinus tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sinoatrial nodal reentrant tachycardia (SANRT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intraatrial reentrant tachycardia (IART)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrial tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multifocal atrial tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrial fibrillation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrial flutter",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            AV junction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            AV nodal reentrant tachycardia (AVNRT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrioventricular reentrant tachycardia (AVRT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Junctional tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Junctional ectopic tachycardia in children",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nonparoxysmal junctional tachycardia in adults",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39035=[""].join("\n");
var outline_f38_7_39035=null;
var title_f38_7_39036="Management strep TSS";
var content_f38_7_39036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid empiric management of streptococcal toxic shock syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Isolation of Group A streptococcus (GAS) from a normally sterile site (eg, blood cerebrospinal, pleural, or peritoneal fluid, tissue biopsy, or surgical wound)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        and",
"       </strong>",
"       hypotension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        plus",
"       </strong>",
"       evidence of failure of two of more organ systems:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renal failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coagulopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Liver involvement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adult respiratory distress syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Erythematous macular rash",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Soft tissue necrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Management",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Hemodynamic support",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Massive amounts of intravenous fluids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vasopressors (eg, dopamine and/or norepinephrine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Surgical therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Prompt and aggressive exploration and debridement of suspected sites of infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Consider surgical intervention in patients who have fever and excruciating pain, particularly with soft tissue swelling or formation of violaceous vesicles or bullae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Empiric antibiotics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Immediately begin empiric antibiotics, following culture of blood and suspected site of infection, with broad-spectrum antibiotics including:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Clindamycin (900 mg IV every eight hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <strong>",
"        plus",
"       </strong>",
"       one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       A carbapenem (eg, imipenem 500 mg every six hours",
"       <strong>",
"        or",
"       </strong>",
"       meropenem 1 g every eight hours)",
"       <strong>",
"        or",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       A combination drug containing a penicillin plus beta-lactamase inhibitor 1 g every eight hours) (eg, ticarcillin-clavulanate 3.1 g every four hours",
"       <strong>",
"        or",
"       </strong>",
"       piperacillin-tazobactam 4.5 g every six hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Tailored antibiotics (eg, once diagnosis of toxic shock syndrome due to GAS is established)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Clindamycin (900 mg IV every eight hours)",
"       <strong>",
"        plus",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Penicillin G (4 million units IV every four hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Intravenous immune globulin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Treatment with intravenous immune globulin (1 g/kg day one, followed by 0.5 g/kg days two and three)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39036=[""].join("\n");
var outline_f38_7_39036=null;
var title_f38_7_39037="GRE binding in asthma";
var content_f38_7_39037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glucocorticoid response element (GRE) binding in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 278px; background-image: url(data:image/gif;base64,R0lGODlhrQEWAeYAAP///4CAgAAAAAAz/wCZM0BAQMDAwIDMmf8AAMDmzUCzZnBwcP+AgEBm/yAgIBAQEPDw8FBQUNDQ0DAwMCBN/6CgoPDz/7CwsBBA///w8P9AQICZ/+Dg4P8QEP/AwMDN/5CQkLDA//8wMNDZ/2BgYP+goP/Q0GCA//9gYDBZ/6Cz//+wsODm/1Bz/5Cm/3CN//9wcP9QUP8gIP/g4GC/gP+QkBCfQHDGjbDfwNDs2SCmTaDZs/D585DTpjCsWeDz5lC5c7Cw769gn49DdmBiSQA/5eDW7x8s34C8ia+Pz3Cplq8PT+8JAwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACtARYBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgQUISAgSoMIgDiAAXBkGosBDCwYsYBQnYKGABAA4PHkzoKGhkAQETMqosyFDCRgALBIAA8EAAhAsCIgCIICCiIAMKgwYwsLLoPQ4CHAA4SZRpAAEBADyN+lNogAJUjWqNxzMi06UCgEKVOhaRwq1o20E4yXBnTwAj/yWAIBlzptmsafOW42BSIYcKOXEqRerAgAMBHBKd1ct4nAGOG4kuqDlBgqAKhx20vdu4s7/FnkPjAy269DzSplO7Q626dTrWrmOTgy279jfatnNrw627dzXevoNDAy68uCeKQi2XIm68eaaTkMMux+u8eqcCIAwYKLDAgU5SzK2Lh/RWKtYC08erz+TgQYDJEa6mX0+f0oWaAh5IWGB3VPj6ABICgXap/BcggBJEUMCCHpli4IH0HcYReg5SB+GFhOS0yoMYihdBgwVa2OGFJDywIHencDiic9BtROF8eUFwVQAWrRiNigKRwBEJNopiAAQSaKedcjCmFV2PoYTVov8AL4InolESJoUkKAH8JdRmTjJ2X34+TckMjgINWKOXnUTnYopPklndgiKxyWOFalYSAgUDDEBBCKk9QBRMbxYZ5yMh1CnoAHiWJgCPECiI5p+S0DmonabFxFGanoA5pQUbPPooBg10+sIGG7jwwagWaAXCgv35ySgiI5wwQAua1ikIC6N+AOoGJ3TagKCcegqqqKQGFOSQi66aSAgNYPACCwA4OigFkNA66q25dsqrrp+GWmupksxZ552JBGvBB8x28kIDqUh6piIDJgbAgEIqN1FFilh6oQUuUECBCtwCEOijhXIira2gVrtrnb02kC2wH/Trr6YBF1JnCwB8MMD/Bp7smkp+QWFpiAE8UfXYhCUxiVK9lJLJwgucRjyIt3a6jMrA1Op6LQaaQnuIoKNeLIgLDbRQ6AYqjICxChsg+4IFuY4gyLkNnOC0xqg4kPIgk/6EErE46dSVYlf3+AGsJ5SLDK2xDoDIAClgcKfPLwzwAqx4DoCz2rvqa3feglCwAcvQUn3KAgXEu8hUWptIQmKII16VUFgZq0IKfjusTNprN6DCALtijEEKAFjwKgBsD6KxxRhT/cG5OAMguClLNnmI4xKQcNXJjZcFAFCQh30hCxt8rkI0zgqqsyGcu14nxsmTjm7zylfss8aBCp0C3mqjgpxCHhvieIYCADCX/0d1ga1mqwOc8ME0/w4qsyDJW+wz3Zm64LzpaqMefaZJ0xk9LgbQEQmIEoD4nAQ9hDEMYsw3JRUka1nWgBm4MicIV2HMArBSFvzQJYjTTU9tFrie3v5XigLs50QoSsSRLiChCNQIM0npHiHsJRx86Ytf9FESZGQnChr2hgUn4NT6jLUJH9pmbBgoG4YgQLgIdElV9FGBvjZguQMt6Yn+8Z1wgMep4dloLBCYAA9DYUTTfMBV6ptSAXwiHzipx4EY2IDZbLSgCThgQd4pVnUwdcMqrshMTNKjcYCIgRYMkYghas4HkqVERG5Ii6WxgBQp4AI/OtKNuuGi5i75ijKq5P+M6XMaJzsJSb1MLo5zvORTYOKRBQkyNXzc1ygLsUpXuhKTpgHiqw45y0HUEj23hGJjkKWsVPZSEE+JzhipVMqBSDAEktRXJY9pFjMt8xOevEf7rvW+fZSgBBnJpj2K962BZKADHcgAODgAoiylBXMCiQECEBADbayFSTcx0SuNkrZ5ikADMWAAA1bgARPgYwXznOcKGLECgS5UEA0dqDAAsxH8tDOLaGHB9XImCA94oAQC1YAGZOBPDaBAoB6dQSu+6YtzJhQB6UxEBkSAAA3QlAEzrelNgxGAlMzlAVjEqFZCoCwhQGwRGfBoDRgAA5F2YJ4iPSkDUiqKc8bUFUn/VapAm+rUl3q1nohgAAJgIAgTNHSsZX3oL3pqgLlUwABEcmdRWBYEmwbBUROkRFaXytV5dkCkMGBADTyqzkvIk56hyKoHlspUkWrgqVCNqkCnSlWEelWhiCgBVBlgUM3WlLPCSOYO93kQjabACCKIQWFJMQOPChQFIvUrYAXrUUdYFrORUCxjufrYhDpWqpT1gEptG9jJblWthmAAZBEATuUmFJzAqAAKGUTaghD1BSaQAQpk0VoPCDQGNp2nDEQq0BLUVhAuTehVAaDbrTp2ub+drEeF+4rCmgAGNbUvfjUAD3GywwIsC4EJOsCAXpjAAxEFL00RIAOSelUG8JUs/0qpygsGaMC8KEBASDGs4WC0C14/qm5ARpCCBrCgBB2ArjHEelkE1GAZHtCAeAsc4xkLAwQP4MDIZCLif6ggjgBAMXKLsYLiGhcGQ2ZMBHj0mALkEZcCYRoG1oeCDhiUmpiI3GPM0+N9kLgBpUKBCIaL5UtEwAFjerIw+fFjjM1UBKstsyUAY7UAHEaGzIxyENc3UxTEWc6W0NGOGNGuhjykS/OqwJhm18x3fLlUA97uQWSElUWTIyEBiCsiQFYWkIiEJHAxWUoY6I82l7UDL5YGpWkUC0EfCh9ZgwmPa3ITDX2NM/2Q8hA1q+JouLpPrjjSaMryFaeM5Xu8C0rk+P/xaEHUoAMeqIawXxElpQybKsUOS+6ykmyFLFsfphZEla9MjWrHYktAzYfjvhaX8ck6VbRs9Dl0jV4x/1ka6A4qK8SUjgrgJ5CJCOChiAIYJ0opgYdxF6PzMQIKgBm9IoBzNvitmpqc6KKFEPZkUKIcGGoGZfhwwQDsJ4gZiEDSgBbFAzC+5nZgkAKiBECkU06KBQC7y+poeAv65YEU05wUscM5OkROckHw+uc1RyHL8xyPl8ccAMolN9Kd4V9p6NxhKJCB1KdeKSt1TOjjIDohMhADiXM9SdsZLZTT4fSx//PeZ+fEj4ZFrLWf4+qEMMHJ4y6NqjND7HnvAFn5fiP/eVuj7YRYgc8JX/h04J0QKO4140UhphDbPRz1MwQMrDz5UlDUABNYOjYNHw0LNCAFTxe3CLbeeVA4wI5AuWalSP+MDyTRchmwKdxb7wklGYBwYJ8onhURPC+6XbW8L4UDSDCBAKw8+L8A2QIWEIE9McL0qDdEdlGe/FHgpKIKlyszKDr8Qtj+BFUccIG7b4qEgCD84leGBF5vR00foviHiDz72y8kAl3eGECiEBJgaYWAfalndB2QZPsHCkuSH/DHdM7AAQ9ofrd3COO2gLBjO3YWAQ9wcxCYDfhngWOGgaagJ8j0IbJXRLQ3DAZ4CG+2eyToCSJhABcgRm0kVNdw/35+1GcwGIOdIFo9sWQt5wwhqH0dwH0+SAq8Y389tIK+YFoHeGqploSlAAEPwT3QVwzXlQhHR4Wwo3ZDmAwBlgjPFm1eaApbU3dhaAymZUyDcIFnaArN90jMIEHB8wIyZW9xODh1thBZqAvbVCd4iAgvuIenEHT/JwzkBCmHYHJIaIijQHdw9Ye5AE+FMHOQiAp0x4QfeAyWOAg9J3mZOArqAnBr2AssECvHY3TMNYqoYCJQ4QCiN3vJQFSwAjCEEHWuiAphYRMFBAkgNonvQhGKBnLHMIYSJAQqlnWst4ui0BMFEAFiBAk7BnAmcTKkNgxtaAhWlQFkZ3bOaAoLAP8RG1F+H5OGltE1bqFvyOSErPBjg2gIh1V2GtCD4RgKEsCJAZcfBbA4ZBEVyGYV3wYM9HYIt4VY96iJCkJdj1A7t5MS2zYI3TYjwtBsLrhcMGWPCckJUWKKkfAS7lY+uPYL4YYIh/VSYLWRpKAhk1BAt4NASaFAE9iOv1CQiHCQL6WAKtkJH2IfLfRCmVF+ftcJFpkIMgZcx7WToVBHJsKQp/gKJYkIHiADq6eUvGhNlIgKNumCVTaFVvkb7ggKRZl/HYB8X6kK0vgR7pGVpRCV2jdSZniWqlAewJeIrbCVhZABYoVTcskKdJmCnDCUlDCWhbAC40VmfYmWKyeST2n/Ci4AZIgwAzGweHKWAAdwmZh5mQlQDfO3ERNAgGQUlpjwcrxUCM8GAxp5SQdAAKzZmqx5ANcgjGxJlBSwc1IZcXGZcqvpmq0Jm4WAA5eJA4KQAMSZADwQD4LpCIDHjZu3fki3m7xJAL4pCDzgAwSgANYJm7wpnO+QnIuAeIaAYjGAmD9HA9H5moSwmjcgCDkgnKwJADtwnf0lmpLweIUwAyOlk5xEnDtwmQqgADrAmjZwntJJCPF5nQeQA4Lwnj1AADQwDG8lCBfAjqPXCstZCHuZmj3CA8TZAwdwA/8ZoATgAwoABMGZAAoKANDJm9MpCAcwoKy5AwDgmj5wnMKw/2x12ZibAJ6EMJUa0IzSYJmZiZmbqQtCOqQHUKScwKEJ4KEgqgAw+p80cKIpqggr6potaqM5cAPyyZpcqgM2Gn1m8h06mgn2OQhkh2rbcKW9uQtsip6T8APEeZk08J+tKaWamQA/YAlHOqRKqqIKsAMJYJ7aSQAAoAAEAATBIAEF8AB3FI36SIuocKGD8Gx+xg1vWqC6kKktagg5MKcHUKeISgA28J83cAA9QJx72goJMKo64Jvv+QMDKqPBEKGq4J2CwKNlJQIykJvaYJ7nqQCoWpzEWqzFGqakwKmfCpwHAATYKaCmOqzGiREJcnGzCQlnyl7NiQ2gaqekSqDCKv+q/zmu5Fquo0qg51mq5rqu43qqmHmu0akD/3mZgvqnW9GRgKmCpUCpAGCYGkCezPCp/jmqJHqqODCtnEoKcmqsDFucQwqvWGoaLJlIoqCr+JmAy/CpHuqsAyqvU3qwyFoICbupBNqpndGTt0qfFGibuSh4GmoLGtusUEoAHnsAgrqqj9CnmWmvtjCyolEi1mqXllCEHUWVQGoLctqfdRqgpTqlN+sNOkukpoGIZdoILYimXQkKUauZjpC0oQqgpFqiw1qliUmHnaCDkFeWLysJPjsIHAqcIMq0YpuqZFu2AkI4CUKhkroJRGsCcDkKmUoDcPus1ymsScqzdpsIPBH/FiRApvFnCVfLXhmarAQqr3mauJYgE4Vzg49LCWgLUYc5Cj8AnNZ5niaLuZQAjdvhuDg4tBhgfJJJmZ2QADsAomF7ABDbpqiLCSXiqAJgjoFJe5F7mmu7CBzarNapAyaqp4PQtrtLCYmSH7O4t5PwuR6Am5jQnrg7oApwA6maCM77vJJwAVHBAZnGliGYAdtKCU1apzQrrDhQt4mwtUkqvpZgNYIQjZR4teIJsIowus0aoD4wpdNqv7EgHVwmtIZAVOgHAPgpA/pJCDlQu1BaqjcgqAZ8C8sHAWHkgaEZCWMIdRq2e8dLA8lrojiAsxmMC0BofZWQaKDpS1q0jT66/3XaC7YKQAPfu8LRFY16+wjXOGojqQh39S1BMJmp1qS2W6o2K7887AsVALyPoI63tnCLEIgDMARIAATW6QPLG7JPPAyKogkR+TjKljIssIhFcMGIG8bGgBmGYwllvDsCmSaDSgSf6MbLQLWUEJI8NsSFkABKwAR5rMfJsD1+aAkIt0CAXAjydAQcZcjNUHkxDAkeJ5RpYllLcFSSvAyfF3oiVmQClQR41U2dTAyvVxic27qnrA2+l6Od28rWsHzN93wKLMvP8H0OeK24XAzuN5Od2MvUYL4gUMkfLMzWABIVZcwViszVMD6MecvOfAxtNJBVO8081ZSOmkLXjM1rhf+V0uzNw6Bj/SebsSzOo6Gy6BwOuLrO2NDO7mwN8BzP1DDP9Nx36nzP22DP+vwM/NzPzfDPAL0MAj3QyVDQBk3N+ZzQ9bzQDI3PDy0PCB3RoeXQFE11Fn3RX5LRGq0ME93RvfDRIL0LIj3SlNd/8kKMxlzSJg0K1UghQWyMLQ0NjzEBXGNr5WHFM/0Mj6E4jHNsujOR1lwIE2kVRn3USJ3USr3UTN3UTv3UUB3VUj3VVF3VVn3VVuHC6yBacGU7JwGRQM1tRq3VRL0gWD3VZn3WVJ3Wag3VbN3WTf3WcB3XWDHXTD3U6UDOlqcR4ePH8BYJ/FzQ/xzYHN3I57zVBhT/SIsMzI1A2K4w2IUdb61gzywNDCy0ES50GUF5CY492ZEt2Snr2aHdGZ3NCpBttqjNywBR2qmNCqxNsa792fPZ2rBd26pNCZQt2+/gf6nA26vg26gA3KYg3KdA3KNg3Dud3Mq93P4Aw8EdV+T7fqTgEAFQzIMQ3Yx9CXJBLxJa3dm9CUGicNgdCuV83d4dCvOSFeOtFTFdCglhijExASHx3ZfQIqMW3/MNCmqH3zlGChJQE1TB3/Q9CRqHEvntCf/NJNYm4EZBxTktCtBBIRCQH+IDaqFwARx8GD9C4e72CQyBFOEz4Q9Q4dObCSMBRhxu4WUSFgQi4iT+CYdBJC7e/+ErMcfHDXBNtjseKQoJl+M57tIxERU+vuOVsnJjMeT5SuBMUn06jh4/zgku4QCHoRNIbhQ27iM4HkhPLgruVuWgIF0k4eWg4BLke+RaTuSaEB86kmNivgk1DXq/2+YZ4dfDDXAukRLqSIqvBgB3DgB5vpRh0ed/jk3RkWknM+ifwBSCPrHgHUhTseisixGL7d5zYdMWcRgXwBNSbAk8UWdEgema/gmg9x4bkRig/ruiQM4CZOpBiOqeMOprfumtvumRgOkj8emzrhWX/IUcQRQSMBK2/IyQERW/Lr2gwBcb4QA+UezB7h9lwewlTgnIznGCAO1jDuxtYe3Mve3c3irt3v7t4B7u4j7u5F7u5n7u6J7u6r7u7N7u7v7u8B7v8j7v9F7v9t4IgQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of dexamethasone (1 &micro;M) on glucocorticoid receptor binding to specific consensus dsDNA binding sequences for GRE in nuclear extracts obtained from peripheral blood mononuclear cells from steroid-sensitive (SS, n=6) and steroid-resistant (SR, n=7) asthmatic patients and from normal subjects (Normal, n=3). Mean values are shown at different times after addition of dexamethasone to the cells.",
"    <div class=\"footnotes\">",
"     * p&lt;0.05.",
"     <br>",
"      &bull; p&lt;0.005 (ANOVA).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Adcock I, Lane S, Brown C, et al, J Immunol 1995;154(7):3503.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39037=[""].join("\n");
var outline_f38_7_39037=null;
var title_f38_7_39038="Chronic rotator cuff tear";
var content_f38_7_39038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic rotator cuff tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 313px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE5AXEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCHwb4X0G48JaJNPomlyyyWMDu72kbMzGNSSSRySe9ba+EfDf8A0L+kf+AUf/xNHgUf8UV4f/7B9v8A+i1reAosIwx4Q8OD5T4f0fnv9ij/APiaR/CfhpRt/wCEf0f6/Yov/ia3flC7Wb5q5bxn4ntdCsz5jDf9aLA9DB8aWvhbRNNkY6Jo63GDtAs4x/7LXgF/LHdXckyW8MKZ4RIwo/IVo+KdeuNdumeWU7Qx2jPasTJOAxxQShCqZ+6v5Um1P7q/lSZ5ozQMNqf3R+VG1P7o/KkzRmgYuFz91fypQE/ur+VNxThQIXan91fypQif3V/KlC04LQA0In9xfyp4jT+4v5U5VqQLQBGIo/7i/lThCn/PNfyqwkDt90Vaj0+4boh/KkMzlhi7xr+VOWBCeI0P/ARW9Bod3KB+7OPpV6Dw7In+sGKLhY5dbVD/AMsk/wC+RUyaejf8sk/75FdemkxqBmpVsol7UgORXS0/55J/3yKk/syMf8sY/wDvkV1f2ZewqNrYelAbHMjTYv8AnhH/AN8CnDTof+eEX/fArpPswx0qJoAKAMIaZB/zwi/74FPGm2/e3i/74FbPlACmFKYGaNKtuvkQ/wDfAp40q1/594f++BV4g4phLCkBUGkW3XyIv++BSnSbb/n3h/74FWtzgU9ZDnmgRR/sm2/594f++BSjSLb/AJ94f++BV7ec0oc0D2KI0q2H/LtD/wB8Cg6Xaj/l2g/79itFWoIzQIzl0y2z/wAesH/fsU8abaj/AJdLf/v0taCZ9Kk2kigZQXTrNQB9jtyW55iX/Cu8+H0Xh/7Qtpqeh6VMW43TWkbH8yK5RV7j7wqxbSSRyiRMhxQB70vgzwpkkeHNEaM9D9hi/wDiaD4M8LZ+Xw3opX/rxi/+JrmfAXi5dq2uotzjAJNeiRkMu5OUbpQM58+DPC/bw5ouP+vGL/4mk/4Qzwv/ANC3ov8A4Axf/E10QXCgU00Ac23gzwxk/wDFOaL/AOAMX/xNMPg3wz/0Lmjf+AMX/wATXSEUxhQBzv8Awhvhn/oXdG/8AYv/AImiugxRQByfgYf8UT4eC85063/9FLW63yrg1ieBfl8CeH2HX+z7f/0WtTeJtbg0XTWurogADvVi2KXirXoNHsJLmZwJFHAJr5r8W+IJ9d1F53ZvKU8DPFXvHfimfX7s7XIgB6A9q5VnGAo+53NBI3OTmjNNJ9OlGaRQUopopwoEJinAUCnAUDBVqSMc0ImanihJNAhsUbM3StC2055exq9pulyMwYjg11mm2SRgb1FIdjmbbRCSMitq00SIAbgPyraaFF5FV33fwmkPYWCztYcfKuR7VZWaBDhY0/IVS8pzzzUsEDZ5FGgGrAUCZCjmmTMrKeKs28JEYyO1EkO5ThaBGQYVfpmomtmTpzW3FbMcfLWhBYRMP3hxU3HoceITnlWp3lY/hNdmNFikPyOtRy+GJHGUcUw2OQ8pG9fzoMIHQZrqW8LXQHyoT74qE6BeRnmM/lTA5Z4ST0pjQgjpXQ3Gk3K5yhH4VUaxkX7y0AYhhPpTTF7VsNaMO1RNbN6UCsZRgzSfZs1rfZTR9nIoDYx/JINSrFWibakMGKAM/wAvmlCVeMFNMNAiqFxTwOKn8qjy6BjUTgGplBHahY27DipkQ9xQAibkIZSQ2c8GvX/h1q4vLDyJXJdB3NeURR5YMfujg1s6Devpt6JYzhGpAe2gAnmhjngVn6HqsOo26hSN+Oa0FAGR3pjGkVG1S445pjCgBlFOxRQBxfgx/L8B+H5M/Kun25P/AH7WvHfjD4t/tG7+w27fKvBAPHSr+ueOv7N8F6Hp1kf3n9nW6tj18pa8huJ3nmknmJMpOeatkEWTSUdeaKQwooooAXFOUUUq0DFQZqRE5p0cZNTxxc0CEhh3Ase1b2iWBuDnbxVSztDKwRe9egaDpogtgMfMRSkMhtLHYFHpWiltkVbjtiTjFXYbQ4qRmdHakimnT2L1uR2Zz1q2lhxnNMDmZLQx4xinW8TFwMD8q6ldKiYgu/608WFrHIPnH50C2KItSsa8dRSNZiNdxNbMpt0jAyOKz5ikhIDcUAZ0jbemKgMjE8GtA2iv3qSPTVPekBRikkB4Jq7FczqOpqYWCp3pTbntS2As22pSpjdk1qRaojj5kX8qyY7c4GRVlLcY4pgaiTWspw6Jz7UTaZZTjOFFZ6xbeRU6E+ppgMk8P2pzjFUJ/DcBPBrZEjY7013NIDmJvDeMlelZ0+iSIeBXcBzjkcU4LGfvAUAebS2MsZIZcAe1V2g54616fLpsFyvIAzWZc+FwSTEaBnANFjr1qMw5PNdPe6FNbsSwOKpNaDGDTEYnkc8U4W3tWt9mAFNMeKAKAhwAKXy6vGLjNQumKQFcg4wOlPjBqQLRtxQB0HhC/NnqSKzna/vXrQP3XTkMK8LtyVnjcHla9Q8I60LqHyJDlwMCmB0pFNIp4UhQDSEUwGY9qKdiigD4TlmZ44gzE7VAGT0AFRscrTQMqPpSE4pgLRmiigBO9PUUAVIooAEFTRpk9KWFKuwxZNAiOCM5q7FESelSQw4q9BCCaAL2jQBZFJFegaYimMVymnQrla6qxTCjFSUaMaxq1WTIirwKgSPoSKuIqbeRQBUM2T8oOaGluR9xTitKJVB/1f6VcREYfdFAHMq9wWJbd+dJK0nfd+ddZHbxk8oKJbOAjlRQI4qWRm6M351EbqSEc5ro7zSM5aEda56/tJIs+YOKAIRrcsfRc/hSx+J7hW/1Yx9KotEByelRyxcfKKWwHR2fiZXcCRQK6C01GGZQVKflXm4j454NAmmi/wBVKR+NMD1uMpKByuamW2HUEV5hY6xcoVBc8V0tlrEsijLUBsdYLUmgW2D0rNtNTYgAmtKLUI/4jQFxTbEcionQ9xWpa3lu5AOK0Ps0Ey5UClawzlzC2OM0+ONgeRW/JY7RwOKz54ih6UWFsQoMGrCSYFQbTjNOjPrTAsNDHOMMAfrWRqOhJJkoAPpWorc8VYjJP3qAPO73TpoJCCp2g9apOgzjFeozWsVwh3qKxL7Q4SpaMVOwzhmTOahdMdq3bmweJm+XpWfIjA4K0CM/byeKjZTmtFYc84pPs/NMRUiT5hWxpFy1pdq4JAqCKzJO7tVuO3BPvQB6fplyt3axyKclhk1bA4Oetcv4OkZCyOflHArqgNxZh0qhkX4UUuRRQB8FL90fSlpF+6PpS0xAtOIpvSlXmgByg1YjTNMRauQpQA+3Sr0UdFvEOKvRRCkMW3i9au28RLcUsEXArX0603tQO1ibTLOQsCc4rprUiIAGktrfYqgDtVo24VdzUhEizdOauwHeKzhGTyOlW7fKCkM041q9CMAZrPhfpVkS4pgXAwWmF/myelV1Jc5qVTk4NAEmA44OKrX9glxCRgE1ZOFIFSDgigVjg77TZbZyduRms2VG3cjFelXMCSLhlFcjrVkYpSVHFAHPGMkmmmDParrx4GajA5oGVTBjkVPbzSRdM08rQEY9BQI2NOvxxuNblvOkhHIrjhGyc1ZguZI+9IDtEGDlWrTsL54TgkmuV0+/DBQx5rdtplamI6621GKVVEhAqaWCGcfuyCa5XBIyDilg1CW3kwrE0x3NiewlhJYAkVRaJg2WGK0bPWlfCzAc+taJihuV3KBg0DOeHFKjndWpcaaRkjoelRx2WBzSAiiY59qmZdw4FTLbgU8IFoEZM+n+aD8orDvtEYHIFdsoz0oaND94UrAebHTnViNpqaLT2P8AB+ld3LbQ4JCjNYuoTrbk7UH5UWFsZEemv1fhanW1tYR8z5P1qtcX7yE84HpVEuWOdxNAG3BqEdrcII8beldlbzB4lkU/K9eXO2AQepORXZ+ErwzWvkuclelCA6TyB60VF8/rRVAfA69BTxSL0FOApgKvIpyDmhBUsS80DHxJ81advHx0qvCnIrUt04pE7ElrGe4rShhz0FO021a4mVQK6yz0hUdd4qblFDS9KknILDArqNP09YSFKirUMGxVEYq7HEFGW60wK20A4x0oYbhz0qVxyaWNc0ARohFTqnFLjFTRDNAwSMjvUq8e9LsNHSgCVGxU6Gq6CrCCgRKOTzTzSKMChqBj0bI5qjqlmJ4jgc1bXoaevzKQaAOEurZoGKtVTy+3rXW63Zbk3gdK5kjL/SgSFsbF7iQYHArZXSTGuSK1PC1oGspJSOhqxqEhEagCkM5t7MKTkVA9l5nQYrUfO45pVHpQIxBYXMYLICQD2rR07UJI5UjnQitq2ZET5sGrkcVjLIm9BmgCW3zLyudp6VI9qc5xWza2saoNg+XHFOnjHaiwGGlqVOTV20uZbZs5JWp3TIwOtIkRPBFGwG1Z3yXKgNgHFWXjUnArEggKtla1IJAowx5qgEliIPFRMdo5FWzKrHFQ3CgrkUwKbzY74qBrrHfNMnBBNVM881IF5Js9T1qvdwLP2BqEkjp0qSKbB5oAxL7SWXc6Z57ViypJESGXArvC6uvrWff6eswORigDjd3B756VseHbs2t4invVXULBoDlR8oNR25K3UT+h/rSEeqfax/dH5UVzX9pUUAfE69BTxTF6CnirAkUVatlyagjGavWq80AWreL5hWvZW5ZwKp265YVt6eu2QUhnQ6LZfZsM3JPNbyPlgTVCyDMq59K0UAxjvSGXopDxirS7mHNU4D0q1uYDigTHeXRtxShiRRgmgYsY55q0hAHAqBUIxViMDvQBPjKimEVOB8opjCgQiripFfFR80vHekMmUk96dUatTy1MQ4HFPRqhJoVqQxbsb4WXrmuQmTy7lkI6muvzuNYeqW4FyJAOKYjqfDEQ/s5lHU1X1WEoOnSpvCbMWCdiK1tTgVg+R0oGcLcBi3FKiNkVqvbZfgUnkYcDFAipHGxcCtOw055LhSc4p8cSxkMwrRhvEjXK4yKAN22t9kagnoKlkiixyRXPPq8nY8VXbUJZP4jVAb5htwxO/n609XtxwuCa5YXDGQ5Y81rWCFsMaVwNpI1A3A8Gsy/vBExAqfUZ/s9spz2rkNSvWbLA0AaB1vE5Xd0NaUWqiQAZrzeWd/PZs96uWupMsgGaQjv5JRIM+tVZBg1QtLsuiknrVwtvWgENJpN+O1LtpcDvQAI5BzVlJwRg1UIycClCEUAWpYY51wQKzpdJG7KirsJOeKuRcn5qAMX+z39TRXQ4WigD4VXoKkUVGv3RUi1QFmFea07SPpVC3WteySgZetY+a2rSPpVG2j6VqWy4pSGdRo65ADVrGEKdwHFUNKXdCCOwrXj5jOaQEUCc5qyBmmhMCnR5JpASLHUqx8U5RxTxmmBFtOasRLxzSKKfnFAEuPelbpUIY5qXcNvNAEDg+tKDxSSE0wyACkA8Nz1qRWqqG5qRWpiJd/NKWqPdSqwNAyQPio7pBIuTQMAEmnXBzakrQBb8PSeVOBmurvFDQbsda4bTJdsqGu1ilE1qB7UkFjBkZUnG7gE1pS2aPbh48ZxVK8t/3uX4HarENyIkCg5FMDLnSRCcg4qk7uhyc4rcmnSTOQKqOIX4OKBGd5h4PPNSRSMZAAKuLbR5HpVu2igSQbsUAQwae88gY5UVtmSKwt8ZBaoZr2OFCFwAK5nU9Q3ucNmlsBY1jUjMCNxx6Vz08pKnk0XFxnJNZ1xcccUARyP87c03djp1qAvk5pN1AjYsb6SJhliR711On3glUHPNcNFJhRmr9lePC4OeKAO6VsmpRtxzWNY6ikirk8mtVHV14NMBwHzZHSnUzODipo13UAPhTOOKtquBTUUKoNKXzxQPYdkUUyigOY+GkHyg1PDjPNRJ90fSpoVyaoDQtlya2bNOlZVqp4raslNIDUtl6VqWy1StU6Vq2yUDOh0M4hIrRTJB7VmaEPmINbrRelIBN3Kj2qeOPcwxUYUZFWLYZkAoAlMeBT48DrTpjgVU3nNAFvaD0pjDFIknrTj81AEWeacHpGXFRNS2Acxz3qJzT8HGaidsUxDS2Kcs2KqvIMmmb6Qy+smaUse1VI5alMgpgWVk3Rgd81NdOFtm/wB2qELjeR7ZqW+kzY5/CgRWtJCpU5rtNCnLKN3Iri7CIsFJ6V02lzqhCikNGnrXTI6ViiXLVt37B7fPtXPdGNMCV8kkgmo4x83NAlzTQ/NAi0sm005X+bJNQgjGTVC9u8HavWkFhdUvBEW+bOTWI8zOdwqSZTISznrULHyxgdKBEMzE85qq/vU8rZqpO+BQMZnk803PPWoQxLGlBOaYF6PoKnjbmqcbVZi5NIRdjdlIKkj6VvaXfHAViawoUxgnvV6GMjlaAOstmEjcc1qxIMCub0YShwTnbXSJMpwD1pgOY4OO1IvJoPLHHSkPy0ASbaKi82igD4ej6CrUHWq0Q+UVagHNUBrWa9K3LNOlZFmvStyzU8Uhmnbr0rWtl4FZ9uvSta2XgUAaui8TYNdHEMhq53TOLtR9K6SIcmkMiI+ap7TiUUvl806JcS0AW7iAsuRVIwletbEg/dj6VSmXNAFONDnJqUNg0pQhahLYagQ9W65qB2+elkbFVmfmgCV5PeqkzmpTyKhkFAFd29qYXIFSlST0psiECkAI/SpVbNVlU1YRDQFhQSr5zVt8PAFPSqgGG5pzzfLgUAXYBtjAB7VZtJikvSs8S7Ywfan2sjM/AoGdRJNm2znqKyBLlyMVaVh5HzHtWcWw520xFtwoAPc00lUXJNQljgFjVW+mzHtU80gHXV+oJCmqLzBxmqMyN1JNOTIWgCZ246monORTlUuKBEQaAKMgYMfSmPHuHStF4cmo3jCigDIMRDGnqmKumLPPrTDDTERxx55q3bpg0tvbk4q/Bb4NIY+BN2CegrUs4PNYbegqvBDg49a29Ph8kcjrQIuwoI4VA4wKEJ304Ak47VajhAXJpjHRMVGSaZLKGPWormXauB2rKmuzHk0CNfPvRWD/AGn70UAfJEA+UVcth81VYB8g+lXLYfNVAbNkOlb1kOlYtkOlbtkOlIpGrbjpWpAOBWdbjkVqwDikBctDsmU966i3IMIPeuXiGSCO1dDpUnmAJSAs5NSR9fehlwaVKYGrEpaHk5OKquNhO6rFqx4FR38ZzxQBTJ3ZxVKb5WqztaPJNVZHDNQIYfmHWonXFOclahLlqBgoOetOZfakRucVKRmkBWxlvQU187/UVYeMlSRRa25bk0CKiIzS47E0t5fraYjCgn1pdTvY7RGUffrmJLtppSX5PajYDUN40svBIqz5nAFZdoyiTnrV9uWBFAF0klF57Voaf8p5qjEMqKtxHZQBoTOVGc8VCJV7AZqCWYuMVHuC9aALdw8aoDuOSKyZpC74Wia5LPjbxT4kDsMcUARxRsWO7mpGtmzkDirqW7cYFXFhOzGKBGXDBjrUwhBNX0tMig2pU0DMyeHA4qqY+Oa25YMrVZ7bigRmeVgZpCm7tV027A89KekI7UDK9rEQa0IVG7kVJBAMdKu29ruagB9jbjcXYZHaryct04pwj8tAtWbOEMpNABbxlmz2qzPIFTbT8CKPNZl1cAMSaNgKuoSYB5rDuJiR61dupfNkbHTNZt5IkKZagRDv9qKp/wBox+1FAHzhD0X6Vdtf9ZVKDov0q7af62rA3rPqK3rLoKwbPqK37LoKRRqW3UVr2+MCsm3HIrVg4ApAW4jhx6VqadLsuBg4FZUXrViNirZFIDrnUYBx1GagH+s9qsWp862U+iio9vzEUwJrZmD9TVmdtw55qspC1IJA1AFG4cnIrLnfaxxWreKMEiseX73zUCY3zC3elXiosbTS76QDweTUkbc8mqYk5IqxByaB2LsSlmwO9WJMWdnI79cHBqbT7fIDGs7xjeLHCIl4yKEJnG38pnlZmJOTxmqq9eetSN0qBjg0wLkBw2TV4S8day4nzxVncQKANu1dsDnNXlfA5xWHp8+DhjVySRgd27igC48nJxxVeSbHU1QnvCM4qhJcyOeM0Ab6XUCgbiCRVq21C23dBXKKrsec1dtEweaAO3tLmCReCBV2LYRkHNclbfIMg1tadcnGCM0gNpI8jIpskVEU3ANWVIegCl5OT0pkkGB0q+UwTSFN1AGU8ORjFJHb89K11twalW2HpQBlxwEdq0rOLamSOamjt/nHFX/ICKOKYWKSQlsseQatWy7QeKeF44odhHESaWwFW+mCKefwrnrly5JzxWhfTqwJzXKarqnlAqlMC1eXKwoDkZrmtWvTJ0bj0qleajLK5BJwaq+XI7AnpSEL9o/2aKl8gelFAHh8XRfpV20/1oqlF/D9Ku2f+sFWB0Fn1FblmelYVmeRW3ZmkNGzbnkVpQnism3PIrThPFIZfjNTg8VWjPAqUNSA63w++62Kk5NWXXaGz1rH8PzbZAtbt17d6EBUPDjJpySDDVDIT5lMVwobNMBztuRvWsuXgnNXYpAWIqtdAGTFAFJjk9eKbvzwOtJIpUmmxDacmgQi8Mc1etTz0qqcZJHerNoRmkB0Vj+7t2ZumM1wniW7E96RnODXZahP5GmEjrtrzK4lMl27n1pgOY+9RHk0pbNIKBiIdr1eQ5WqRXBzV22GVoAliXBq0SxXBJxTVTGKkUUhFZ4yT7U1U2npVzbmnrEDQBBHGTzVqGI5qeGIYHFWYoxmgBkakVoWsgSq5UA0nJ6UBsbttMrAZxWhACDuB4rmIXZGFb9ldBowDQBosC3NCAin27hgBVvygR0oEQxKSc1Oq06NQOKsxRZNMYtvDnkinSp83PSrCjYuKjcE80AV2XB46Vn6nOFG3OK02+VSTXF+I77bOVU0AyprF2saNhua4y7Z5pCRkita4DXEhLHvSeQqLgDmgRkRWeSGerGwLxV3aMY71XeL5qQEe0UVJ5VFAHz3F/D9Kv2v+sFUYhwv0FXbf74qxm5aZzW3ZtjFYdo3IrZtOaQGxCeRWnEflrIhPIrUiPyCkMuQsc8mrORiqSnFTq+aANPSbny7lQfWuxc+ZEre1cDEwWVWFdvpr+bZD6UgKcjEMc1AzZJqxdAbiKrPhVzTAYgIOc02bOc96YzkGkEwPWgCJ0J61EUq4SCKZszQIrMvzDFW7KPMwGKYqZkrS02LNytIZR8Xz+RZhQccV52shLMSetdj8QpSJFQVwrttYCmIuq+aljHPNUomwavwfMaAJgmRVi34NNRDipI8BuaBloZPSpEBpYlyBU+zFIQkaZq0kIxTIlNXIxigBEi4FSooXrTlp2wvQBE4z0pEXmrKxdqlWHFAECxk1ahBSnogAFPxmgC7ZTbSNxzW3bybxnPFc9ChJGO1bNgTwDTEa8UWcGraIB0FR25AVR7VZzxQURPTTwOakI5qtdybFoEVb+cRQOTXnd8rXV4z5O3Ndhq0m6LGfvVy10RDlR1NAFZ4VX5hVSZvSrUhPlAE81SCMWpAQsGaQEfjUqxlpNx6VMkexXZh3pXlUNEg6tj+dAhdi/3RRWz/AGaaKAPlCHov0q5b9aqRfcX6Vag61YzYtM5HNblk2MVg2rdK2LQ0gNmE8itGJuKyYG5FaETcUhl5XqdHGKpKwzU6MKALanC5Jrr/AA3cboNpOa4rdla6TwrKPMCmpYI27mLEhJ71TmXJx2rX1BcYIrIuSV5phsVZFGDVXI3VbflaqlMtQA9Mk1YRDikgTpVngCgBkUXz9K2dIgGWYjn1rPgXLitvT12xsaAPM/HshbVtueAOlcoV3Pk84NdP4wBfWXNYUcfX61QiAIVJNXrNuajeIkU+1Xa1INjRjbB5qYAdcVAg3HirH8OKBly05q0V5qnYKd2K01jJNIQkSmrcUZJp9tDyKvRxAGgCGODPUVYSHA6VaSP5RT9lAFTycHNPVM1PsJqaKLHWgCsIeKVITuq5s5p0cfzUARwQNv4rZtLfYAxFR2cO5vpWgTtG0UbAOib5sVbB4qpEnNWugqgBztGazrl9+c1fY8c1QuiM8UgMTVWG3A7VzF+CWyetdNqKEn61jXMG+kBkRhnLZ5oA8vJY4q5Nst4znqK5vUtQJDBDQInv7/qq9F6+9Hh22k1bWYFRjtHz/TBziucNwzAluh4Nel/C7SjHay3TD52OU/3cc0Adz9lh/uLRUnHrRQB8KRfcH0qzB1qCL/Vr9BU0PBqxmpbHBFbNqeKwoTgitmzORQBrQNyK0Im4rLhPIq7G3FJjLymp0NUkarCNQBaV/k962/DkgW6Qe9YAYYArU0WTbfxj3FQwPSblN0Kn2rFulHcVt53W6/SsW7B3mmIogdc9KryHDcCrkmAKryqCM0wJbQ561YK5NQ2q4FWk+9SGWbaPpxW5DHtt+KzLRORW1tIt6API/Ei7tUkzydxrLSIbjxWx4gQnVJP941nAEMaYFcxEnrUsVtmpI1Jar0URxQIghiIPFXY4RjkU6OLmrKoQKQbDLePEoxxWvFGOKz4xiQVpwk5FAFmGLBq7Gg7jNQwoSc1cjXFADsYHFOA9ak28UqrQMaqGpFX1pwHanhCaYiMR89aswx+1RhGzWhZx5xmgCaBPLUEDGaeRzuNSOBjA7UijPFMB0YJOafI20c09RsQVUuZM0ARSTncRniq7tvPFQzSYJpkcwU80gGXMO/qax9QkSBcZGavapeCJSQetcfqF55zHJ4pAU9VvS5YA8GsOVQ6nnmr12d64Wora2Ln5qBEGi6VJqWoxW6525yffFe66RaJp9rHDGoGxduBXF+AtNC3DXO3iP5c/UV3p4G4HJY5oQDdh/u0VL5relFUB8Hx/cX6VKnFMjH7pPoKeKYF6B+ma1rN6xoSOK07NhQM2YW5FXo24rKhfkVejfikBfR6nR6pI3SrCMKQy2rZJ+lX9MfF3Ee+azYiMn6VcsGAuov8AepMEet2Sl7RSeflrNvEwxrV0f57Nf92qGoId5oAyHXOc1Wwd2CeKtTZHFVyKBE0Rx3qylUkfkVoWy7hS2GamnjIGa2ZOLQ1mWC4Fasw/0Q00B5LrQJv5ST/Eao7MmtLVxuvpf941V2FcUCC3g56VoRxUW0fANWlXBoGQrGQamValCilIAoEQYw1almoIBIzWfjkVqWQ+WgZei4q1GOahiFTp1oESgc+1Sqo9KRBUwHFADUUE9KXGDUirgZpPvGmAsYJYVqxKFjyBg1Tt05q+BhcUAMQEsc1NEgDcikUAAU9jtXNMCK4fBIqjM3FTzPk1UlIxSAozA7ye1ZuqXa28RKnBq9eTiJGzXHarcNLIcn5aBDLvUTcABmNZUzGRtqrxUd1HIeYulaNgY/I+cfPSAjjtFCKSAcin2cDS3ywqvBpJTJnCdT0rsPB+kuMXFyvPUZoA6PSLNLKxSJVAOPnx3NXuMD26UhOSSOlIxpgP3n1oqLdRQB8p+KPBsmm+HdF1a2QvbXFhbzPgfxNGrH9TXE4IAZwBuOABX134Z0q21f4X6Ba3UYaJ9KthyO/lLmvAfiT4CufC0xckvDIxKH+73q2FrHDxda0bU1mR8fWr1s1IDXhbkVfjbisqFuRV+NuKBl9DyKsoRVBG6VajapAuxGrVicXAJ7HiqMbcirNu2JRQM9m8O5NonP8ACKj1AATGm+F3Js4/90Uupg+bSWw2Yt0p3HFVZW2rV2dSMk1RkIY4oENjHINbFjjArKTsK1LPpQBu2C8j0rSuwBbVR07tWjeLm2pjPKb2Mm/mJ/vGoWjJbFal5F/pch/2jVcx/OKRI+BCFFW0UdxRGowBUwTilsMiK+1NK+1WdlNKUxFQD5q1bEVQZcHNXbJ8GgDUSpVpkYyAfWrKJxQBJGhwDU4WhFwopSTTACD61JCgJqLmrEAJoAtW0fzHNWdvNNiUhQaeQetAxO9Nnb5Kf61UnfnFAiFuQc1WmIVDUkkm0NWdcTZU0gMrUpvv7jkdq5x4zLIfSt26iMmSelZ02Ihx1oEVpIVhiNYUs7RTnB4rXupWZayobSW/vBFGM5oA3/DUf9o3SY529a9OQeXEkQGABWB4U8PjSolkf/Wkcj3roidzHPFC0AOnAppoppNMBaKTNFAGb8OufAXhvPKf2Xa8f9slqH4geHR4k8OT25A87B2HuKl+Hny+APDIHOdMtj/5CWuj5Lrg4Her2Ktc+IdY0yfStSe0uo2RwxA461HC3z7cYIr6t8dfD7T/ABJHJLsVbwL8rYr5m8QaHc6Bqc1jdqdxOEehkbEUTc9a0ITxWXD8pAJzitCE8VJReQ1ZjPFUkPNWYzxQBcjNWoTzmqcRq1CeaQ0eweEWzZxZP8Iq9qoHmKQKyPBUu+zUegrY1cYUGpWwMwro9fSs84LcCtCcbhVFl2mmIag+atmwXgZFZ0EeWFbdlFhRQM1dNXkVrXK5t6o2CYxWlOP3FMDzi9T/AEqX/eNQCPnOK0bqPN1L/vGojHikIZGg9KlC80+JakCc0DIStMIqyy1C45oEVpl4qawA3YIpduVpbTiXFAGxD2HarsIqnDVyJsUDJyccU0nNNkakQ5piJUyW9qu2y/vB6VWiWtC1TjNAFlgR06U3cacTxTMZNAB91STVKVhyTVuU4UZ6Vi6nc7TtU80AV7qf5yAaqlC7DsKWNC5LNSTyBUwvUUgKd83l7gOlYNy5JJIrVu33AZ61mXEbyuEjFIRnHLttXJJNd14Q0eO3g+0SRgydQT1qHQfDanZNcDtnmurUCIBI/uCgLDtxYbm6mkbnrSkgnjpTSaoBDTTSk00mgBaKbmigDP8Ah2ceAvDJHX+zLb/0UtdKD61zPw7/AORB8Nf9gy2/9FLXSCqKF4DCTJJHavMPjH4LbW7T7fZIPNQdB9K9NH+tP0oP/HpL9DTiTJHxfNZ3NlcGG4i2sOOang3Khzya7H4l/wDIZf8A3q5CL79JiRYhJPWrUZqpD1q1HSHYtxVaiPNVYqsxdaQ4nqHw9bNqc+tdHrn3UA6GuZ+Hn/HqfrXUa391KlFGAehqsRluRkVZP8VQfx0ySxbpyOK2LIHvWZb1rWdAGxZDpWhPjyKo2dXrj/UGmM4S6H+kyf7xppXIqa7/AOPiT/eNMHSkIdGnAp5QDtSx9qe1AFSTOTzUYBPWppKYvWgCLBGabag+dUj9DTbf/WUAa8R4qdCc1WiqdOtAE/XrT4hzTBUkX3qSGW4F59q0YsKvAqlB2q4vSrEOJpATR2oFICC/k8uPJNc9J+9k3NWzrH+rFY6fcpAML7chTiqc7dasP1NVZ6BFGcMc4GSelbXhzTGciWdfzrPg/wBatdnYf8eg+lISJcBRtXoKb04FKPuikNUUJ04FNJNOphoEBNNJpTTTQAZopKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior view of the right shoulder demonstrates superior migration of the humeral head with significant narrowing of the acromio-humeral distance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39038=[""].join("\n");
var outline_f38_7_39038=null;
var title_f38_7_39039="Holter monitor PI";
var content_f38_7_39039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Holter monitor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 494px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    People with possible heart problems are sometimes asked to wear a device called a Holter monitor for one or two days. The device measures the electrical activity in the heart. It helps doctors pinpoint heart rhythm problems. You will have \"electrodes\" stuck to your chest that are connected to wires leading to the monitor. These electrodes tell the monitor how often your heart beats and if it has a normal rhythm. While you have a Holter monitor on, you should do your normal activities but keep the electrodes, wires and device dry. Some people have an abnormal heart rhythm only during certain activities or certain times of the day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_7_39039=[""].join("\n");
var outline_f38_7_39039=null;
